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ABSTRACT 
 
LEILA FAMILY: Associations between genetic polymorphisms in DNA bypass polymerases 
and base excision repair genes with the risk of breast cancer 
(Under the direction of Andrew F. Olshan)  
 
  Mutations in BRCA1, a DNA repair gene, have been associated with a lifetime increased 
risk of breast cancer (1). Therefore, researchers hypothesized there may be other DNA repair 
genes associated with breast cancer risk. However thus far, studies of common low-penetrant 
DNA repair SNPs have not yielded consistent results. In this proposed study, we hypothesized 
one or more of the following mechanisms may explain the lack of main SNP effects:  combined 
SNP effects, modification by race or breast cancer subtype, and functional redundancy. To 
evaluate these hypotheses, we used genotype data from the Carolina Breast Cancer Study (1,972 
cases and 1,776 controls) to investigate race-specific, subtype-specific, and combined SNP 
associations using unconditional logistic regression in two DNA damage pathways, base excision 
repair (BER) and translesion synthesis (TLS).  For BER, we evaluated the association between 
31 single-nucleotide polymorphisms (SNPs) in 15 genes and breast cancer risk. SKAT, a 
pathway-based analytic method, was used to evaluate the combined SNP effects within the BER 
pathway. Among Whites, our results showed a significant positive association for NEIL2 
rs1534862 and a significant inverse association for PCNA rs17352.  Among African Americans, 
we found a suggestive positive association for UNG rs3219275 and an inverse association for 
NEIL2 rs8191613. Tumor subtype analysis showed that NEIL2 rs1534862 was associated with 
luminal and HER2+/ER- subtypes. SKAT analysis showed no significant combined effects 
between SNPs. For DNA bypass polymerases, we evaluated the association between 22 single-
 iv 
 
nucleotide polymorphisms (SNPs) in 7 bypass polymerase genes and breast cancer risk. We 
found similar increased odds ratios for breast cancer with three POLQ SNPs (rs487848, 
rs532411, rs3218634), which were also in high LD in both races. Furthermore, analysis by 
specific tumor subtypes showed all three SNPs were associated with increased risk of luminal 
breast cancer.  These significant findings need to be replicated independently in other studies. 
Overall, our results did not indicate associations with breast cancer, which may concur with the 
theory that our cells possess an intricate system of functionally redundant DNA repair 
mechanisms in order to avoid the catastrophic effects of genomic instability.  
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CHAPTER 1. REVIEW OF THE LITERATURE 
1.1 Introduction 
 
In the past few decades, there have been significant strides in breast cancer research in 
both etiology and treatment. Breast cancer is one of the most investigated types of cancer in the 
US, garnering a large proportion of both private and public cancer research funding as well as 
media attention. Consequently, the results spawned from these research efforts have afforded 
many women new treatment and prevention options improving overall survival from breast 
cancer, with an estimated 3 million survivors in the United States (2). 
1.2 Definition of breast cancer  
The term “breast cancer” refers to a malignant tumor that has developed from cells in the 
breast. There are two main types of breast cancer: ductal carcinoma and lobular carcinoma.  
Most breast cancers are categorized as ductal carcinomas; that is they originate from the ducts, 
the passages that transfer milk from the lobule to the nipple. Lobular carcinoma originates from 
the lobules, the milk-producing glands.  A less frequent type of breast cancer can begin in the 
stromal tissues, which include the fatty and fibrous connective tissues of the breast (2) (Figure 1) 
Breast cancer can be further classified as invasive or noninvasive. Invasive cancer has 
spread from the milk duct or lobule to other tissues in the breast. Noninvasive or in situ cancers 
are confined within the ducts or lobules and named accordingly, ductal carcinoma in situ (DCIS) 
and  lobular carcinoma in situ (LCIS).The majority of in situ breast cancers are DCIS, which 
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accounted for about 83% of in situ cases diagnosed during 2004-2008. Lobular carcinoma in situ 
(LCIS) is a marker for an increased risk of invasive cancer in the same or both breasts (2).  
1.3 Epidemiology of breast cancer 
1.3.1 Breast cancer incidence   
 
Breast cancer is the most commonly diagnosed (non-skin) cancer in women in the United 
States, representing 29% of all female cancer cases (3). According to the American Cancer 
Society (ACS) 2013 Cancer Statistics Report, there will be an estimated 232,340 new cases of 
invasive and 64,640 new cases of carcinoma in situ this year (3). In North Carolina, there will be 
an estimated 7,090 new cases of female breast cancer in 2013 (3). In 2012, the age-adjusted 
incidence rate for breast cancer in the United States was 124.3 per 100,000 women per year. 
These rates are based on cases diagnosed during 2005-2009 from 18 SEER geographic areas (4). 
At a population level, women have a 12% risk (1 in 8) of developing breast cancer in the course 
of their lifetime.   
After increasing for more than two decades, female breast cancer incidence rates began to 
slowly decrease in 2000, and then dropped abruptly by about 7% from 2002 to 2003. This large 
decrease was thought to be due to the decline in use of hormone replacement therapy (HRT) after 
menopause that occurred after the Women's Health Initiative ended their clinical trial early. The 
preliminary data showed that the risks of HRT may outweigh their benefits. The study linked the 
use of hormone therapy to an increased risk of breast cancer and heart disease (5). In the past 
couple of years, breast cancer incidence rates have stabilized (3). 
Age-adjusted breast cancer incidence rates (per 100,000) also vary by race. White women 
are at the highest risk of breast cancer (122.3) followed by African Americans (116.1). Asians 
and American Indian women have the lowest risks, 84.9 and 89.2 respectively (3). In North 
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Carolina, the incidence rates (per 100,000) are slightly higher for Whites and moderately higher 
for African-Americans compared to the national average (124.5 and 122.3 respectively) (3). 
According to data from 18 SEER geographic regions, while incidence is similar for 
premenopausal White and African-African women, after menopause the incidence rates diverge, 
and postmenopausal White women have substantially higher incidence compared to 
postmenopausal African-American women (4) (Figure 2). 
1.3.2 Breast cancer mortality 
Although breast cancer mortality has declined by 30% in the past 25 years, it is still the 
second leading cause of cancer mortality in the United States after lung cancer for women 
(2).The ACS estimates 39,620 deaths due to breast cancer in 2013. Breast cancer accounts for 
about 3% of all-cause mortality and 14% of all cancer deaths in the US (2). At the state level, 
there will be an estimated 1,260 deaths from breast cancer in North Carolina in the year 2013. 
Death rates from breast cancer have been declining in the past few decades especially in 
premenopausal women. These decreases are believed to be the result of earlier detection through 
screening and increased awareness, as well as improved treatment.     
 There are differences in survival by both age and race. Although the mortality gap has 
lessened over the past several years, African-American women have higher mortality rates from 
breast cancer compared to White women, especially for younger women, despite the fact that 
Whites have a higher incidence (4) (Figure 2). Understanding this survival paradox is the first 
step in helping to improve breast cancer survival among younger African American women. 
1.3.3 Non-genetic risk factors of breast cancer 
 
In the past two decades, there have been a multitude of epidemiological studies 
evaluating the risk factors for breast cancer, primarily among postmenopausal White women.  
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Many of these individual studies yielded inconsistent results due to small sample size. The 
Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC) was established to 
aggregate data from multiple studies (10,000s of cases and controls) for a number of putative risk 
factors such as menarche and menopause, abortion, breastfeeding, alcohol and tobacco, and 
family history (6-10). Results from the Collaborative Group studies have provided conclusive 
evidence for several hormone-related factors such as nulliparity, older age at first birth, younger 
age at menarche and older age at menopause, long-term use of HRT being associated with 
increased risk of breast cancer (11-14). Lifestyle factors such as moderate alcohol use and 
postmenopausal weight gain have also been established to be positively associated with risk 
while physical activity has been associated with an inverse association (9, 11-19).The strongest 
risk factors are older age and personal family history; the latter which is correlated with genetic 
factors.  
1.3.3.1 Non-genetic risk factors of breast cancer by race 
 
Results from past breast cancer research studies may not provide a fully representative 
story. Most of this research relied on data collected from postmenopausal White women. In the 
past, it was difficult to examine risk factors in other racial/ethnic groups, since many studies did 
have enough power to evaluate breast cancer by race. Recent studies consisting of larger, more 
diverse cohorts of women have allowed researchers to re-evaluate these “well-established” risk 
factors by race (20, 21). These studies have identified several risk factors that may differ by race. 
For example, the effects of body mass index (BMI) may vary by race. While higher BMI in post-
menopausal White women may increase breast cancer risk, in African-American women of any 
age BMI may act as a protective factor (22). While increasing parity and early age at first birth 
are considered protective factors in White women, these factors may have the opposite effect in 
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African-American women.  Multi-parity was associated with increased risk of breast cancer 
among younger African-American women (for 3 or 4 pregnancies: OR =1.5, 95% (CI): 0.9, 2.6; 
for 5 or more pregnancies: OR = 1.4, 95% CI: 0.6, 3.1), but not among younger White women 
with the same number of pregnancies (20). 
1.3.4 Genetic risk factors of breast cancer 
Family history, one of the strongest risk factors for breast cancer, is linked to inherited 
genetic susceptibility.  About 20 - 30% of women with breast cancer have a family history of the 
disease. Having one first-degree relative (i.e. mother, sister) may increase risk by two-fold while 
having two first-degree relative may increase risk by as much as three-fold (10, 23, 24). In the 
CGHFBC cohort, risk ratios for breast cancer increased significantly with increasing numbers of 
affected first-degree relatives compared with women who had no affected relatives (p<0.0001) 
(10). However a recent study reported no significant differences by the number of affected first-
degree or second-degree family history (24).  Overall, only 2.5% of breast cancer cases were 
found to be attributable to a positive family history (23). 
In 1990, BRCA1 was identified as one of the first breast cancer susceptibility genes 
followed by the discovery of BRCA2 (1, 25).  BRCA1 and BRCA2 genes are frequently mutated 
in familial breast and ovarian cancers. Women who carry these mutations have a lifetime 
increased risk of developing breast cancer (10). The average cumulative risks of breast cancer 
among BRCA1 and BRCA 2 carriers by age 70 are 65% (95% CI: 44-78%) and 45% (95% CI: 
31-56%) respectively (26). However, BRCA1 and BRCA2 mutations are estimated to account for 
only 5-10% of all breast cancers and 15-20% of familial cases (27, 28). Several moderate 
penetrant genes such as ATM, CHEK2, PTEN, and TP53 that predispose patients to genetic 
syndromes such ataxia telangiectasia, Li-Fraumeni, and Cowden’s syndrome have also been 
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consistently associated with higher risk of breast cancer (28, 29). Recent studies have identified 
BRIP1 and PALB2 as two novel breast cancer susceptibility markers involved in DNA repair (30, 
31).  Many of these genes are involved in the regulation of DNA repair and checkpoint signaling 
(28). 
It has been proposed that there are other common low-penetrant genes that may modify 
breast cancer risk in BRCA1/2 carriers.  Antoniou and others established the Consortium of 
Investigators on Modifiers of BRCA1/2 (CIMBA), a large research collaborative between 40 
study centers in 22 countries to investigate potential modifiers in this high risk subgroup. Results 
from these studies demonstrated that common variants in LSP1 and ZNF365 as well as several 
susceptibility loci, 2q35, 8q24, 12p11, 12q24, 9p21, 9q31.2, were associated with breast cancer 
in BRCA1 and/or BRCA2 carriers (32-40)  
With the completion of the Human Genome Project in 2003 (41), researchers were 
enabled to use this cache of comprehensive genome-wide data to evaluate associations that were 
not possible with candidate gene studies. Large collaboration efforts such as Cancer Genetic 
Markers of Susceptibility (CGEMS) and Breast Cancer Association Consortium (BCAC) 
increased sample size and hence power in genome-wide association studies (GWAS). As a 
result, since the advent of GWAS, several breast cancer susceptibility markers from genetic 
association studies have been replicated and several novel susceptibility markers have been 
identified (42-47). While GWAS have enhanced our current understanding of breast cancer 
susceptibility genes and loci, these known genetic factors still only account for about 28% of the 
inherited causes of the disease (28). 
 7 
 
1.3.4.1 Genetic risk factors of breast cancer by race 
 
In addition, genetic risk factors may vary by race. Compared to White women with breast 
cancer, African American cases are less likely to have a BRCA1 mutation (48). Furthermore, 
recent results from GWAS suggest that susceptibility loci may differ by race. Initially, many 
GWAS loci such as TERT-CLPM1L were identified in populations of European descent (33, 47, 
49). However, Zheng 2012 failed to replicate this positive association in women of African 
descent (50). In addition, GWAS studies have shown modification by race for various breast 
cancer susceptibility loci (51).  
1.4 Heterogeneity of breast cancer 
 
Research from the past decade has shown that breast cancer is a complex and 
heterogenous disease involving multiple pathways and a combination of genetic and non-genetic 
risk factors. There is evidence of heterogeneity by both hormone receptor status and more 
recently by intrinsic tumor subtype.  Historically, breast cancer tumors are classified based on 
their hormone receptor status (i.e. estrogen receptor (ER) and progesterone receptor (PR)) and 
HER2 status mainly to guide clinical treatment options (52). Endocrine therapies such as 
aromatase inhibitors were used for hormone receptor positive (ER+ and PR+) tumors, while 
therapeutics such as Herceptin were used for tumors overexpressing HER2 (52). Tumors that 
were negative for all three of these markers were classified as triple-negative and were not 
candidates for endocrine therapy targeted treatments. Several studies show risk profile 
differences between hormone-positive vs. hormone-negative tumors (53, 54).  A Carolina Breast 
Cancer Study (CBCS) report showed that several hormone-related factors were associated with 
stronger increased risks for ER+PR+ than for ER-PR- breast cancer; including early age at 
menarche,  nulliparity/late age at first full-term pregnancy or a high body mass index (BMI) 
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among postmenopausal women and high waist to hip ratio (WHR) among premenopausal 
women.  Conversely, family history and medical radiation exposure were associated with ER-
/PR- tumors (53). Prospective data from the Nurses’ Health Study confirmed significant 
differences by ER/PR status for age, menopausal status, postmenopausal BMI, adverse effect of 
first pregnancy, and past use of postmenopausal hormones (54). Additionally, risk factors 
profiles may vary by HER2/neu status. A CBCS report showed that early age at menarche, 
higher WHR, and family history of breast or ovarian cancer were associated with increased odds 
ratios (ORs) for both HER2/neu+ and HER2/neu- breast cancers while breastfeeding for more 
than a year was inversely associated (53). 
  Recent technological developments in microarray analysis have led to the molecular 
subtyping of breast cancer tumors to further discern breast cancer heterogeneity. Perou et al. used 
cDNA microarrays to measure the gene expression of more than 1700 genes. A hierarchical 
clustering algorithm identified four different patterns of gene expression in in vitro human breast 
cells and tumors: ER+/luminal, basal-like, HER2+/ER-, and normal (55, 56). In a second study 
with more samples, Perou et al. further dichotomized luminal tumors into luminal A and luminal 
B (56). In addition, Sorlie et al. was able to define these molecular types using a set of only 534 
genes (57). Nielsen et al. used immunohistochemistry to categorize molecular profiles based on a 
panel of four antibodies (ER, EGRF/HER1, HER2, and cytokeratin 5/6) and found that this 
method was equivalent to the gene expression technique (58). Carey further updated IHC 
subtype definitions to include PR status as well as dichotomize HER2 status into HER2+ or 
HER2- (59). Therefore, breast cancer tumors were classified into 4 distinct molecular subtypes: 
luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+/HER2+), HER2+/ER- (ER-, 
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PR-, HER2+), basal-like (ER-, PR-, HER2-, CK 5/6+ and/or EGFR+) and an unclassified 
category (59). 
1.4.1 Non-genetic risk factors of breast cancer by subtype 
More recently, molecular profiling of breast cancer tumors has enabled researchers to 
evaluate risk factors based on these “intrinsic” subtypes. Several studies have observed 
differences in the associations between breast cancer risk factors and subtypes of breast cancer. 
Basal-like subtype may have a different risk factor profiles compared to the luminal A subtype 
(22, 60-65).  Compared to the luminal A subtype, basal-like cases were also more likely to have 
younger age at menarche (62), younger age at first full-term pregnancy(22, 62, 66), higher parity 
(22, 62, 66, 67)  were less likely to breastfeed (22, 62, 64, 66, 67). While long term breastfeeding 
(>6 months) was inversely associated with breast cancer across subtypes, the protective effect 
was strongest for basal-like tumors (68). In addition to reproductive factors, obesity or elevated 
BMI was also associated with increased risk of basal-like breast cancer and luminal B cancers 
compared to luminal A cases, especially for premenopausal women (22, 62, 64, 66, 68). Many 
studies also reported that family history may play a bigger role for women with basal-like tumors 
compared to other subtypes, especially for premenopausal women (24, 61, 64, 69).  
 Reports from the CBCS have suggested heterogeneity among in situ tumors, Phillips et 
al. showed that many risk factors for invasive and high grade in situ tumors were similar, but 
differed from risk factors for low or medium grade in situ tumors in both strength and magnitude 
of effects. For example, higher parity showed a strong inverse association with high grade DCIS 
but had a weaker inverse association for low to medium grade DCIS. In addition, ten or more 
years of oral contraceptive showed a positive association with high-grade DCIS and IBC but an 
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inverse association for low to medium DCIS (70). In summary, there may be heterogeneity 
within in situ tumors which needs to be further investigated.  
In addition, basal-like tumors have poorer prognoses compared to luminal tumors (57, 59, 
71). Basal-like tumors showed more aggressive features compared to Luminal A, including 
higher mitotic index (P < 0.0001), higher grade (P < 0.0001), and a higher frequency of p53 
mutations (P < 0.001)(57). In situ basal-like cancers also shared similar poor clinical outcomes 
with invasive cases (72) 
Several studies have shown that basal-like tumors occur at a higher incidence among 
African-Americans compared to whites (71, 73, 74). In a study of Ghanaian women, African-
American and white women from the US, proportion of African ancestry was significantly 
associated with triple-negative tumors. Ghanaians had the highest prevalence of triple-negative 
tumors (82.2%), followed by African Americans (32.8%) and White Americans(10.2%) (75).  
1.4.2 Genetic risk factors of breast cancer by subtype 
 
Carriers of BRCA1 mutations are at higher risk of developing basal-like tumors (76-81). 
It has been estimated that 80-90% of cancers in BRCA1 mutation carriers are of basal-like 
subtype (81). Furthermore, the prevalence of BRCA1 mutation carriers in triple-negative tumors 
was approximately 20% and 11%, respectively, in two studies (79, 80). Therefore, loss of 
BRCA1 function may have an etiological role in the development of the basal-like phenotype. 
Expression microarray analyses have also indicated similarities in gene expression between 
BRCA1 cancers and sporadic basal-like cancers (82).  BRCA1-mutated and basal-like tumors 
share many similar characteristics including higher levels of genomic instability compared to 
ER+ or luminal tumors. Compared to other subtypes, basal-like tumors have the highest levels of 
genomic instability as represented by greater number of insertions, deletions and copy number 
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alterations.  At least three studies reported loss of 5q and gain of 10p in basal-like cancers (83-
85). Van Loo et al. showed that basal-like tumors were associated with low ploidy, high 
frequency of loss of heterozygosity (LOH), and the highest frequency of copy number events 
when compared to the other subtypes (86). There are also a higher number of chromosomal 
rearrangements and aneuploidy increase in defective DNA repair genes. These results provide 
evidence for both deficient DNA repair genes and basal-like breast cancer being associated with 
genomic instability.  
Recently identified breast cancer susceptibility loci in GWAS (CASP8, FGFR2, TNRC9, 
MAP3K1, LSP1, 8q24, 2q35, 5p12, 16q12) may also vary by tumor characteristics such as 
hormonal status or intrinsic subtype. Susceptibility loci in FGFR2, TNRC9, 8q24, 2q35, and 
5p12, 9q13.2 had stronger associations for estrogen receptor-positive (ER+) disease than 
estrogen receptor-negative (ER-) disease (51, 87-89). Two candidate loci in CASP8 (rs1045485, 
rs17468277) and TGFB1 (rs1982073), were strongly associated with the risk of PR- tumors and 
16q12 and 2q35 were associated with basal-like subtype (87). 
A common variant at the TERT-CLPTM1L locus was also found to be associated with 
estrogen receptor-negative breast cancer (90). Of note, this locus was not replicated in women 
with African ancestry (91). In a recent population-based case-control study, Domagala et al. 
found several CHEK2 mutations associated with different molecular subtypes of breast cancer. 
Truncating mutations were associated with luminal B, and I157T CHEK2 mutation was 
associated with luminal A. (92, 93). The GWAS discovery of a novel locus 19p13 was shown to 
both modify risk of breast cancer in BRCA1 mutation carriers as well as in hormone receptor 
negative and triple negative cases in the general population (32, 33, 43). In the CIMBA study, 
analyses based on tumor histopathology showed that 19p13 variants were associated with ER- 
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breast cancer for both BRCA1/2 mutation carriers (32, 33). Results from the Breast Cancer 
Association Consortium (BCAC) further showed that 19p13 was associated with triple negative 
subtype (43).  MERIT40 interacts with BRCA1 and plays a role in the repair of double-strand 
break in the HR pathway. These results provide evidence that DNA repair may vary by breast 
cancer tumor subtype.  
1.4.3 Summary of breast cancer risk factors 
Breast cancer is a multifactorial disease, which results from the combined effect of 
genetic and non-genetic risk factors that can vary by both race and subtype. Linkage association 
studies were the first to hint at a genetic component underlying familial breast cancer. 
Furthermore, women with a first degree family history of breast cancer were found to be at 
almost twice the risk as women without a family history (10).  Therefore, a positive family 
history of breast cancer may serve as a surrogate for shared genetic variation (94).  
1.5 Variation in DNA repair capacity 
The discovery of mutations in BRCA1 in the early 1990s offered insight into the genetic 
etiology of familial breast cancer. Carriers of BRCA 1/2 mutations were found to have deficient 
DNA repair capacity (DRC) compared to normal controls (95). Experimental studies showed that 
the near complete loss of DNA repair capacity can lead to genetic instability and a high risk of 
developing cancer (96). However the prevalence of BRCA1 mutations and mutations in other 
moderate to high penetrant DNA repair genes such as BRCA2, ATM, CHEK2, PTEN, BRIP1, and 
PALP2 are rare in the general population and only explain 15-20% of genetic susceptibility to 
breast cancer (25, 97-99).  
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1.5.1 Low-penetrant common DNA repair variation in breast cancer  
 
The polygenic model of cancer was proposed to explain the missing heritability (100, 
101). Under this model, a combination of multiple low penetrance genes would contribute to 
overall genetic risk. There is increasing evidence that mild reductions in DNA repair capacity, 
assumed to be the consequence of common genetic variation, can also affect breast cancer 
susceptibility. The extensive variation in the coding regions of DNA repair genes and the large 
number of genes in each DNA pathway results in complex genotypes with potential to impact 
cancer risk in the general population (94, 102). In our proposed study, we focused our 
investigation on these variants in common, low-penetrant DNA repair variants to evaluate their 
potential association with breast cancer.   
1.6 DNA damage responses   
 
The combination of endogenous and exogenous sources of DNA damage can result in as 
many as one million DNA lesions per cell per day (103).  Endogenous sources include 
replication errors and spontaneous reactions, while exogenous sources of DNA damage include 
X-rays, oxygen radicals, alkylating agents, UV light, polycyclic aromatic hydrocarbons (PAHs), 
IR, and anti-tumor agents. Unrepaired DNA damage can result in gene mutations such as point 
mutations, deletions and insertions as well as chromosomal alterations such as chromosomal 
rearrangements and aneuploidy. In order to maintain genomic stability, organisms have evolved 
a complex series of damage repair responses to process DNA damage in a timely and efficient 
manner including 1) apoptosis, 2) checkpoint signaling 3) DNA repair and 4) damage tolerance 
(Figure 3). The proposed study will focus on the latter two mechanisms, specifically base 
excision repair and translesion synthesis. 
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1.6.1 Overview of DNA repair  
 
DNA repair mechanisms protect somatic cells from mutations in tumor suppressor genes 
and oncogenes that can lead to cancer initiation and progression. Over the course of evolution, 
cells have evolved several DNA repair pathways for repairing distinct types of DNA damage. 
Specialized DNA repair pathways include direct reversal repair, mismatch repair (MMR), base 
excision repair (BER), nucleotide excision repair (NER), and recombinational repair 
(homologous recombination (HR) and non-homologous end-joining (NHEJ) (104). Figure 4 
summarizes the source of DNA damage, the ensuing DNA lesion, and the DNA repair pathway 
used to repair the lesion. Functional DNA repair plays an important role in tumor suppression. 
There have been dozens of epidemiological studies examining common variation in multiple 
DNA repair pathway. The focus of this study will be on single nucleotide polymorphisms (SNPs) 
in the BER pathway.   
1.6.2 Overview of base excision repair (BER)  
 
Base excision repair (BER) is the fundamental pathway responsible for the repair of 
damaged DNA bases induced by various sources of endogenous and exogenous damage. BER is 
specialized to repair non-bulky DNA base lesions such as base adducts and abasic sites caused 
by deamination, alkylation, or oxidation.  The repair process consists of five enzymatic steps: 1) 
cleavage of the sugar-phosphate chain, 2) excision of the abasic (AP) site, 3) removal of the 
remaining sugar-phosphate chain, 4) DNA synthesis, and 5) ligation (105). Table 1 summarizes 
BER genes and their functions in DNA repair.   
To date, there are at least 11 known human DNA glycosylases.  DNA glycosylases play 
an important role in the initial recognition of a lesion and recruitment to the site of the damage 
(106). Different glycosylases are specialized for different lesions and some glycosylases may 
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recognize more than one substrate (Table 2).  DNA glycosylases initiate repair by releasing the 
modified/damaged base out of the double helix and cleaving the N-glycosidic bond of the 
damaged base, resulting in an apurinic/ apyrimidinic (AP) site. The location and type of the AP 
site can also be determining factors on which glycosylase is recruited to the site (107, 108). If the 
AP site was created by a glycosylase that does not possess AP lyase activity (UNG, SMUG1, 
TDG, MPG, MDB4, MYH), or NTH1 and OGG1, repair of the AP site is APE1-dependent. A 
newly discovered family of glycosylases (NEIL1, NEIL2, and NEIL3) was shown to efficiently 
repair AP site independently from APE1 (107, 109, 110).  
The repair of AP sites is crucial since they can interrupt normal DNA replication, and 
become a threat to genomic integrity.  APE1 or a member of the NEIL family converts the lesion 
into a single-strand break (SSB). The SSB requires removal of the altered 3′-terminal groups 
prior to ligation.  After removal of obstructive termini, replacement of the excised nucleotide can 
be completed either via short-patch where a single nucleotide is replaced or long-patch BER 
where 2-10 new nucleotides are synthesized (111). Choice of pathway depends on several 
different factors including the type of lesion, the cell cycle stage, and whether the cell is 
terminally differentiated or actively dividing (112).  The short-patch pathway requires a different 
set of genes from the long-patch pathway (111, 113). The main distinction is whether the abasic 
sugar is oxidized or reduced, which dictates if POLB is involved (short-patch) or not (long-
patch) (114). 
 Finally, the posttranslational modification of proteins is mediated by poly (ADP ribose) 
polymerases (PARPs). Members of the PARP family (PARP1, PARP2, and PARP3) catalyze the 
transfer and polymerization of ADP ribose (115). RFC1 loads the PCNA clamp onto DNA, 
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thereby recruiting DNA polymerases to the site of DNA synthesis to the 3’ end of primer, 
promoting DNA synthesis (116, 117). 
1.6.2.1 Base excision repair and breast cancer 
 
It has been proposed that base excision repair may be involved in tumor suppression 
(118, 119).  Experimental studies have demonstrated that deletion of certain BER genes is 
associated with an increased mutation rate in a variety of organisms, and hypothesize that this 
loss could contribute to the development of cancer in humans (105). In addition, several dozen 
case-control genetic association studies have been conducted (Table 3).The following section 
summarizes the experimental and epidemiologic literature for the association between base 
excision repair and breast cancer.  
 
1.6.2.1.1 UNG  
 
While no variants have been associated with breast cancer, two novel SNPs (UNG 
Arg88Cys and UNG Gly143Arg) have been identified using mutational analysis in colorectal 
cancer and glioblastoma cell lines, respectively (106, 120). In an in vivo study, knockout of the 
UNG gene led to carcinogenesis in mice. Older (>18 months) UNG knockout mice developed B 
cell lymphomas compared with only 1.3% of control animals (121).  
1.6.2.1.2  SMUG1  
 
In a 2011 Western New York Exposures and Breast Cancer (WEB) report (1,077 cases, 
1,910 matched controls),  two polymorphisms in the SMUG1 promoter region (rs2029166 and 
rs7296239) were found to moderately effect the risk of breast cancer in heterozygotes (OR=1.3, 
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95% CI: 1.1-1.5)(122). Another study examined the association between SMUG1 variants and 
uracil blood concentration in 431 participants from the Boston Puerto Rican Health Study and 
found a significant association with the SNPs studied. Increased level of uracil misincorporation 
may induce mutagenic lesions and possibly lead to increased cancer risk (123).  
1.6.2.1.3 MBD 
 
Frameshift mutations in MBD4 have been associated with gastrointestinal cancers in two 
Asian study populations (124, 125). The Glu346Lys polymorphism has been associated with 
lung, esophageal, and gastrointestinal cancers (125-127). To our knowledge, there are no 
experimental or epidemiologic studies investigating genetic variants of MBD4/MED1 with breast 
cancer risk.  
1.6.2.1.4 MPG  
 
Based on the literature, there are no known experimental or epidemiologic studies 
associating genetic variants of MPG with breast cancer risk. Three laboratory studies reported 
altered expression of MPG in human gonad cells and astrocytic tumors (128-130). 
1.6.2.1.5 MYH/MUYTH  
 
Mutations in the MUYTH gene result in MAP (MUTYH-associated polyposis) a heritable 
predisposition to colorectal tumors (131, 132). While a Dutch study initially reported increased 
mutation frequency of several MUTYH SNPs among women of families with HBCC (Hereditary 
Breast and Colon Cancer) (133), a validation study failed to replicate these results in a larger 
case-control study (132). In a Chinese case-control study (545 cases, 545 controls), there were no 
associations with breast cancer overall, but the dominant model for AluYb8 insertion was 
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significantly associated with increased risk of early-onset breast cancer (<55 years old) 
OR=1.51: 95% CI: 1.09-208) (134).  
 
1.6.2.1.6 TDG  
 
Polymorphisms G199S and V367M are the most common genetic polymorphisms in 
human TDG. A recent Polish study revealed a possible association with these TDG 
polymorphisms and lung cancer however these results may be biased due to small sample size 
(135). Further studies are needed to fully understand the relationship between TDG and cancer.  
1.6.2.1.7 OGG1  
 
Functional lab evidence has suggested that rs1052133 (S326C) in OGG1 may be 
associated with decreased DNA glycosylase activity in the repair of 8-oxoG, a mutagenic 
byproduct of exposure to reactive oxygen (136). However, the results from epidemiological 
studies have been less conclusive. At least six independent epidemiologic studies have evaluated 
the association between the S326C polymorphism with breast cancer risk (137-142). Two reports 
suggested an increased risk for S326C (137, 138) while two reports failed to find any significant 
association (141, 143). An earlier review by Goode had identified S326C as being associated 
with increased breast risk (144), however two recent meta-analyses were not able to replicate this 
finding (145, 146). In a review of 14 functional studies and 19 epidemiological studies, Weiss et 
al. found no significant association between the OGG1 polymorphism and breast cancer (146). A 
recent case-control study in China (518 cases, 777 controls) showed two functional variations in 
5'-UTR of OGG1 gene were significantly associated with the risk of breast cancer (OR=2.0 95% 
CI: 1.0-3.9 and OR=2.4 95% CI: 1.2-5.0) (147).  
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1.6.2.1.8 NEIL1  
 
In experimental studies, NEIL1 have been shown to interact with other BER genes 
including POLB, LIG3, and PCNA (109, 148). In an in vitro study, NEIL1 downregulation 
enhanced spontaneous mutation by three-fold in Chinese hamster and human cell lines (149). To 
our knowledge, no epidemiologic studies have been conducted. 
1.6.2.1.9 NEIL2  
 
NEIL2 was shown to interact with POLB and LIG3 (109, 110, 150). Variant risk 
genotypes in NEIL2 have been associated with increased risk in SCCOOP (head and neck 
cancers) and lung cancers (151, 152). In an in vivo study, NEIL2 expression was significantly 
reduced by over 50% in the presence of 2 SNPs (rs74800505 and rs8191518) which were in 
significant LD (153).  NEIL2 rs6982453 was associated with a significantly protective effect in 
breast cancer in the Multiethnic Cohort Study (OR=0.86, 95% CI: 0.79-0.94, p<0.001) (154). 
1.6.2.1.10 APE1  
 
A number of functional polymorphisms have been identified in APE1 with the most 
commonly studied SNP being APE1 Asp148Glu (155). This polymorphism has been associated 
with risk of bladder, lung, prostate and gastric cancers (156-159). Overexpression of APE1 has 
been linked to chemotherapy and radiation therapy resistance (160). However the epidemiologic 
evidence for APE1 and risk of breast cancer is inconclusive. While two case-control studies 
reported a borderline significant protective association for carriers of heterozygous variant 
(Asp/Glu) in Thai and White American women respectively (138, 161), two other reports found 
null associations for African American and White American women respectively (143, 161). A 
meta-analysis of 8 studies did not reveal any significant association for APE1 Asp148Glu for any 
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genetic models (162). However, a recent lab study has linked deregulation of APE1 acetylation 
to triple negative breast cancer (163). 
1.6.2.1.11 POLB  
 
DNA polymerase beta or POLB has been shown to be overexpressed in several cancers 
(164-166). Seven germline mutations (P242R, E295K, G231D, K289M, E232K, T233I) have 
been identified in POLB (167). In an in vitro study, Yamtich et al. 2012 found that expression of 
these variant germline SNPs could be related to increased cancer susceptibility following 
treatment with an alkylating agent (165). Gieseking also identified two POLB SNPs (E232K and 
T233I) to be associated with lower fidelity when processing undamaged DNA, which may lead 
to mutagenesis (168).Estimates of somatic mutations in Pol β range from 15% to 75% of tumors 
in various types of cancer (169, 170). Functional analyses have implicated many of these variants 
in cancer etiology and/or progression (170-173). An in vivo study showed that overexpression of 
POLB variants in mouse cells resulted in cellular transformation. Furthermore, knockout of 
POLB caused embryonic lethality. While there have been no positive associations between 
POLB and breast cancer, there have been multiple reports suggesting POLB involvement in lung 
and colorectal cancers in other epidemiological studies (174-176)  
1.6.2.1.12 XRCC1  
While the majority of studies did not find any significant associations (177-183), the 
XRCC1 Arg399Gln polymorphism was associated with a protective effect in one report (184) 
and an increased risk in seven other reports (105, 138, 139, 185-188). We suspect that these 
significant positive findings were mostly false positives due to study design and low power 
issues. Several of these studies had smaller sample sizes which may not have had adequate 
power to detect modest SNP effects. This was evidenced by wide confidence intervals or high 
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CLR indicating imprecise estimates in several studies (138, 139, 186, 187, 189, 190). In addition, 
results may be biased due to selection of controls (i.e. hospital-based controls (189) or cases (i.e. 
cases selected for family history) (184). Alternatively, since the majority of significant findings 
were from studies in Asian populations, there is the possibility of effect modification by Asian 
race/ethnicity. At least four independent meta-analyses of XRCC1 Arg399Gln have provided 
evidence for this theory (143, 191-193). Additionally, two U.S.-based population-based case-
controls studies found no overall associations, but showed subgroup effects for African-
American and postmenopausal women in the CBCS and WEB study, respectively (92, 137). 
While no significant associations were observed in premenopausal women, postmenopausal 
women with any Gln variant had increased risk of breast cancer (OR = 1.24; 95% CI: 1.01-1.51) 
(137). Duell found a similar increased risk for African-Americans in the CBCS (OR=1.5 95% 
CI: 1.1-2.3) (92). 
Two reports found an increased risk for at least one variant of XRCC1 Arg194Trp (161, 
189), while another report did not (92).  In a meta-analysis of 11 studies including both White 
and Asian populations, Zhang found no association between Arg194Trp and breast cancer risk 
(143). 
The majority of these studies reported no association with XRCC1 Arg280His with the 
exception of one population-based case-control study of women from Cyprus. Loizidou et al. 
found homozygous carriers of XRCC1 280His to have an increased risk of breast cancer 
(OR=4.7; 95% CI: 1.0-21.7, P=0.03). Although this study contained 1,109 cases and 1,177 
controls, a highly imprecise estimate was reported (194). The authors reported that this SNP 
failed HWE (p<0.05) which may indicate genotyping error. Meta-analyses of XRCC1 Arg280His 
have yielded conflicting results. While Hung did not find any association between cancer risk 
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and the XRCC1 Arg280His SNP, two other meta-analyses reported an overall increase risk of 
cancer for the variant genotypes (His/His + Arg/His) compared with the wild-type homozygote 
genotype (Arg/Arg) (191, 195). 
1.6.2.1.13 LIG3  
 
Knockout of LIG3 are embryonic lethal in mice (196). However, to our knowledge, there 
are no known LIG3 SNPs that have been studied for association with cancer in the epidemiologic 
study literature (114). 
1.6.2.1.14 FEN1  
 
FEN1 was significantly upregulated and aberrant expression was associated with 
promoter hypomethylation in breast cancer cells in a gene expression study of 241 matched pairs 
of cancer and normal tissues (197).  
1.6.2.1.15 PARP1  
 
PARP1 has been shown to inhibit DNA repair in both the short and long patch pathways 
(198, 199). Conversely, cells deficient in PARP1 show increased rates of repair (198). Bieche 
and colleagues reported overexpression of PARP1 and low genomic instability in a study of 
breast cancer cells (200). In another study, inhibition of PARP1 was shown in tumors from 
BRCA mutation carriers (201). However, a recent meta-analysis of 8 studies did not show an 
association between PARP1 V762A and breast cancer (162).  
In a lab-based study, PARP1-deficient cells were assessed for their capacity to repair AP 
sites induced by uracil or 8-oxoguanine. For both DNA lesions, PARP1-deficient cells were 
about half as efficient as wild-type cells for short-patch repair synthesis, and were highly 
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inefficient in the long-patch repair pathway. Inefficient BER occurred when both PARP1 and 
POLB were absent (199).  
In a subset of Nurses’ Health Study II cohort (NHS II), Han 2009 found PARP1 
rs10915985 to be significantly associated with premenopausal breast cancer in the additive 
model (OR=1.31, 95% CI: 1.04-1.64), however this SNP was not genotyped in CBCS (202).  
1.6.2.1.16 PCNA 
 
Several yeast models have associated PCNA mutations with cancer and genomic 
instability (203). In addition, Ma and colleagues sequenced the coding region and adjacent 
noncoding region of PCNA in 60 individuals and identified 9 sequence variants, including 7 
SNPs which were located in introns involved in the control of PCNA gene expression.  Results 
from the analyses showed no associations with melanoma, breast cancer or lung cancer 
compared with healthy controls (204). 
1.6.2.1.17 RFC1  
  
Experimental studies in have shown RFC1 to function in both DNA replication and 
repair, specifically NER (116, 205).  Replication factor C (RFC) is a five-subunit DNA 
polymerase accessory protein that functions as a structure-specific, DNA-dependent 
ATPase. RFC acts as a sensor in the DNA damage checkpoint pathway and plays a role in DNA 
synthesis. To our knowledge, we are not aware of any epidemiologic studies examing RFC1 
variants. 
1.6.2.2 Critique and Summary of BER literature 
 
Despite the strong associations of BRCA1 and BRCA2 and moderate penetrant genes such 
as CHEK, PALB, and ATM with breast cancer risk, the risks conferred by individual low 
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penetrant BER genes for breast cancer have been underwhelming and attempts to understand the 
contribution of low penetrant SNPs has been challenging. To date, there have been dozens of 
population-based case-control genetic studies, including the Carolina Breast Cancer Study 
(CBCS), that have investigated the association between common genetic variation in BER genes 
(XRCC1, OGG1, APE1, NEIL1 and NEIL2) and breast cancer risk  (92, 143, 182, 184, 189, 206-
208). Most studies examined BER SNPs in the XRCC1, APE1, and OGG1 genes. While the 
majority of studies of White women showed no significant associations with XRCC1 SNPs 
(rs1799782, rs25489, and rs25487), several studies in non-White populations indicated potential 
effect modification by race/ethnicity for rs25487, Arg399Gln.The evidence for OGG1 
Ser326Cys and APE1 Asp148Glu polymorphism and breast cancer risk was null to weak (137, 
138, 141-143). Additionally, findings from other BER SNPs studies have been inconclusive.  
This failure to reveal significant associations between individual BER SNPs and breast 
cancer is not surprising, given that carcinogenesis is a multistep, multi-genic process. Therefore 
it is plausible that any one single genetic polymorphism would not have a dramatic effect on 
cancer risk. Interaction between multiple common low-penetrant SNPs may be needed to 
produce a significant effect. The polygenic model of cancer posits that although the risks 
conferred by an individual locus are small, some risks may act multiplicatively or additively. In 
this model, each variant is only one of the many genetic and environmental causal factors, each 
of which are neither necessary nor sufficient to individually cause the disease. Therefore, 
accumulation of mutations may be more important than a single SNP mutation (209).  
 Supporting evidence for the polygenic or multi-SNP effect in DNA repair is abundant. 
Despite not finding main effects, many DNA repair studies have found significant multi-SNP 
effects. As an example, Harlid et al. 2012 examined the individual and joint effects between 10 
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GWAS-validated breast cancer SNPs in a large European biobank-based study (3,584 cases, 
5063 controls) and found a highly significant trend for increasing breast cancer risk with 
increasing number of previously validated risk alleles (p-trend 5.6 x 10
-20
) and for the maximum 
versus the minimum number of risk alleles (OR=1.84, 95% CI: 1.59-2.14) (210). 
 Recent studies have used hierarchical modeling and other multi-SNP methods to evaluate 
cancer risk at a gene or pathway level in various cancers (158, 211, 212). For breast cancer, two 
reports from the Cancer Genetic Markers of Susceptibility (CGEMS) Project, a study nested 
within the Nurses’ Health Study, evaluated the combined effects of low-penetrant SNPs in 
multiple DNA repair pathways using Admixture Maximum Likelihood (AML) and Kernel 
machine tests (202, 213). Han 2009 found several significant main effects for SNPs in PARP1, 
NEIL2, APE1, and POLD for premenopausal women (p<0.05)(202), while a second report failed 
to replicate any of this findings in postmenopausal women (213). 
Another potential theory relates to the functional redundancy of genes to maintain 
genomic stability. For example, in mouse models, knockouts of core BER proteins such as 
XRCC1, POLB, APE1, and FEN1 all result in embryonic lethality (214-217). Furthermore, the 
coding regions of PCNA and FEN1 are highly conserved (204). On the other hand, for DNA 
glycosylases with multiple redundant pathways, there are no obvious phenotypes in nullizygous 
mice lacking a single oxidative DNA glycosylase. Studies of double knockout mice have shown 
they are prone to tumorigenesis.  Chan et al. showed that targeted deletion of NTH and NEIL1 
resulted in mice with a higher frequency of lung and liver tumors compared to single knockout 
mice (218). In another experimental study, knockout of MYH or OGG1 individually showed very 
little effect, however MYH/OGG1 double mutant mice showed high susceptibility to tumor 
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formation (219). These studies suggest functional redundancy of DNA glycosylases and 
highlight the integral role of BER genes to preserve genomic integrity. 
1.6.3 Overview of DNA tolerance   
 
The process of maintaining accurate DNA replication is essential to the genomic stability 
of all cells. In the event that DNA damage should escape repair surveillance prior to initiation of 
DNA replication, organisms have evolved a series of tolerance mechanisms for allowing 
replication and cell division to process.   
The first step in DNA replication involves the unwinding of DNA at the origin. The 
replication fork is a structure that forms within the nucleus during DNA replication. It is created 
by helicases, which break the hydrogen bonds holding the two DNA strands together. The 
resulting structure has two branches, each one made up of a single strand of DNA. These two 
strands serve as the template for the leading and lagging strands, which will be created as DNA 
polymerases match complementary nucleotides to the templates. The leading strand is 
synthesized continuously in the direction of replication fork, 5’ to 3’, while the lagging strand is 
synthesized in small pieces (Okazaki fragments) backward from the overall direction of 
replication (220, 221). Several DNA polymerases are involved in DNA replication.  DNA 
polymerase alpha initiates DNA synthesis on both the leading and lagging strands providing an 
RNA primer and synthesizing approximately 20-30 bases of DNA. Pol epsilon (POLE) and pol 
delta (POLD2) elongate these primers created by pol alpha (222). PCNA is the sliding clamp for 
POLD1 and POLE (223). POLD1 and POLE also possess proofreading 3’-5’ exonuclease 
activity that is important in preventing mutations. 
DNA replicative polymerases, such as pol alpha, pol epsilon (POLE), and pol delta 
(POLD) which carry out the bulk of DNA synthesis, have evolved to be very precise and 
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efficient, with an estimated error rate of 1 in 10 billion base pairs (224). Despite this high 
fidelity, a replication error may generate a one-sided double-strand break (DSB) or degrade to a 
full DSB if it not repaired prior to initiation of DNA replication (225, 226). In order to resume 
DNA replication at a stalled replication fork, two damage tolerance mechanisms have been 
proposed; template switching in homologous recombination (HR) and translesion synthesis 
(TLS) (227).  Posttranslational modification of PCNA by ubiquitin may play a role in 
determining which DNA repair tolerance mechanism to employ. Studies showed that the mono-
ubiquitylation of PCNA may activate translesion synthesis by damage-tolerant DNA 
polymerases, while poly-ubiquitylation of PCNA may activate error-free pathway involving 
template switching in HR (228-231). During template switching in HR, although normal 
synthesis of DNA is blocked by a lesion on one of the template strands, synthesis on the 
undamaged template strands can continue to a limited extent. The newly synthesized daughter 
strand is used as the template, hence the term “template switching”. If template switching is 
unsuccessful, translesion synthesis is activated to bypass the lesion (119, 222, 227). 
1.6.4 Overview of translesion synthesis (TLS)  
 
The focus of this study will be on the second DNA tolerance mechanism: translesion 
synthesis (TLS). Translesion synthesis is conducted by a specialized type of DNA polymerases. 
Aptly named, bypass polymerases do not directly repair the damage, but rather bypass or tolerate 
the damage to prevent replication fork stalling. Unlike replicative polymerases, bypass 
polymerases lack 3' to 5' exonuclease (proofreading) activity and are able resume replication 
without an undamaged template (232, 233). However, this also contributes to their low fidelity 
and potential mis-incorporation of nucleotides (234).  
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 Evidence from experimental studies shows bypass polymerases as being both efficient 
and mutagenic. The ability of DNA bypass polymerases to bypass DNA lesions was first 
described in yeast. Nelson and colleagues found that REV3L (pol zeta) successfully mediated the 
bypass of UV-induced thymine-thymine cyclobutane pyrimidine dimers (TT-CPDs) and REV1 
was able to insert deoxycytidine monophosphate (dCMPs) opposite abasic sites (235, 236). 
These findings were subsequently followed by the discovery of UV lesion bypass activity of 
human pol-eta, which was shown to be defective in a group of xeroderma pigmentosum (XP) 
patients (237, 238).    
 Reduced fidelity of DNA bypass polymerases may be dependent on a number of factors 
including physical structure, location within the cell cycle, and type of lesion. All DNA 
polymerases possess a “right hand-like” structure, which share three common domains (palm, 
thumb, and little fingers). However, differences in the active sites between family members may 
contribute to the low fidelity of these proteins (239-241). The discovery of the crystal structures 
of several Y-family DNA polymerases have implicated that more open active sites may be the 
reason for the error propensity of low-fidelity polymerases (242).  
The level of fidelity of bypass polymerases has also been shown to be lesion specific. 
Different lesions are bypassed in an efficient or mutagenic manner depending on the bypass 
polymerases involved (Table 4). Experimental studies have suggested the “two-step two-
polymerase model”, in which one bypass polymerase initiates insertion while a second extends 
past the lesion (243) For example, members of the Y family DNA bypass polymerases (POLH, 
POLI, POLK) bypasses the lesion while pol zeta (REV3L) allows the cell to continue replication 
past the lesion (233, 243, 244). In a yeast cell line study, AP sites were bypassed by POLH with 
assistance from REV3 for DNA extension (245). Another study provided evidence for a similar 
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process between POLI and REV3L (233). In an in vitro study conducted by Seki et al., although 
POLQ was unable to bypass a cyclobutane pyrimidine dimer or a (6-4) photoproduct alone, 
when combined with POLI it could successfully insert a base opposite a UV-induced (6-4) 
photoproduct and complete bypass (246). The experimental evidence reveals a comprehensive 
system of functionally redundant genes that are specialized to bypass several types of DNA 
lesions.  
1.6.4.1 DNA bypass polymerases and cancer 
  
As opposed to the extensive literature on DNA repair genes and mechanisms and cancer, 
less is known about bypass polymerases and their potential role in cancer. To date, there have 
been at least 15 different DNA polymerases identified in humans, which are specialized for 
replication, repair or the tolerance of DNA damage. The focus of the second aim of this study 
will be on DNA bypass polymerases, POLI, POLH, REV1, POLL, POLM and REV3L. Given 
their intrinsic nature of reduced fidelity and mutagenic potential in the repair of certain DNA 
lesions, several DNA bypass polymerases are suspected to be involved in cancer risk. It has been 
proposed that point mutations may arise from the error-generating activities of DNA bypass 
polymerases which may lead to carcinogenesis. However, a second perspective considers 
efficient bypass polymerases as maintaining genomic integrity. That is, DNA bypass 
polymerases may defend against chromosome instability in cells. At least one DNA bypass 
polymerase, REV3L (pol zeta), has been identified as a suppressor of spontaneous tumorigenesis 
(247). 
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1.6.4.1.1 POLH  
 
POLH is a member of the Y Family that encodes the protein pol eta. The identification of 
mutations in POLH in xeroderma pigmentosum (XP) cells marked one of the first links between 
bypass polymerases and cancer (248, 249). Other studies have also confirmed that the loss of 
functional POLH increases sensitivity to UV radiation and also increases the risk of xeroderma 
pigmentosum, a rare type of skin cancer (225, 250). McGregor and colleagues reported that the 
frequency of UV-radiation induced mutations in the XPV cells was significantly higher than 
those in normal cells (251). Using a knockdown approach, Albertella et al. showed that inhibited 
expression of POLH was associated with a 3.6 fold increased mutation frequency when 
compared to control cells (250). Glick et al. failed to find POLH mutations in XP patients (252).  
However, as a result of functional redundancy in TLS, XPV patients that are unable to bypass 
across CPD due to a mutated POLH gene may be able to bypass the lesion through an alternate 
but more error-prone mechanism using POLI or POLK for insertion and REV3 for extension 
around the CPD (243).  
Mutations in POLH may also cause arrest of DNA replication at sites of DNA damage 
(225, 233, 238). Cleaver et al. demonstrated that XP variants cells lacking POLH exhibited 
stalling at the S phase checkpoint following UV damage (225). POLH physically interacts with 
PCNA-binding motifs at oxidative DNA damage sites (230).Two independent studies found 
somatic POLH mutation (G153D) in 2-9% of breast tumors (253) 
 
 
 
 31 
 
 
1.6.4.1.2 POLI  
 
POLI is another member of the Y family DNA bypass polymerases that encodes the 
protein pol iota. It may be associated with increased spontaneous mutagenesis during DNA 
replication. In an in vitro study of breast cancer cells, Yang and colleagues found that POLI 
expression was elevated and correlated with a significant decrease in DNA synthesis fidelity 
(254).  
1.6.4.1.3 REV1 
 
While REV1 has restricted DNA polymerase activity, its main function is to serve as a 
scaffolding protein that recruits and coordinates other DNA bypass polymerases (POLI, POLH, 
POLK, REV3L) to the site of the lesion (255-257). In addition, REV1 is able to insert 
deoxycytidine monophosphate (dCMPs) opposite abasic sites (255).  
REV1 has been implicated in cancer in several experimental and epidemiologic studies. 
Lawrence et al. showed that REV1 contributed to 98% of all base pair substitution errors and 
90% of frameshift mutations induced by UV damage in yeast cells (258). A few studies have 
also linked mutations in REV1 to lung and cervical cancer (259). REV1 mutants show decreased 
spontaneous and induced mutagenesis by DNA-damaging agents. In an in vitro study, Clark et 
al. demonstrated that reduced levels of REV1 were associated with a 75% reduction in UV-
induced mutations (260). 
1.6.4.1.4 POLQ  
 
             POLQ is a member of the A Family that encodes the protein polymerase theta. The high 
error rate for POLQ is closely related to Family Y polymerases (238).   Most recently, POLQ has 
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been implicated in breast cancer. In a study conducted by Lemee 2010, levels of POLQ were 
upregulated in breast cancer cells (261). Another study also found elevated levels of POLQ 
expression compared to normal cells (222). Higgins et al. linked this overexpression of POLQ to 
poor prognosis in early breast cancer patients (262). Recently, POLQ was implicated as being 
involved in BER. POLQ-deficient mutants exhibit hypersensitivity to oxidative base damage 
induced by H2O2 (263).   
1.6.4.1.5 REV3L 
 
REV3L or pol zeta is a member of the B family. The ability to bypass DNA lesions was 
first discovered in yeast when REV3 was shown to bypass UV-induced thymine-thymine 
cyclobutane pyrimidine dimers (TT-CPD)(264). Deletion mutation or loss of REV3 may enhance 
spontaneous tumorigenesis (247, 265).  In a mouse model, Wittschieben and colleagues showed 
that REV3L-deficient cells had enhanced tumorigenesis in mammary cells (247). In another lab-
based study, Stone et al. compared wildtype and mutated REV3 and found that yeast strains with 
the variant allele were more prone to mutagenic bypass (266). These results corroborate the role 
of REV3L as an inhibitor of spontaneous tumorigenesis. 
1.6.4.1.6 POLL  
  
POLL is a member of the X Family that encodes the protein polymerase lambda. POLL is 
thought to have dual functions in TLS and BER (267-269). POLL shares homology with POLB 
(270, 271) which may explain its role as a backup polymerase for POLB.  Auofouchi 2000 
showed that mRNA expression of POLL is downregulated when treated with DNA damaging 
agents such as UV light or H2O2. A novel nonsynonymous SNP (Arg438Trp) was shown to have 
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reduced base substitution fidelity in in vitro activity assays and increased mutation frequency in 
mammalian cells (272).   
1.6.4.2 Critique and summary of bypass polymerase literature 
 
While other DNA repair pathway genes have been studied extensively in breast cancer, 
the focus on DNA bypass polymerases is relatively recent. The discovery of germline mutations 
in POLH in patients with Xeroderma pigmentosum (XP), a rare form of skin cancer, was the first 
evidence that bypass polymerases may be involved in human cancer (249). However, the 
literature on bypass polymerases and breast cancer is sparse. We identified four experimental 
studies (166, 254, 261, 273) and two epidemiologic reports from the NHS (Nurses’ Health 
Study) (202, 213). In an in vitro study of breast cancer cells, Yang et al. reported elevated POLI 
expression (254).  Wang et al. found POLB overexpression in several cancer cell lines and 
tumors (166).  Finally, POLQ overexpression in tumors was associated with poor prognosis of 
breast cancer (261, 273).  
1.6 Conclusions  
 
The overall BER DNA repair literature does not provide conclusive evidence for single 
common genetic polymorphisms (SNPs) as contributing to breast cancer risk. However, we 
propose there are several potential explanations for the observed lack of significant main SNP 
effects in BER. First, many genetic association studies may have been underpowered to detect 
modest effects in common low-penetrant SNPs, yielding false positive results. Second, several 
studies showed increasing risk with increasing number of SNPs or combined SNP effects, which 
may concur with the polygenic model. Third, several studies suggested subgroup effects by 
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race/ethnicity. Finally, other redundant DNA damage response mechanisms may be involved in 
maintaining genomic stability.  
Researchers have identified at least 15 different DNA polymerases in humans which are 
essential for DNA replication, DNA repair and the tolerance of DNA damage. DNA bypass 
polymerases are key players in translesion synthesis (TLS) that serve as a backup if other DNA 
repair mechanisms fail. While bypass polymerases do not directly repair the damage, they 
tolerate or bypass the damage and prevent replication fork stalling, sparing the cell from going 
into apoptosis or DNA damage induced mutagenesis. Both in vitro and in vivo studies have 
shown that DNA bypass polymerases can efficiently bypass lesions that were not properly 
repaired by the classical DNA repair pathways. However, these bypass polymerases may also 
induce mutations due to their low fidelity. To further clarify their roles, we propose investigating 
the role of these bypass polymerases in breast cancer. 
Although we have identified many of the genetic and environmental risk factors of breast 
cancer, there are still other (genetic) factors yet to be identified to account for the missing 
heritability of the disease. In this proposed study, we seek to identify SNPs in DNA damage 
response pathways that may be associated with breast cancer and breast cancer subtype. We 
propose a candidate pathway approach to evaluating the SNPs effects of bypass polymerases in 
breast cancer. These bypass polymerase genes have yet to be fully explored in epidemiological 
studies of breast cancer. Only two recent reports from the NHS II have explored the association 
between DNA bypass polymerases SNPs within breast cancer (202, 213). Therefore, additional 
studies exploring these associations are needed. This current study proposes using data from the 
Carolina Breast Cancer Study, a large racially diverse study population of women with breast 
cancer, to further elucidate the role of bypass polymerases genes and base excision repair genes 
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in breast cancer by race and subtype. We will also conduct pathway-based analyses to assess 
combined SNP effects. 
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Table 1. Functions of BER genes 
 
 
 
DNA glycolyases Type of base damage Function References
Monofunctional glycolyases
UNG Deamination removes uracil from DNA Broderick 2006, Moon 1998, Nilsen 2003
TDG Deamination removes thymine moieties from G/T 
mismatches, C/T and T/T mismatches, 
removes uracil and 5-bromouracil from 
mismatches with G
Visnas 2008, Hardeland 2001
SMUG1 Deamination removes uracil from DNA Marian 2011, Chanson 2009
MBD4 Deamination U or T opposite G at CpG sequence Yamada 2002, Song 2009, Hao 2004, Miao 
2008
MPG Alkylation alkylated bases, 3-methyadenine (3-meA), 
methylguanine, etheno A and guanine, 8-
oxoG
Kim 2002, Kim 2003
MYH Oxidation removes As that are mispaired with G, C, or 
oxo-G
Dallosso 2008, Out 2012, Wasielewski 2010, 
Rennert 2012, Beiner 2009, Zhu 2011
Bifunctional Glycolyases
OGG1 Oxidation 8-oxoG opposite C Tani 1998. Roberts 2011, Sangrarang 2009, 
Sterpone 2010, Rossner 2006, Goode 2002
NEIL1 Oxidation removes oxidized pymidines, 8-oxoG Das 2006, Dou 2008, Maiti 2008
NEIL2 Oxidation removes oxidized pymidines, oxidized 
cytosine
Das 2006, Conlon 2005, Dey 2012, Zhai 2008, 
Kinslow 2008, Haiman 2008
Other BER genes Class/Type
APE1 (APEX1) AP endonuclease Recognizes and cleaves the phosphodiester 
bond 5' attached to the AP site
Agachan 2009, Kuasne 2011, Popanda 2004, 
Canbay 2010, Zawahit 2009, Smith 2008, 
Sangrarang 2008, Zhang 2006, Poletto 2012
PARP1 (ADRPT1) Modifies nuclear protein by poly-ADP-
ribosylation
Allinson 2003, Dantzer 2002, Bieche 1996, 
Fong 2009
PARP3 (ADRPT2) Modifies nuclear protein by poly-ADP-
ribosylation
Matsutani 2002
POLB DNA polymerase Gap filling enzyme in short-patch BER Lang 2007, Yamtich 2012, Wang 1995, 
Makridakis 2012, Starcevic 2004, Dalal 2005, 
Donigan 2012, Kazma 2012, Nemec 2012
LIG3 Ligase Catalyzes the nick-sealing step in short-
patch BER along with cofactor XRCCI
Puebla-Osorio 2006
XRCC1 Ligase central scaffolding protein binding LIG3, 
DNA polymerase B, and PARP
Chacko 2005, Smith 2008, Sangrarang 2008, 
Silva 2007, Sterpone 2010, Mitra 2008, 
Hussein 2012  Ali 2008
PCNA scaffolding protein senses DNA strand breaks and initiates DNA 
damage signaling (Scheiber), 
posttranslational modification by ubquitin
Malkas 2006, Ma 2000
RFC1 large subunit of 
replication factor C
 binds to the 3' end of primers and promotes 
synthesis of both strands
Overmeer 2010, Fotedar 1996
FEN1 endonuclease removes 5' flap in long patch BER Singh 2008
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Table 2. DNA Glycosylases 
 
 
`
List of BER Glycosylases and associated substrate(s)
Glycosylase Damaged base type Substrates, Base released
UNG Deamination Uracil, U:G, U:A, 5-FU
TDG Deamination U:G,, Etheno C:G, T: G
SMUG1 Deamination Uracil, U: A, U: G
MBD4 Deamination Uracil or T
MPG Alkylation 3-MeA, 7-MeA, 3-MeG, 7-MeG
MYH Oxidation A:G, A: 8-oxoG
OGG1 Oxidation 8-oxoG: C, faPyG
NTH1 Oxidation Tg, Cg, 5ohC
NEIL1 Oxidation 8-oxoG
NEIL2 Oxidation 8-oxoG
NEIL3* Oxidation oxidized purines
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Table 3. Associations between BER genes and breast cancer risk 
  
OR (95% CI) OR (95% CI)
Gene/SNP Study Year Country Study Population Cases Controls Arg/Gln Gln/Gln
XRCC1 Brewster 2006 United States All 321 321 1.5 (0.9-2.0) 1.1 (0.7-1.8)
rs25487 Chacko 2005 India Asian 123 123 2.0 (1.2-3.6) 2.7 (1.1-6.6)
Costa 2007 Portugal European 285 442 0.5 (0.4-0.8)
Deligezer 2004 Turkey Asian 151 133 0.9 (0.5-1.5) 1.3 (0.6-2.6)
Duell 2001 United States Black 253 266 1.5 (1.1-2.3) 2.1 (0.6-7.3)
Duell 2001 United States Caucasian 386 381 1.1 (0.8-1.5) 0.8 (0.5-1.3)
Dulfloth 2005 Brazil Mixed 86 120 1.1 (0.7-1.8) 1.7 (0.7-4.2)
Figueiredo 2004 Canada Caucasian 402 402 0.9 (0.7-1.2) 0.9 (0.6-1.4)
Forsti 2004 Finland All 223 298 1.1 (0.8-1.6) 0.9 (0.5-1.7)
Hussein 2012 Egypt Caucasian 100 100 1.7 (0.9-3.1) 1.6 (0.6-4.1)
Kim 2002 Korea Asian 205 205 0.8 (0.5-1.2) 2.4 (1.2-4.7)
Lozidou 2008 Greece Caucasian 1,109 1177 0.6 (0.8-1.1) 0.9 (0.7-1.2)
Metsola 2005 Finland Caucasian 483 482 1.2 (0.9-1.7) 1.4 (0.8-2.3)
Mitra 2008 India Asian 155 235 0.9 (0.6-1.5) 2.9 (1.7-5.1)
Moullan 2003 France Caucasian 254 312 0.9 (0.6-1.3) 1.0 (0.6-1.6)
Pachkowski 2006 United States Caucasian 1,281 1,137 1.1 (0.9-1.3) 1.0 (0.8-1.3)
Pachkowski 2006 United States Black 786 681 1.1 (0.9-1.5) 1.8 (0.8-3.8)
Patel 2005 United States All 502 502 1.0 (0.7-1.4) 1.3 (0.8-2.0)
Roberts 2011 United States premenopausal 1,099 1,945 0.9 (0.6-1.2) 0.8 (0.6-1.2)
Roberts 2011 United States postmenopausal 1,099 1,945 1.2 (1.0-1.5) 1.3 (0.9-1.8)
Sangrajrang 2008 Thailand Asian 507 425 1.2 (0.9-1.6) 1.8 (0.9-3.3)
Shen 2005 United States All 1,067 1110 1.1 (0.9-1.3) 1.0 (0.7-1.3)
Shu 2003 China Asian 1,088 1182 1.0 (0.8-1.1) 1.2 (0.9-1.7)
Smitha 2003 United States Caucasian 253 268 1.0 (0.7-1.5) 1.1 (0.6-2.0)
Smithb 2003 United States Caucasian 162 302 0.7 (0.4-1.2) 1.1 (0.5-2.7)
Smith 2008 United States Caucasian 336 416 1.0 (0.7-1.4) 0.9 (0.6-1.5)
Smith 2008 United States Black 63 78 1.1 (0.4-2.9) 2.1 (0.09-52.2)
Sterpone 2010 Italy Caucasian 43 31 4.8 (1.6-14.8) 4.4 (1.1-17.1)
Thyagarajan 2006 United States Caucasian 460 324 1.3 (0.8-2.0) 0.9 (0.5-1.7)
Zhai 2006 China Asian 523 639 0.8 (0.6-1.1) 1.0 (0.6-1.7)
Zhang 2006 Poland Caucasian 1995 2296 1.1 (1.0-1.3) 1.1 (0.9-1.4)
Zhang 2006 United States Caucasian 3368 2880 1.1 (0.9-1.2) 0.9 (0.8-1.1)
His/His + Arg/His**
XRCC1 Chacko 2005 India Asian 123 123 0.6 (0.3-1.0)
rs25489 Lozidou 2008 Greece Caucasian 1109 1177 4.7 (1.0-21.7)
Metsola 2005 Finland Caucasian 483 482 1.2 (0.8-1.7)
Pachkowski 2006 United States Caucasian 1281 1137 1.2 (0.9-1.6)
Pachkowski 2006 United States Black 786 681 1.3 (0.8-2.0)
Sangrajrang 2008 Thailand Asian 507 425 1.3 (0.9-1.9)
Smith 2008 United States Caucasian 336 416 0.7 (0.4-1.2)
Smith 2008 United States Black 63 78 0.7 (0.1-3.0)
Zhang 2006 United States Caucasian 1898 1514 1.1 (0.8-1.4)
**dominant model, not enough homozygous variants to do general/codominant model, referent genotype: Arg/Arg
 39 
 
 
  
Study Year Country Study Population Cases Controls Arg/Trp + Trp/Trp**
XRCC1 Brewster 2006 United States All 321 321 1.2 (0.7-1.8)
rs1799782 Chacko 2005 India Asian 123 123 2.0 (1.1-3.5)
Deligezer 2004 Turkish Asian 151 133 0.5 (0.2-1.2)
Duell 2001 United States Black 161 166 0.7 (0.4-1.2)
Duell 2001 United States Caucasian 251 234 0.7 (0.3-1.4)
Forsti 2004 Finland All 223 298 1.3 (0.6-2.6)
Kim 2002 Korea Asian 205 205 1.1 (0.7-1.6)
Lozidou 2008 Greece Caucasian 1109 1177 1.0 (0.8-1.3)
Mitra 2008 India Asian 155 235 0.4 (0.2-0.7)
Moullan 2003 France Caucasian 254 312 1.0 (0.6-1.7)
Pachkowski2006 United States Caucasian 1281 1137 0.9 (0.7-1.2)
Pachkowski2006 United States Black 786 681 1.0 (0.7-1.3)
Patel 2005 United States All 502 502 0.6 (0.4-0.1.0)
Roberts 2011 United States premenopausal 1099 1945 0.9 (0.7-1.3)
Roberts 2011 United States postmenopausal 1099 1945 1.2 (1.0-1.5)
Sangrajrang2008 Thailand Asian 507 425 1.1 (0.8-1.4)
Shen 2005 United States All 1067 1110 0.9 (0.7-1.2)
Silva 2007 Portugal Caucasian 241 457 2.0 (1.2-3.3)
Smitha 2003 United States Caucasian 253 268 1.6 (0.9-2.9)
Smithb 2003 United States Caucasian 162 302 2.0 (0.9-4.6)
Smith 2008 United States Caucasian 336 416 1.2 (0.7-2.0)
Smith 2008 United States Black 63 78 0.4 (0.1-1.7)
Sterpone 2010 Italy Caucasian 43 31 1.8 (0.4-7.7)
Thyagarajan2006 United States Caucasian 460 324 1.2 (0.8-1.9)
Zhang 2006 United States Caucasian 1898 1514 0.9 (0.8-1.2)
**dominant model
Asp/Glu Glu/Glu
APE1 Sangrajrang2008 Thailand Asian 507 425 0.6 (0.4-0.9) 0.9 (0.7-1.3)
rs1130409 Smith 2008 United States Caucasian 336 416 0.7 (0.5-0.9) 0.8 (0.5-1.2)
Smith 2008 United States Black 63 78 1.0 (0.4-2.4) 0.9 (0.3-3.0)
Zhang 2006 United States Caucasian 1898 1514 1.0 (0.9-1.2) 1.0 (0.8-1.3)
Cys/Cys Ser/Cys
OGG1 Choi 2003 Korea Asian 475 500 1.0 (0.8-1.4) 1.3 (0.9-1.9)
rs1052133 Roberts 2011 United States premenopausal 1099 1945 1.0 (0.7-1.4) 1.2 (0.5-2.5)
Roberts 2011 United States postmenopausal 1099 1945 1.0 (0.8-1.2) 1.2 (0.8-1.9)
Sangrajrang2008 Thailand Asian 507 425 1.4 (1.0-2.1) 1.0 (0.7-1.3)
Sterpone 2010 Italy Caucasian 43 31 1.4 (0.5-3.6) 0.8 (0.1-6.7)
Vogel 2003 Denmark Caucasian 452 434 0.8 (0.6-1.1) 1.0 (0.5-1.9)
Zhang 2006 United States Caucasian 1898 1514 1.0 (0.8-1.2) 1.0 (0.7-1.4)
Val/Ala Ala/Ala
PARP1 Zhai 2006 China Asian 523 639 0.9 (0.6-1.2) 0.9 (0.6-1.3)
rs1136410 Smith 2008 United States Caucasian 336 416 0.7 (0.5-0.9) 0.7 (0.3-1.9)
Smith 2008 United States Black 63 78 4.6 (0.9-23.1)
Zhang 2006 United States Caucasian 1898 1514 1.0 (0.9-1.2) 0.9 (0.6-1.4)
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Table 4. Efficient and Mutagenic Bypass of DNA Lesions 
  
Type of Lesion Mode of formation Efficient Bypass Mutagenic Bypass
Endogenous
AP site Hydrolytic depurination POL alpha (Avkin 2002) POLB (Blanca 2004, Efrati 1997)
POLD (Avkin 2002) POLK (Ohashi 2000)
POLE (Avkin 2002) POLH (Masutani 2000)
POLH (Choi 2010) POLL (Maga 2002, Blanca 2004)
POLD/PNCA (Choi 2010) POLM (Zhang 2002)
POLB (Gieseking 2011) REV1 + POLH (Choi 2010)
POLQ (Seki 2004) POLI + POLH (Choi 2010)
8-oxo-G Guanine oxidation POLK (Haracska 2002) POLK (Irimia 2009, Zhang 2000)
POLH (Maga 2007)
POLD (Avkin 2002)
POLM (Zhang 2002)
POLI (Zhang 2001, Vaisman 2001)
POLL (Maga 2007, vanLoon 2010)
Thymine Glycol pyrimidine oxidation POLK (Fischhaber 2002) POLQ (Seki 2004, Arana 2008)
POLN (Takata 2006) POLN (Takata 2006)
POLB (Belousova 2010) POLM (Kusumoto 2002)
POLL (Belousova 2010)
POLK + REV3 (Yoon 2010)
Exogenous
[6-4] photoproduct UV light POLB (Servant 2002) POLB (Servant 2002)
POLH + REV3 (Johnson 2001) POLI + POLQ (Seki 2008)
POLI + REV3 (Johnson 2000) REV1 (Zhang 2002)
X+REV3 (Yoon 2010) REV3 (Guo 2001)
POLQ (Seki 2008)
cyclobutane 
pyrimidine dimer 
(CPD)
POLB (Servant 2002) POLI+REV3 (Ziv 2009, Vaisman 
2003)
POLH (McCulloch 2008, Masutani 
1999, Albertella 2005, Hendel 2008, 
Broyde 2010)
POLK+REV3 (Ziv 2009)
POLM + REV3 (Zhang 2002)
platinum DNA 
adducts
POLH + REV3 (Bassett 2002, 
Sharma 2012, Chaney 2005)
POLB (Bassett 2002)
Benzo[a]pyrene-
guanine (BP-G)
POLK (Zhang 2002, Ohashi 2000, 
Avkin 2004, Suzuki 2002)
POLK + REV3 (Sharma 2012, Lin 
2006)
REV3 (Johnson 2000) POLH + REV3 (Shachar 2009, 
Goodman 2002)
POLM (Zhang 2002)
cis-syn TT dimer POLK + REV3 (Haracska 2002)
POLM (Zhang 2002)
POLH (Broyde 2010) POLH (McCulloch 2008)
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Figure 1. Breast Anatomy 
Source: www.homeopathynow.com 
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Figure 2. Breast cancer incidence and mortality by race and age  
 
Sources: Incidence: North American Central Cancer Registeries, 2009. Mortality: National 
Center for Health Statistics. 
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Figure 3. DNA Damage Responses 
  
 44 
 
 
 
Figure 4. Sources of DNA Damage and associated lesion and repair pathway genes 
(Adapted from Wood 2005) 
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Figure 5. Short-patch vs. long-patch BER 
 
 
 
 
 
 
 
 
 
 
 
 46 
 
 
 
CHAPTER 2. METHODS 
2.1 Specific Aims 
 
The American Cancer Society estimates 226,870 new cases of invasive breast cancer and 
64,640 new cases of carcinoma of the breast in situ, which will represent 29% of all female 
cancer cases in the United States in 2012 (3).  Previous studies have identified both non-genetic 
and genetic risk factors for breast cancer. Among the most well-known genetic factors are 
mutations in BRCA1, a DNA repair susceptibility marker. It has been hypothesized that deficient 
DNA repair due to mutations in BRCA1 may contribute to increased breast cancer risk. However, 
BRCA1 mutations are rare and together with BRCA2 only account for 5-10% of all breast cancer 
and 15-20% of familial cancers, leaving a large proportion of breast cancer without a known 
genetic component. Consequently, other genes including DNA repair genes in multiple DNA 
repair pathways have been investigated for their association with breast cancer incidence. DNA 
repair is one of several DNA damage response mechanisms that have evolved to respond to 
ubiquitous DNA damage and base excision repair, is one such repair pathway. Other non-repair 
DNA tolerance mechanisms such as TLS (translesion synthesis) may also play a role in breast 
cancer. The impact of genetic variation in BER and TLS pathways will be evaluated using 
genotyped data from the Carolina Breast Cancer Study (CBCS), a large population-based case-
control study. To assess the individual and combined effects of DNA repair and DNA tolerance, 
adjusted unconditional logical regression models will be used to estimate odds ratios and 95% 
confidence intervals.  
 
 47 
 
 
The specific aims of this study are as follows: 
Specific Aim 1:  To estimate the association between breast cancer risk and genetic variation in 
base excision repair genes (BER).  
A) To assess the race-specific effects of SNPs in BER genes on breast cancer risk, odds 
ratios (ORs) and 95% confidence intervals (CI) will be estimated using unconditional 
logistic regression, adjusting for ancestry informative markers (AIMs) and offset 
term. 
B) To assess the subtype-specific effects of  SNPs in BER genes on breast cancer risk, 
odds ratios (ORs) and 95% confidence intervals (CI) will be estimated for SNPs using 
unconditional logistic regression, comparing cases of each subtype (combined 
luminal, HER2+/ER-, and basal-like) to all controls.   
C) To assess the combined pathway effects of SNPs within the base excision repair 
pathway on breast cancer risk (SNP-set Kernel Association Test (SKAT) will be used 
to estimate global p values for 2 SNPs sets (White and African American).  
 
Specific Aim 2:  To estimate the association between breast cancer risk and genetic variation in 
DNA bypass polymerase genes.  
A) To assess the race-specific effects of SNPs in bypass polymerase genes on breast 
cancer risk, odds ratios (ORs) and 95% confidence intervals (CI) will be estimated 
using unconditional logistic regression, adjusting for ancestry informative markers 
(AIMs) and offset term. 
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B) To assess the subtype-specific effects of  SNPs in XX bypass polymerase genes on 
breast cancer risk, odds ratios (ORs) and 95% confidence intervals (CI) will be 
estimated for SNPs using unconditional logistic regression, comparing cases of each 
subtype (combined luminal, HER2+/ER-, and basal-like) to all controls.   
C) To assess the combined pathway effects of SNPs within the DNA bypass polymerase 
genes on breast cancer risk (SNP-set Kernel Association Test (SKAT) will be used to 
estimate global p values for 2 SNPs sets (White and African-American).  
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2.2 Study population: Carolina Breast Cancer Study (CBCS) 
 
To accomplish these specific research aims, we will utilize genotype data from extant 
DNA extracted from blood samples from Phase I (1993-1996) and Phase II (1996-2001) of the 
Carolina Breast Cancer Study (CBCS). Study design and methods have been described 
extensively in (274, 275). CBCS is a large population-based case-control study that incorporates 
both randomized recruitment to oversample understudied populations such as younger and 
African-American women as well as rapid case ascertainment system which allows access to 
state reported data in a time efficient manner In addition, as a part of the study, biologic samples 
were collected which allowed for the DNA extraction and genotyping of various putative breast 
cancer genes, including DNA repair and bypass polymerase genes. CBCS also collected tumor 
tissue samples from participants which allowed for tumor subtyping via immunohistochemistry 
(IHC) as a surrogate for gene expression.  
2.2.1 Case ascertainment  
 
 Case eligibility was determined using the following criteria: female, between the ages 20 
and 74 years at the time of diagnosis, living within the 24 county study area in North Carolina, 
primary diagnosis of an invasive breast cancer between May 1, 1993 and September 30, 1995 
(Phase I enrollment) or primary diagnosis of an invasive or in situ breast cancer between May 1, 
1996 and September 30, 2001 (Phase II enrollment).  
 Eligible cases were identified from the Rapid Case Ascertainment program within the 
North Carolina Central Cancer Registry (NCCCR). By law, all breast cancer cases in North 
Carolina (invasive and in situ) are reportable to the North Carolina Center Cancer Registry 
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(NCCCR). Hospitals are required to send timely reports to the registry for all newly diagnosed 
cases, while physicians are required to report cancer cases that are not diagnosed in the hospital 
(276). With some cases of breast cancer that are rapidly fatal, timeliness of reporting can be 
critical. To ensure that cases were reported in a timely manner, CBCS collaborated with CCR to 
develop and implement a rapid case ascertainment system (RCA) (277). The CCR closely 
coordinated with hospital registries and were given an incentive to forward pathology reports to 
CCR as soon as they were received. Therefore, CBCS received expedited reports from CCR 
usually within a month of the diagnosis.  Cases were invited to participate in the study based on 
the county of residence during their time of diagnosis, which included 24 central and eastern 
North Carolina (Figure 6). In addition, participants were required to live in the same county as 
they did at the time of their diagnosis.  
2.2.2 Control ascertainment 
 
Controls for the study were also female residents of North Carolina residing in one of the 
24 study counties. Controls ages 20-64 at study entry were selected from the North Carolina 
Department of Motor Vehicle (DMV), while controls ages 65-74 were selected from the U.S. 
Health Care Financing Administration (Medicare) records. Controls represented the pool of 
women ages 20-74 living in the 24-county study region without a previous diagnosis of invasive 
or in situ breast cancer at the time of selection into the study. Controls were also matched to 
cases based on 5-year age categories and self-reported race (African-American and White). 
2.2.3 Randomized recruitment 
 
As an alternative to frequency matching, "randomized recruitment" or probability 
matching individually randomizes subjects to be recruited or not based on available screening 
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variables and disease status (278). In CBCS, these screening variables were the participant’s race 
and age abstracted from pathology reports for cases and DMV and Medicare records for controls. 
This information was used to ensure that the sampling probabilities were approximately equal 
across race and age categories. These sampling probabilities were different for invasive cases in 
Phases 1 and 2. Table 5 shows the sampling probabilities for invasive cancers in both phases of 
the study, stratified by age and race. In phase II of the study, 100% of the in situ cases were 
sampled. To increase power, African-American cases and all cases younger than 50 years old 
were oversampled. Controls were probabilistic matched to cases by race and five year age group. 
To account for this “biased” sampling design, race and age was adjusted for in all logistic 
regression models using an offset term. The offset term is defined as the natural log of the ratio 
of the sampling probability for a case in the specific age-race strata to the sampling probability 
for a control in the same age-race strata (i.e. a non-black case aged 30-34 will have same offset 
term as non-black control aged 30-34, despite different sampling probabilities). Therefore, each 
CBCS participant will have their own offset term based on their race and age category.  
2.2.4 Subject recruitment and enrollment 
 
After receiving identifying information from NCCCR about a potential study participant, 
the participant’s treating physician was sent a letter requesting permission to contact their 
patient. If physician permission was obtained, cases were sent a study brochure and a letter 
inviting them to participate. Physician consent was not obtained for 7% of eligible cases. If 
physician consent was obtained, a CBCS recruiter contacted the potential study case via 
telephone to assess interest and study eligibility.   
Contact rates was defined as the percentage of women who were identified as potential 
study participants with whom contact was achieved (279). While contact information was readily 
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available for cases, contact information (i.e. telephone numbers) were not provided from DMV 
or HCFA records and a variety of strategies were employed to contact eligible controls (280). 
Contact rates were 98% for cases (3,292 out of 3,360) and 83% for controls (3,706 out of 4,465).   
Cooperation rates were defined as the number of completed interviews divided by the 
number of women who were successfully contacted and eligible. Cooperation rates differed by 
case status (79% for cases and 71% for controls). In addition, the age/race specific cooperation 
rate ranged from 72% for older African-American women to 84% for young white women.   If 
the study recruitment specialist confirmed the woman met all eligibility criteria and verbally 
agreed to participate in the study, an at-home interview with a trained study nurse was scheduled.  
The overall response rate was defined as the number of completed interviews divided by 
the number of potentially eligible women selected for the study. Overall response rates for both 
phases of the study were 77% for cases and 57% for controls.  Total enrollment included 1,803 
invasive cases and 1,564 matched controls, and 508 in situ cases and 458 matched controls. 
Among cases, older African-Americans had the lowest overall response rate (70.8%) while 
younger Whites had the highest overall response rate (82.7%). Among controls, younger 
African-Americans had the lowest overall response rates (47.8%) while older Whites had the 
highest (77.9%).  African-American in situ cases and controls were also were less likely to be 
selected into the study. 
2.2.5 Baseline study interview  
 
Prior to beginning the interview, a written signed informed consent was obtained.  The 
subjects were required to initial a special section describing potential genetic research on their 
samples. The consent also assured participants that their blood samples would be used only for 
research purposes and safeguards were in place to ensure their confidentiality. Any questions or 
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concerns were addressed by the study nurse and participants were assured that their participation 
was voluntary. In addition, participants were given medical record release forms and HIPAA 
forms to sign allowing CBCS to obtain pathology reports and formalin-fixed paraffin-embedded 
(FFPE) tumor blocks.  The tumor tissue blocks were used to both confirmed diagnosis by a 
pathologist as well as to conduct IHC subtyping. FFPE tumor blocks were obtained and 
successfully sectioned for 80% of cases and immunochemistry was completed for 62% of cases 
(281). 
The baseline interview consisted of a nurse-administered questionnaire consisting of 
known and suspected breast cancer risk factors such as family history, personal medical history, 
occupational history, and exposure to known reproductive and lifestyle factors. In addition, 
participants completed a self-administered quality of life survey, and height, weight, waist 
circumstance, and hip circumstance were measured by the study nurse.  
At the end of the interview, the nurse interviewer collected a 30 mL blood sample. 
Whites were more likely to provide blood samples than African-Americans. There were no 
significant differences in other risk factors for those who provide a biological sample and those 
who did not (281, 282). Women who refused the blood sample were given the option of 
providing a buccal cell sample using mouthwash or having their blood drawn at their physician’s 
office to be sent into the study. If the biologic sample was collected at the interview site, the 
study nurse transported the sample back to the laboratory at UNC to be processed. DNA was 
extracted from peripheral blood lymphocytes using an automated ABI-DNA extractor in the 
UNC Tissue Procurement Facility and stored at    .  Blood samples were collected and DNA 
successfully extracted from peripheral blood lymphocytes on 89% of cases and 90% of controls. 
 54 
 
2.3 Exposure assessment 
2.3.1 CBCS SNP selection 
 
Single nucleotide polymorphisms or SNPs are the most common type of genetic 
variation. It is estimated that there are 100,000-300-000 nonsynonymous coding SNPs in 
humans, representing 1% of all SNPs. The other 99% of SNPs include intronic (63%), 
untranslated regions (11%), synonymous (1%), locus regions (24%), splice site (<1%) and 
uncoding variants (<1%). A SNP occurs when a single nucleotide at a particular DNA location 
differs between members of a population and occurs at a frequency greater than 1% in the 
general population (283). In this study, a candidate gene approach was utilized to select SNPs in 
the BER and TLS pathways. The candidate gene approach focuses on associations between 
genetic variation within pre-specified genes of interest (i.e. DNA repair pathway genes) and 
phenotype (i.e. breast cancer). This is in contrast to genome-wide association studies (GWAS) 
which scan the entire genome for common genetic variation. Candidate genes are most often 
selected for study based on a priori knowledge of the gene’s biological functional impact on the 
trait or disease in question. The candidate gene approach is hypothesis-based, relying on prior 
functional SNP data from laboratory studies or computer simulations (284, 285). Identifying 
potential functional SNPs may help to define a biological mechanism through which genotype is 
causally associated with breast cancer (286). A functional SNP is defined as a polymorphism in a 
codon that leads to an amino acid change that alters gene product and function and case-control 
status (287, 288). 
Two publicly available SNP databases, the Single Nucleotide Polymorphism Database 
(dbSNP) and SNP500Cancer, were used to select 1,536 SNPs for CBCS. Preference was given to 
non-synonymous and promoter SNPs in genes that have been implicated in one or more cancers 
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(289). SNPs in the CBCS were selected based on the following criteria: gene previously 
identified in the base excision DNA repair or bypass polymerase pathway; experimental 
evidence (In vitro/in vivo/in silico studies) demonstrating functional effect; non-synonymous 
missense coding variants, upstream regulatory regions, splice variants, or 5'UTR variants, and at 
least 5% minor allele frequency in African-American or White populations. 
2.3.2 Genotyping analysis 
 
A total of 1,536 SNPs which passed all four Illumina reviews were selected in each 
pathway to be genotyped. There were 284 SNPs chosen in DNA repair pathways, including 59 
SNPs in BER and 30 SNPs in bypass polymerase genes (Table 6, Table 7). SNPs were 
genotyped from biological samples collected at the time of baseline interview. High-throughput 
genotyping of selected SNPs was conducted at the Mammalian Genotyping Core Facility at the 
University of North Carolina at Chapel Hill using the Illumina high-multiplex GoldenGate 
Genotyping Assay with Sentrix Array matrix. This process has been documented in detail 
previously by (290). Briefly, the GoldenGate Assay queries genomic DNA with three 
oligonucleotide probes for each locus and creates DNA fragments that can be amplified by 
standard PCR methods using universal primers (290).The oligo mix contains two allele-specific 
and one locus-specific probe. The 3′ ends of the two alternative allele specific probes are 
complementary to two universal primers, U1 and U2, with the 5′ end complementary to the 3′ 
end of the locus. Each probe sequence terminates at the SNP that is to be assayed with an allele 
specific base. The third probe, the locus specific probe, is complementary to the genomic DNA. 
DNA polymerase is added to close the gap between the allele specific and the locus specific 
probes and the paired fragments are ligated together. The probe fragments are then separated 
from the genomic DNA and PCR results in a single strand hybridized to the BeadArray (290, 
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291). The genotype of an individual at a SNP is thus determined by comparing the relative 
hybridization intensities of the two probling sequences (Teo 2012). Large-scale genotyping 
depends on automated strategies (i.e. genotype calling) to translate the hybridization intensities 
for the two alleles at each SNP into a categorical genotype call.  
2.3.3 Genotyping quality control 
 
CBCS investigators utilized several quality control measures to measure and improve 
overall data accuracy. Upon arrival, all samples were labeled with a unique bar code with the 
BSP identifier, type of contained material, volume, concentration, date of creation, and locked in 
a secure storage facility. Case and control samples were randomly distributed on the panel. 
Systematic bias can arise if cases and controls are genotyped separately, since different error 
rates or genotyping success rates may lead to falsely different allele frequencies. In addition, 
blind duplicate samples, and negative and positive lab controls were used. A 4% (169 out of 
3,857) random subsample of genotypes was repeated for each locus to test concordance with the 
original sample.  Replicates that did not show greater than 99.5% concordance were excluded 
(291).  Six subjects (3 cases and 3 controls) were excluded due to issues in non-blind DNA 
samples.  
In addition, there were several potential sources of pre-genotyping error such as poor 
assay design and post-genotyping error such as low call rates, low signal intensity, 
indistinguishable genotype clusters. Departures from Hardy-Weinberg equilibrium may also 
indicate genotyping error. To assess these errors, individual call rates were examined, and there 
was careful inspection of assay intensity data and genotype clustering images. 103 samples with 
a call rate <95% were excluded.   
Out of 1,536 SNPs, 163 (11%) SNPs were excluded due to genotyping error.  Out of 
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2,311 cases and 2,022 controls enrolled in CBCS, 2,045 (88%) cases and 1,818 controls (90%) 
submitted a DNA biological sample. After all exclusions, a total of 1,972(85%) enrolled cases 
and 1,776(88%) enrolled controls were successfully genotyped (Figure 8).  
2.4 Outcome Assessment 
 
Diagnosis of invasive or in situ breast cancer from the pathology reports were confirmed 
via medical records. Centralized review of pathology was conducted for all cases using original 
or recut H&E sections (292). Details on the quality control procedures for tumor blocks are 
outlined in Dressler 1999 (293). A total of 1,845 cases had tumor tissue available.  
2.4.1 Ascertainment of intrinsic subtype markers  
 
Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples were available for 80% 
of invasive cases and sent to the UNC Immunohistochemistry Core Laboratory to be sectioned 
and subtyped (22, 59, 72). Since gene expression analysis using DNA microarray technology 
was not possible on FFPE samples at the time, immunohistochemistry markers were used as a 
surrogate method to subtype the tumors (58). 
A total of 1,424 (77% of available tumor blocks) were successfully subtyped and 
classified into one of five “intrinsic” subtype groups:  luminal A (ER+ and/or PR+, HER2-), 
luminal B (ER+ and/or PR+, HER2+), HER2+/ER- (ER-, PR-, HER2+), and basal-like (ER-, PR-
, HER2-, HER1+ and/or CK 5/6+), with those negative for all 5 markers considered 
‘unclassified’ (59)(Figure 8). 
Estrogen and progesterone status was abstracted from medical records for 80% of cases. 
For the remaining 20% of cases, ER and PR IHC assays were conducted using stored tumor 
tissue. Tumors with more than 5% of cells showing nuclei-specific staining were considered 
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receptor positive (53). A 10% random sample of ER+ and ER- tumors reported in medical 
reports were tested in the lab to evaluate concordance between the two data sources. There was a 
kappa statistic of 0.62 between the medical records and the lab data based on a previous CBCS 
report (281). HER2 status was detected using the CB11 monoclonal antibody.  A case was 
considered HER2 positive if at least 10% of observed cells showed signs of staining. This 
method had high concordance (81%) with PCR-based measures of HER2 gene expression (293). 
EGFR (HER1) and CK 5/6 assays were defined as being positively expressed if the tumor 
displayed any signs of staining (58). Table 8 shows the distribution of subtypes by race. 
For the current study, we classified tumors as either luminal (ER+ and/or PR+; n=788), 
basal-like (ER-, PR-, HER2-, CK 5/6+ and/or EGFR+; n=199) or HER2+/ER- (n=94). We 
excluded ‘unclassified’ tumors from further analysis due to their uncertain status. The major 
distinction between the two luminal subtypes are their proliferation signatures, measured by the 
expression of CCNB1, MKI67, and MYBL2 (49). HER2 expression only identifies about 30% of 
luminal B tumors.  In the current study, we did not have information about these proliferation 
markers and therefore combined Luminal A and B tumors into a single ‘luminal’ category (48, 
49) (Figure 11). Additionally, most other studies do not have subtype data available and only 
have estrogen receptor status data. Therefore, we conducted an additional exploratory analysis 
using estrogen receptor (ER) status to evaluate comparability to “intrinsic” subtype results. We 
found that ER positive effects were concordant with luminal subtype results; while ER negative 
(ER-) effects correlated with those of basal-like and HER2+/ER- subtypes (Table 15). There 
were no differences between CBCS cases with and without subtyping data in terms of age, 
menopausal status, or family history. 
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2.4.2 IHC for in situ cases 
 
Phase 2 of the CBCS also included women diagnosed with ductal carcinoma in situ breast 
cancer (DCIS), lobular carcinoma in situ (LCIS), and mixed DCIS and LCIS (72). Tumor tissue 
was collected from 79% of in situ cases and sent to the UNC Immunohistochemistry Core 
Laboratory for subtyping (22). IHC subtyping procedures were slightly modified for in situ 
tumors due to availability of tumor samples. ER positive tumors were defined as having an 
Allred score >2 with nuclear staining.  PR status was not determined independently due to the 
high correlation between ER and PR positivity (294). However a recent study suggested that IHC 
of PR could add prognostic value and identified cases with better outcomes (295). HER2 positive 
tumors were defined as having more than 10% of cells stained greater than 3 using DAB 
chromogen or greater than 2 or 3 using SG chromogen. As for CK 5/6 and EGFR in invasive 
cases, tissue with staining of 1+ or greater was defined as positive for expression (72). 
DCIS was the most common subgroup of in situ breast cancer and was defined in the CBCS by 
microinvasion of less than or equal to 2mm (296). 
Of the 2,311 cases enrolled into the study, 1,220 (53%) cases had both complete subtype 
and genotyped data (Figure 8). The subtype distribution of those with genotyped data is very 
similar to the subtype distribution of all CBCS participants (22). 
2.5 Covariate Assessment 
2.5.1 Traditional Confounding 
 
 Confounders are “factors (exposures, interventions, treatments) that explain or produce 
all or part of the difference between the measure of association and the measure of effect that 
would be obtained with a counterfactual ideal”(288). Confounding has also been described as a 
mixing of two or more effects. The bias caused by traditional confounding in conventional 
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epidemiological studies typically does not apply to genetic epidemiological studies. Potential 
non-genetic confounders (i.e. reproductive factors) can be associated with the outcome (i.e. 
breast cancer) but they are unlikely to be related to the genotype (Figure 9), especially with the 
genes under investigation in this project.  If they are an intermediate variable between genotype 
and breast cancer, adjusting for these covariates could induce bias. 
2.5.2 Confounding by ancestry (population stratification)  
 
While traditional confounders may not be relevant in genetic association studies, there is 
the possibility for confounding by race/ancestry or population stratification. Population 
stratification or may occur if one or more subpopulations have a higher prevalence of an allele 
and a higher risk of disease (283). According to Barnholtz-Sloan, two criteria must be fulfilled in 
order for population stratification to exist. First, the frequency of the marker gene of interest 
must vary significantly by race/ethnicity and second, the background disease prevalence must 
also vary significantly by race/ethnicity (297) (Figure 11). Therefore, population stratification 
refers to differences in allele frequencies between cases and controls due to systematic 
differences in ancestry rather than association of genes with disease (298). 
Population stratification may be a possible source of bias among admixed groups such as 
African-Americans and Latinos (299). Several studies of African populations have indicated that 
levels and patterns of LD in these populations differ from those in non-African populations due 
to admixture with other African and non-African populations.  LD block size tends to be shorter 
in individuals of African ancestry and longer in Caucasians due to genetic drift and 
recombination (298, 300). Barnholtz-Sloan also argues that “classifying individuals into classes 
that represent heterogeneous racial/ethnic groups may also misclassify a person’s actual ancestral 
background and limit assessment of variation within racial/ethnic groups that is relevant for 
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understanding disease risk or outcome (297). Therefore estimation of individual ancestry should 
better capture the variation in ancestry within a subpopulation and account for residual 
confounding. These arguments validated the necessity of controlling for admixture in race-
stratified analysis in the current study. 
There have been several analytic approaches proposed to control for population 
stratification in genetic association studies.  The two most common methods for estimating 
individual ancestry are using maximum likelihood estimates (MLE) or a structural association 
approach (301, 302). Structured association can use markers pre-selected to differ between 
ancestral populations (AIMs) or random genetic markers (297). STRUCTURE, a structured 
association program, uses Bayesian Markov Chain Monte Carlo method to estimate allele 
frequencies in subpopulations and individual ancestry proportions (302).  
In addition, the genomic control method, proposed by Devlin and Roeder, calculates a 
variance inflation factor for a set of random, unlinked SNPs across the genome, and adjusts all 
SNP association tests by the inflation factor (303). Genomic control makes the assumption that 
the variance inflation is constant across all loci being tested. If this assumption is violated, 
overadjustment or underadjustment of variance may occur for different loci, which may result in 
reduced power to detect risk alleles. Marchini argues hat using too few markers for genomic 
control could lead to false positives, while using too many markers could lead to decreased 
power (304). 
Finally, a principal components method has been touted as a method to assess population 
stratification. This method uses genotype data to estimate axes of variation that can be 
interpreted as describing continuous ancestral heterogeneity within a group of individuals (305). 
These axes of variation are defined as the top eigenvectors of a covariance matrix between 
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individuals in the study population that was formed using genotype information from random 
markers or AIMs. One of the main advantages of the principal components method is that it is 
more efficient in determining population structure using a large number of markers (i.e for 
GWAS). However the principal component methods can have a higher rate of type I error when 
the number of markers is low and may not be appropriate for a study such as CBCS (305). 
 
In this proposed study, we will use the MLE methods proposed by Barnholtz-Sloan 
(297).  Estimates of genetic ancestry will be derived from genotyped AIMs, which are unlinked 
markers found throughout the genome that show large allele frequency differences between 
ancestral populations (297).In CBCS, a set of 144 ancestry informative markers (AIMs) were 
selected to maximize the differences or δ in allele frequencies between African-Americans and 
White participants in the YRI and CEU HapMap data respectively (306) (Table 9). Proportions 
of ancestry for each ancestral population should sum to 1 since there are only two ancestral 
populations used for this study (301) Initially, a set of 200 AIM SNPs were selected from the 
panel of 5,400 AIMs identified at UC Davis Rowe Program representing four genetically diverse 
populations: two West African populations, European Americans, and African Americans. 158 
(79%) passed the initial Illumina review and a subset of those SNPs (144 or 91%) were 
successfully genotyped. This set of SNPs provides nearly uniform coverage of the genome. 
Among African-American CBCS participants, the median proportion of European ancestry was 
0.19 (average= 0.22), with most women in the 0 to 0.50 range. In Whites, most women had 
between 80% and 100% European ancestry, with a median proportion of 0.94 (average = 0.93) 
(307). 
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2.6 Statistical Analysis 
2.6.1 Assessment of Hardy-Weinberg Equilibrium 
 
The Hardy-Weinberg Equilibrium (HWE) states that “under certain assumptions, the 
genotype and allele frequencies in a large, randomly mating population remain stable over 
generations and that there is a fixed relationship between allele and genotype frequencies” (283).  
 
   ∑
       
  
 
   , with 1 degree of freedom (df) 
Deviations from HWE will be measured through a Pearson’s chi-square test with the null 
hypothesis assuming that alleles are chosen randomly and that the observed genotype proportions 
match the expected genotype proportions (p
2
, 2pq, q
2
). However this goodness of fit test is 
sensitive to small sample size or rare allele frequencies and an exact test will be performed in 
these scenarios (308).   
There are several reasons that a SNP may deviate from HWE among controls, including 
genotyping error, chance, failure of HWE assumptions (i.e. random mating), population 
stratification, and even a true genetic disease association. Examining deviations from HWE 
among cases is not performed since this may reflect a true mutation and cannot be distinguished 
from genotyping error. Barring chance and assuming the other conditions under HWE to be 
minimal, any SNP with a p-value less than 0.05 will be considered in violation of HWE due to 
genotyping errors and excluded from further analyses.  
 
2.6.2 Genetic Model Specification 
 
There are several genetic model choices available to test whether a specific SNP is 
associated to breast cancer (309). If there is no prior information about mode of inheritance of 
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the variant, an additive or general (co-dominant) genetic model can be used to estimate having 
one or two copies of the variant. The additive model makes an additional assumption that the 
relationship between the log ORs is linear. For the additive model, genotypes are coded as an 
ordinal variable (‘0’ for no risk alleles, ‘1’ for a single copy of risk allele, and ‘2’ for both copies 
of the minor allele). This model generates two ORs, one comparing homozygote variant to 
homozygous wildtype (referent) and one comparing the heterozygote to the homozygous 
wildtype (referent). The additive model uses a 2 df test, while the dominant model uses a 1 df 
test. The dominant model assumes that one copy of the variant allele increases risk. Since many 
of our selected SNPs had non-polymorphic or rare homozygous variants, we used a dominant 
model for all SNPs. We combined the homozygous variant and heterozygous genotypes and 
compared them to the homozygous wildtype genotype to obtain a single effect estimate and 
corresponding 95% confidence intervals.  
2.6.3 Race-specific effects 
 
 We explored whether the effects of BER and TLS SNPs vary by race. Race was coded as 
a dichotomous variable, 0 for White and 1 for African-American, based on participant’s self-
reported race. Less than 2% of participants self-identified as another race and will be excluded 
from the analysis.  
Unconditional binary logistic regression will be used to estimate odds ratios (ORs) and 
95% confidence intervals (CIs) to capture race-specific effects of base excision genes (Specific 
Aim 1B) and DNA bypass polymerases (Specific Aim 2B)  with breast cancer, adjusted for age, 
proportion African ancestry, and offset term using  SAS version 9.3 (SAS Institute, Cary, NC) . 
The following binary model was used:  
 Logit [D=1|X=x] = α + β1X1 + β2 age + β3 ancestry + offset 
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where D represents the outcome of interest (invasive or in situ breast cancer) coded 
dichotomously as 0 for control and 1 for case, α represents the model intercept, β1 is equal to the 
log OR for the effect of each additional copy of the variant alleles and  x1 is equal to the number 
of copies of the variant allele. The offset term is designed to adjust for selection bias induced by 
randomized recrutiment sampling method. Each CBCS participant will have a value for the 
variable CBCSOFF (offset term).  
2.6.4 Subtype-specific effects  
Specific Aims 1B and 2B will assess potential heterogeneity of SNP effects across strata 
of breast cancer subtype. “Intrinsic” subtypes have been classified into 5 different categories: 
luminal A, luminal B, HER2+/ER-, basal-like, and unclassifed. However, different markers 
continue to emerge in defining subtypes and there are no universally accepted classifications of 
breast cancer subtype across studies. The major distinction between the two luminal subtypes are 
their proliferation signatures, measured by the expression of CCNB1, MKI67, and MYBL2 
(49). HER2 expression only identifies about 30% of luminal B tumors.  In the current study, we 
did not have information about these proliferation markers and therefore will combine luminal A 
and B tumors into a single ‘luminal’ category (48, 49). Furthermore, Leong et al. describe 
methodological issues in using IHC to detect HER2 expression (310). A recent study comparing 
concordance of PAM50 with IHC showed that ER positivity by IHC was strongly associated 
with luminal (A and B) subtypes (92%) (311). Therefore, we will conduct  a case-control 
analysis estimating three ORs:  luminal cases compared to controls,  HER2+/ER- cases 
compared to controls, and basal-like cases compared to controls. 
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2.6.4 Correction for multiple testing 
 
Conducting multiple tests in genetic association studies may increase the likelihood of 
obtaining false positives. A false positive occurs when a test statistic suggests that the null 
hypothesis should be rejected even though it is true.  We considered two different methods that 
control for the type 1 error rate. The Bonferroni method controls the family-wise error rate or the 
probability of at least one false positive. This method is computationally simple, dividing the p-
value cutoff (usually alpha= 0.05) by the number of tests conducted. While the Bonferroni 
correction method may be overly conservative for studies with thousands of multiple 
comparisons such as GWAS, it has been shown to be robust for up to a few hundred tests and 
easy to calculate (312). Furthermore, it is important to control the false negative rate. The false 
discovery rate or FDR has been touted a less conservative alternative to the Bonferroni method 
(313).  In FDR, p-values of each SNP are ranked, and all SNPs except the largest are corrected 
by multiplying by the total number of SNPs being tests divided by the p-value’s rank. Therefore, 
the FDR is the proportion of the rejected null hypotheses which were incorrectly rejected, or a 
type II error. FDR can be estimated using PROC MULTITEST in SAS (314). Ideally, it is 
important to balance both types of error. In this study, we will use FDR to adjust for multiple 
comparisons. 
However, both the Bonferroni and FDR make the independence assumption which may be 
violated if SNPs are found to be correlated (in high LD). LD refers to the non-random 
association between two alleles at two loci on a chromosome in a natural breeding population 
(283).Two SNPs are in LD if they are inherited together more often than expected by chance 
(285). There are several methods that measure linkage disequilbirum between SNPs including D’ 
and r
2
 (209, 315). The r
2
 statistic or correlation coefficient squared is a measure of how well the 
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identity of one allele at a polymorphic locus predicts the identity of the allele at another 
polymorphic locus. An r
2
=1.0 indicates that the examined loci are in “perfect LD” (209). The 
measure r
2
 is complementary to D’. r2 is equal to D2 divided by the product of the allele 
frequencies at the two loci. The absolute value of D’ is determined by dividing D by its 
maximum possible value, given the allele frequencies at the two loci. If D’=1, then SNPs are in 
complete LD. Values of D’<1 indicate that the complete LD has been disrupted. D’ values <1 
can be biased in small sample, therefore only D’ values close to one provide a useful 
information.  R
2
 has a more inituitive interpretation and will be used to evaluate potential LD in 
this study.  
2.6.5 Combined within-pathway effects 
 
When the number of susceptibility loci is small, the logistic regression model is an 
appropriate method for evaluating SNP-SNP interactions; however when there are multiple loci 
and interactions, the classical modeling approach may lack power due to high dimensionality of 
the data. There are several statistical methods available to reduce the dimensionality of the data 
and detect higher-order statistical interactions such as Monte Carlo methods, hierarchical 
modeling, machine learning, MDR, classification trees, and recursive partitioning (316-326) A 
common approach is to test the individual significance of each SNP, using the most significant p 
value as the p value for all the SNPs, then adjusting for multiple comparisons (327). However 
this test will have low power if the individual SNP are not in high LD with the causal variant. 
Omnibus tests for multiple SNPs or haplotypes allow for simultaneous analysis of all SNPs, but 
are based on a large number of degrees of freedom. To reduce the number of degrees of freedom, 
several approaches have used U-statstics, which summarizes the genomic similarity (genotype) 
to phenotype similarity (disease status) (328-331) . Kernel regression methods are closely related 
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to U-statistics in that they convert genomic information for a pair of individuals to a kernel score 
representing either similarity or dissimilarity, creating a positive semidefinite matrix when 
applied to all pairs of the individuals (332).  
In this proposed study, we will use a logistic kernel machine test (LKMT) as proposed by 
Wu to evaluate the combined effects of SNP in two biologically driven pathways (BER and 
TLS) using the software package SKAT(SNP-set Kernel Association Test) package in R. This 
pathway-based method combines machine learning and kernel regression models. First, a set of 
“different but correlated SNPs are grouped based on prior biological knowledge” to create a 
SNP-set. The formation of SNP-sets harnesses the LD between SNPs to increase power (328). 
This prior biological knowledge could be based on several potential correlations between SNPs, 
including physical proximity to a gene, evolutionarily conserved regions, and SNPs within a 
haplotype block (333). For the purposes of this study, we will group our SNPs based on 
established DNA repair pathways (BER and TLS). This will allow us to assess the combined 
effects of a panel of predetermined SNPs that interact in the same pathway.  
The second step evaluates the association between each SNP and breast cancer using 
logistic kernel-machine-based multi-locus test. This test combines the logistic kernel-machine 
testing approach of Liu (334) with the kernel framework suggested by Kwee (335). The LKMT 
uses a semi-definite kernel function to represent the influence of all SNPs in the SNP set. The 
choice of kernel changes the underlying basis for the nonparametric function defining the 
relationship between case-control status and the SNPs in the SNP-set. Choosing an appropriate 
kernel will increase power of the study. There are several choices for kernel type including 
linear, Gaussian, Identical-by-state (IBS), and weighted IBS (330, 333). In this study, we will use 
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a linear kernel since we are assuming a log linear model. The probability of being a case depends 
on the SNPs only through the function h(Z) therefore H0=h(z)=0. If the focus is hypothesis 
testing, the null hypothesis is h(Z)=0. Using a variance component score test, we will get an 
estimate for testing the global null hypothesis equals zero (333). A significant score test indicates 
that combined effects exist between SNPs. The estimate derived from this pathway-based test is 
a global p value representing the combined effect of individual SNPs in the BER and DNA 
bypass polymerases (TLS) pathways. Therefore, it may not be possible to estimate the 
interactions between pairs or sets of individual SNPs or distinguish which SNP is actually 
driving the association, if a significant association is found. Also, it is not possible to capture 
multi-SNP or epistatic effects among SNPs in separate SNP sets.   
This method has a number of advantages over other multi-SNP methods (330, 331, 336). 
There is no need for a parametric model a priori which allows for estimation of joint and 
nonlinear effects. While Schaid’s method makes the assumption that all variants have the same 
direction of effect, this method allows for flexibility in the functional relationship between the 
SNPs in a SNP set and the outcome. (330). Additionally, similar to hierarchical modeling, 
kernel-based machine learning logistic regression reduces the number of hypothesis being tested, 
which lowers the significance threshold and increases power. This is especially relevant for 
SNPs which have moderate or low individual effects. In summary, the advantages of this method 
are the reduced numbers of hypothesis being tested, improved power when SNP have modest 
effects, and model flexibility to account for non-linear effects. In addition, one of the most 
important features of this model is that it can simultaneously account for covariates, which is a 
limitation of most other similar methods (333). 
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2.7 Power calculations 
 
QUANTO Version 1.2.4 was used for power calculations (337). The study had a fixed 
sample size of 3,748 genotyped cases and controls with a control-case ratio of 0.90 (1,972 cases 
and 1,776 controls). For Whites, the overall sample size was 2,346 (1,229 cases and 1,117 
controls) with a control-case ratio of 0.91.  For African-Americans, the overall sample size was 
1,400 (742 cases and 658 controls) with a control-case ratio of 0.89. For luminal subtype 
calculations, the overall sample size was 2,571 (795 luminal cases vs. 1,776 controls) with a 
control-case ratio of 2.23. For basal-like subtype calculations, the overall sample size was 1,976 
(200 basal-like vs. 1,776 controls) with a control-case ratio of 8.88. For HER2+/ER- subtype 
calculations, the overall sample size was 1,870 (94 HER2+/ER- cases vs. 1,776 controls) with a 
control-case ratio of 18.9.We anticipated that the estimates for HER2+/ER- and basal-like 
subtype tumors will be less precise than those for luminal subtype tumors due to sample size 
limitations. Based on the previous literature of genetic association studies of DNA repair and 
breast cancer, we estimated effects ranging from OR=1.0 to OR=2.0. Tests for statistical 
significance were two-sided with an alpha level of 0.05. Given our sample sizes, assuming 80% 
power, we can detect minimum ORs of 1.2-1.4 depending on the MAF in Whites, 1.3-1.6 in 
African-Americans, and 1.5-1.9 for luminal subtype (Figures 12-16). 
2.8 Limitations 
 
2.8.1 Exposure (genotype) misclassification 
 
There is the potential for exposure misclassification due to genotyping errors in the 
laboratory. However, several measures were in place to minimize genotyping errors. In the 
overall study, blind duplicates of 169 samples were assayed to measure the reproducibility and 
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no SNPs were excluded. Assay intensity data and genotype cluster images were reviewed for all 
SNPs. Out of 2,039 cases and 1,818 controls, 103 subjects (64 cases and 39 controls) and 204 
samples had low call rates (<95%) for SNPs and were therefore excluded.   
In the current study, a total of 8 SNPs were excluded due to low signal intensity or 
indistinguishable genotype clusters. In addition, tests of Hardy-Weinberg equilibrium were 
conducted. Four SNPs in the BER pathway failed HWE and were excluded from subsequent 
analyses. Overall, there were 3,748 or 97% of enrolled participants (1,972 cases and 1,776 
controls) with successfully genotyped data. A comparison of participants with and without 
genotyped data did not show significant differences (data not shown).    
2.8.2 Outcome (phenotype) misclassification 
 
CBCS had detailed subtype data on tumors from a majority of cases (62%) allowing a 
unique investigation of the genetics of specific breast cancer subtypes. However, cases with 
subtype data were more likely to be African American and to have a later stage at diagnosis, 
which may bias estimates for SNPs related to race or disease aggressiveness (22). However, 
there were no significant differences for age, menopausal status, or family history between 
CBCS cases with and without subtyping data. 
In phase 2 of the CBCS, in situ cancers were enrolled in the study. There has been some 
debate to whether in situ cases should be included along with the invasive cases. Millikan argues 
that identifying risk factors in in situ tumors that occur during an earlier or intermediate stage of 
cancer progression may be informative for developing new preventive and treatment measures 
(74). Furthermore, studies have shown that in situ and invasive tumors share similar risk factor 
profiles and clinical features with effects in the same direction, albeit with varying magnitude of 
effects (70, 72, 338, 339).  
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Due to a lack of fresh frozen tissue samples, gene expression microarray analysis in 
CBCS phase 1 and 2 was not feasible and IHC was used as a proxy method in Phase 1 and 2 to 
subtype tumors. Several studies have evaluated the concordance between IHC and gene 
expression. While studies showed good correlation for ER and HER2 IHC markers with gene 
expression, there has been some debate on the lack of sensitivity for staining CK 5/6 in 
identifying basal-like cancers using IHC methods (58, 296). 
The definitions for “intrinsic” molecular subtypes are constantly evolving. We have yet 
to develop a standardized definition for the molecular subtypes. Therefore, comparability 
between study results may be compromised. In many studies, triple negative is used as a proxy 
for basal-like tumors. While approximately 70% of triple-negative breast cancers express basal 
markers, the remaining 30% are grouped together as unclassified (66). Cheang identified 
differences in prognostic values between basal-type and triple-negative cancers, with basal-like 
phenotype as a better prognostic predictor than triple-negative phenotype (340).Therefore, It is 
important to distinguish between triple-negative and basal-like subtypes (341). ER/PR status was 
successfully abstracted from medical records for 80% of cases. For the remaining 20% of cases, 
this data was obtained using IHC methods if tissue was available (281).  
2.8.3 Covariate misclassification 
 
CBCS participants self-reported their race during the baseline interview. Participants who 
self-reported race as other than White or African-American were excluded due to small sample 
size (2%). Barnholtz-Sloan 2005 reported that adjusting for individual European ancestry 
provided a better fit to the data compared with adjusting for self-reported race only 
(301).Therefore, all models in the study will be adjusted by AIMs to control for residual 
confounding by race (i.e. population stratification).  
 73 
 
2.8.4 Selection bias  
 
The parent study made an intentional effort to oversample African-Americans into the 
study.  Younger African-American women have been traditionally understudied in breast cancer 
research therefore special efforts were made to include study counties with high proportions of 
African American women living in rural areas. There are also statistical advantages to 
randomized recruitment. Potential sampling bias from randomized recruitment was adjusted 
using an offset term in the analysis (278). Despite randomized design and intensive recruitment 
efforts, African-American women were less likely to be enrolled in the study compared to 
Whites. Among cases, older African-Americans had the lowest overall response rate (70.8%) 
while younger Whites had the highest overall response rate (82.7%). Among controls, younger 
African-Americans had the lowest overall response rates (47.8%) while older Whites had the 
highest (77.9%).  African-American in situ cases and controls were also were less likely to be 
selected into the study. 
The final data set included 1,809 white women (55%) compared to 1,505 African-
American women (45%). This could potentially have implications for power in detecting effects 
in African-Americans. Comparing MAFs in CBCS controls stratified by race to MAFs in public 
databases (i.e. HapMap) would be one method to assess potential selection bias. 
2.8.5 Missing data  
 
Out of total of 4,333 enrolled participants,  2,045 (88%) of cases and 1,818 (90%) 
controls provided a DNA sample at interview leaving 272 cases and 204 controls either had 
insufficient DNA for genotyping or did not have a sample for genotyping. There were 
differences between by race and case status for those who were genotyped successfully and those 
who were not. African-Americans and cases were less likely to have genotyped data (281). 
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However, there were no differences between genotyped and non-genotyped participants for age, 
race, and family history. In addition, 47% of enrolled cases did not have IHC data available for 
subtyping, but there were no differences between those with and without subtype information 
(307). 
There were a few novel bypass polymerase SNPs that were identified after CBCS 
completed its genotyping phase and as a result are not included in the analysis. Two recently 
identified bypass polymerases (POLK and POLN) were not genotyped in CBCS. Of significance, 
several SNPs in POLK (rs3213801, rs5744533, rs3756558) have been found to be significantly 
associated with pre-menopausal breast risk (p<0.05) (202) and interact with other Y family 
members (243, 255). 
In addition, although we had measured data on environmental/lifestyle risk factors, no 
gene x environment interactions were tested. This was after consideration of low power to detect 
interaction effects in the current study.  
2.9 Strengths of the study 
 
The innovative study design of integrating population-based epidemiology with genetic 
and molecular data is one of the main strengths of the study (275). The molecular subtyping of 
tumors has revealed new insights into the heterogeneity of breast cancer (22, 59, 72, 307).  In 
addition, the use of population-based controls representing women from the same geographic 
region strengthens the external validity of the study. The 24 study counties were selected to 
represent a larger African-American and rural population (281). In addition, CBCS took the 
initiative to collaborate with hospital registrars in the state to design the Rapid Case 
Ascertainment System, a system designed to minimize the delay in contacting cancer patients 
who may be otherwise been lost to study participation due to death or relocation.  
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 Another benefit of randomized recruitment was the oversampling of younger and 
African-American women to allow better representation of these two understudied subgroups 
(277). Probability matching increases the relative sample size for younger African-Americans. 
There are also advantages over traditional matching techniques such as frequency matching 
including the simultaneous recruitment of cases and controls in a more time efficient manner. 
Another advantage is the ability to estimate effects associated with matching factors with better 
precision than under random sampling (278).   
CBCS included a racially diverse study population that allowed for results to be stratified 
by race. Several CBCS studies have been able to report significant race-specific effects, which is 
important due to the differences in genetic architecture among those with African descent (342, 
343). . As mentioned above, LD block size tends to be shorter in admixed populations such as 
African-Americans due to genetic drift and recombination.  
Despite finding no significant main effects, a CBCS report found a XRCC1 SNP to be 
associated with African-American race.(92). Another CBCS report found several SNPs in NER 
genes to be associated with an increased risk in African Americans (344). Many earlier studies 
lacked the power to obtain precise estimates for African-Americans. Similarly, this proposed 
study will have the power to report race-specific estimates.  
This is one of the first studies to look at the effects of bypass polymerases on breast 
cancer risk. To date, only two other reports from the NHS II cohort have evaluated bypass 
polymerase SNPs in breast cancer (202, 213) .  
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2.10 Public health significance  
  
 The results of this proposed study may enhance our understanding of the complex 
biological processes involved in the development of breast carcinogenesis. The role of bypass 
polymerases in breast cancer has not been fully elucidated and this proposed study will be one of 
the first to further examine this association. Ultimately these results may inform future research 
on DNA bypass polymerases as potential targeted preventative strategies and therapies for breast 
cancer, especially for women with basal-like tumors that are resistant to traditional 
chemotherapy (345, 346). Furthermore, the CBCS dataset allows for the evaluation of both race-
specific and subtype-specific associations. Since younger African-Americans carry a 
disproportionate burden of basal-like disease, the results derived from this study will be directly 
generalizable to this high-risk subgroup. In the future, the hope is that cancer therapies can be 
selected based on genomic profiles that identify tumor subtypes and other biological markers 
(347).  
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Figure 6. Carolina Breast Cancer Study Area (Phase 1 and 2) 
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Table 5. CBCS Sampling Probabilities 
 
Phase I invasive cases Age <50 Age ≥ 50 
African American  100% 75% 
White 67% 20% 
Phase II invasive cases   
African American 100% 100% 
White 50% 20% 
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Table 6. Base Excision Repair SNPs 
 
Gene
Type of 
variant
Original SNP 
set selected
Failed Pre-
genotyping
Failed Post-
genotyping
Successfully 
Genotyped
Allele Not 
Polymorphic
Failed HWE 
Included in 
Final Analyis
XRCC1 Arg194Trp rs1799782 rs1799782 rs1799782
Arg280His rs25489 rs25489 rs25489
Arg399Gln rs25487 rs25487 rs25487
N576T rs2307177 rs2307177 
V72A rs25496 rs25496 rs25496 (W) rs25496 (AA)
3'UTR rs2682558 rs2682558 rs2682558
T304A rs25490 rs25490 
5'UTR rs3213245 rs3213245 
APE1 Asp148Glu rs3136820 rs3136820 rs3136820
5'UTR rs1760944 rs1760944 
Q51H rs1048945 rs1048945 rs1048945 (AA) rs1048945 (W)
OGG1 Ser326Cys rs1052133 rs1052133 rs1052133
A85S rs17050550 rs17050550 
R229Q rs1805373 rs1805373 rs1805373 (W) rs1805373 (AA)
MUTYH Gln324His rs3219489 rs3219489 rs3219489
R507Q rs3219497 rs3219497 rs3219497 (W) rs3219497 (AA)
V8M rs3219484 rs3219484 rs3219484 
MBD4 splice rs140696 rs140696 rs140696
E346K rs140693 rs140693
S342P rs2307289 rs2307289 rs2307289 (W) rs2307289 (AA)
A/T/ S 273 rs10342 rs10342 
MPG 5'UTR rs710079 rs710079 
rs3176380 rs3176380
rs2234890 rs2234890 
rs710080 rs 710080 rs710080
NTHL1 D239Y rs3087468 rs3087468 rs3087468 
TDG G199S rs4135113 rs4135113 rs4135113 
(AA)V367L rs2888805 rs2888805 
5'UTR rs4135038 rs4135038
UNG 3'UTR rs1018784 rs1018784 
3'UTR rs3219275 rs3219275 rs3219275 (W) rs3219275 (AA)
7
9
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POLB Splice rs2307155 rs2307155 
P 242 R rs3136797 rs3136797 rs3136797 (AA) rs3136797 (W)
LIG3 R 867 H rs3136025 rs3136025 rs3136025 (W) rs3136025 (AA)
5'UTR rs12945428 rs12945428 
3'UTR rs4796030 rs4796030 rs4796030 
NEIL1 D 252 N rs5745926 rs5745926 rs5745926 (W) rs5745926 (AA)
NEIL2 R 103 W rs8191612 rs8191612 
R 103 Q rs8191613 rs8191613 rs8191613
R 257 L rs8191664 rs8191664 rs8191664 (AA) rs8191664 (W)
3'UTR rs1534862 rs1534862 rs1534862
SMUG1 3'UTR rs3136391 rs3136391 rs3136391 (W) rs3136391 (AA)
5'UTR rs3087404 rs3087404 rs3087404
POLE2 L 458 V rs34574266 rs34574266 
PCNA intron rs25406 rs25406 rs25406
intron rs17352 rs17352 rs17352
splice rs17349 rs17349 rs17349
3'UTR rs3626 rs3626 
RFC1 splice rs17288820 rs17288820 rs17288820 (W) rs17288820 (AA)
I 598 V rs2066791 rs2066791 rs2066791 (W) rs2066791 (AA)
5'UTR rs17287851 rs17287851 rs17287851 (W) rs17287851 (AA)
FEN1 5'UTR rs412334 rs412334 rs412334
3'UTR rs4246215 rs4246215 
PARP1 K 123 R rs1805407 rs1805407
V 762 A rs1136410 rs1136410 rs1136410
A 188 T rs1805409 rs1805409 rs1805409
5'UTR rs907187 rs907187 
PARP3 S 92 N rs34224216 rs34224216 rs34224216
Q 270 R rs323870 rs323870 rs323870
Table 6. continued
8
0
 
 
 81 
 
 
 
Table 7. Bypass polymerase SNPs 
Gene
Type of 
variant
Original SNP 
set selected
Failed Pre-
genotyping
Failed Post-
genotyping
Successfully 
Genotyped
Allele Not 
Polymorphic Failed HWE 
Included in 
Final Analyis
POLH T 329 I rs 35675573 rs 35675573 rs 35675573
M 647 L rs 6941583 rs 6941583 
M 595 V rs 9333555 rs 9333555 rs 9333555
3'UTR rs 6899628 rs 6899628 rs 6899628
upstream rs 9333500 rs 9333500 
POLI H 449 R rs 3730823 rs 3730823 rs 3730823
F 507 S rs 3218786 rs 3218786 rs 3218786
A 706 T rs 8305  rs 8305  rs 8305  
POLL R 438 W rs 3730477 rs 3730477 rs 3730477
splice rs 3730475 rs 3730475 rs 3730475
T 221 P rs 3730463 rs 3730463 rs 3730463
POLM V 246 F rs 28382653 rs 28382653 rs 28382653
G 220 A rs 28382644 rs 28382644 rs 28382644
E 107 D rs 28382635 rs 28382635 rs 28382635
POLQ A 581 V rs 487848 rs 487848 rs 487848
H 1201 R rs 3218651 rs 3218651 rs 3218651
A 2304 V rs 532411 rs 532411 rs 532411
Q 2513 R rs 1381057 rs 1381057 rs 1381057
L 2538 V rs 3218634 rs 3218634 rs 3218634
R 1953 Q rs 3218637 rs 3218637 rs 3218637
T 982 R rs 3218649 rs 3218649 rs 3218649
R 66 I rs 702017 rs 702017 rs 702017
REV1L V 138 M rs 3087403 rs 3087403 rs 3087403
F 257 S rs 3087386 rs 3087386 rs 3087386
N 373 S rs 3087399 rs 3087399 rs 3087399
REV3L Y 1078 C rs 458017 rs 458017 rs 458017
S 1142 L rs 3218600 rs 3218600 
T 11461 I rs 462779 rs 462779 
P 1713 S rs 17539651 rs 17539651 rs 17539651
V 2986 I rs 3204953 rs 3204953 
8
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Figure 7. Enrolled cases with genotyped data 
 
  
Contact rate: 3292/3360=98% Contact rate: 3706/4465=83.0%
Cooperation rate: 2412/3042=79.3% Cooperation rate: 2243/3164=70.9%
Overall response rate: 2412/3110=77.6% Overall response rate: 2243/3923=57.2%
CBCS Cases CBCS Controls
3360 Sampled 4465 Sampled
220 MD Refusals
221 Ineligible 441 Ineligible
39 Deceased 101 Deceased
68 Unlocatable 759 Unlocatable
2811 Eligible 3164 Eligible
410 cases refused 921 controls refused 
133 mini surveys 255 mini surveys
2279 Enrolled 1988  Enrolled
260 Did not provide 
DNA sample
40  Did not provide 
DNA sample
2019 with DNA 
sample
1948 with DNA 
sample
201 Insufficient DNA/
Failed genotyping QC Failed genotyping QC
1946 successfully 
genotyped
1747 successfully 
genotyped
736 No tumor tissue/
Subtype incomplete
1210 successfully 
subtyped
73 Insufficient DNA/
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Table 8. Subtype distribution by race 
 
 
Tumor Subtype 
White 
 N (%) 
African-American  
N (%) 
Luminal (n= 788) 601(70.9) 332 (57.0) 
Basal-like (n=199) 
 
103(12.2) 122 (21.0) 
 
HER2+/ER- (n=94) 68 (8.1) 48 (8.3) 
 
Unclassified (n=129) 71 (8.4) 79 (13.6) 
      
Total N=1210 843 581 
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Figure 8. Enrolled cases with complete IHC and genotyped data
Reason for exclusion
Submitted tumor tissue (N=1845) No tissue provided (N=466)
No subtype data available (N=752)
Luminal A Luminal B HER2+/ER- Basal-like Unclassified
N=796 N=137 N=116 N=225 N=150 Not successfully genotyped (N=204)
Complete IHC and genotyped data (N=1220)
Luminal A Luminal B HER2+/ER- Basal-like Unclassified
N=679 N=116 N=94 N=200 N=131
Sent for IHC analysis (N=1424)
2311 cases enrolled
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      From O’Brien 2013 
 
Figure 9. Directed Acyclic Graph (DAG) 
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Figure 10. Confounding by ancestry 
From Walchoder 2000
  
 
Table 9. Set of 144 Ancestry Informative Markers (AIMs) 
rs12094678 rs11264110 rs10908312* rs7161* rs6666101 rs7512316 rs4659762 rs12129648 rs798443 rs12612040 rs1508061 rs7575147* 
rs3755446 rs10195705 rs1257010 rs4149436 rs17049450 rs17261772 rs1117382 rs1372115 rs12692701 rs1982235 rs7424137 rs12997060 
rs10202705 rs3791896 rs11901793 rs155409* rs1303629 rs13318432 rs2660769 rs1462309 rs6414248 rs1256197 rs13080353* rs6765491 
rs9849733 rs833282 rs4859147 rs6820509 rs2687427 rs9306906 rs4619931 rs12640848 rs7689609 rs10028057* rs6535244 rs385194 
rs1372894 rs316598 rs13169284 rs16891982 rs10056388 rs13173738 rs10041728 rs33957 rs1917028 rs1380014 rs13178470 rs6556352 
rs857440 rs2451563 rs10806263 rs6937164 rs4896780* rs10952147 rs7810554 rs7788641 rs17520733 rs10254729 rs10255169 rs344454 
rs4602918 rs4143633 rs1870571 rs12676654 rs13261248 rs9297712 rs7021690 rs10124991 rs1415723 rs3861709 rs10962612* rs1885167*
rs2777804 rs1412521 rs870272 rs2488465 rs1335826 rs9416972 rs1733731 rs2184033 rs4529792 rs503677 rs9416026 rs11000419 
rs1911999 rs1125217* rs7107482 rs11607932 rs7111814 rs11223503 rs2416791 rs1490728 rs10842753 rs7134682 rs328744 rs3759171 
rs2596793 rs645510 rs9525462 rs9543532 rs4885162 rs9530646 rs6491743 rs1477921 rs222674 rs2246695 rs710052 rs12900552 
rs1470608 rs12900262 rs4489979 rs7086 rs4923940 rs12594483 rs567357 rs735480 rs1426654* rs17269594 rs6494466 rs9806307 
rs4506877 rs4350528 rs9923864 rs7187359 rs12926237 rs11150219 rs7189172 rs1862819 rs4792105 rs12945601 rs1043809 rs2593595 
rs4793237 rs228768 rs11652805 rs4789070 rs897351 rs8113143 rs1991818 rs1011643 rs2426515 rs6023376 rs4811651* rs2075902 
rs4823460 
*SNPs which failed genotyping (i.e. weak signal intensity or in distinguishable genotype clusters)87
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Figure 11. Classification schema for tumor subtypes 
 
  
 89 
 
 
 
 
Figure 12. Power curves for African Americans  
 
Assumptions: Additive genetic model: two-sided α=0.05; Control to Case Ratio:  
0.89 P(Breast Ca at baseline)=0.01 
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Figure 13. Power curves for Whites 
 
Assumptions: Additive genetic model, two-sided α=0.05; Control to Case Ratio: 
0.91; P(Breast Ca at baseline)=0.01 
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Figure 14. Power curves for luminal vs. controls 
 
Assumptions: Additive genetic model, two-sided α=0.05; Control to Case Ratio: 2.2 
P(Breast Ca at baseline)=0.01 
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Figure 15. Power curves for Basal-like vs controls 
 
Assumptions: Additive genetic model, two-sided α=0.05; Control to Case Ratio: 8.8 
P(Breast Ca at baseline)=0.01 
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Figure 16. Power curves for HER2+/ER- vs controls 
 
Assumptions: Additive genetic model, two-sided α=0.05; Control to Case Ratio:18.8  
P(Breast Ca at baseline)=0.01 
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CHAPTER 3.  SINGLE NUCLEOTIDE POLYMORPHISMS IN BASE EXCISION 
REPAIR PATHWAY GENES AND ASSOCIATION WITH BREAST CANCER AND 
BREAST CANCER SUBTYPES AMONG AFRICAN AMERICANS AND WHITES 
 
3.1 Introduction 
 
 The role of DNA repair in the initiation and progression of cancer has been the subject of 
much investigation, both experimental and epidemiologic.  Evidence has supported the role of 
deficient DNA repair as biologically relevant for breast tumorigenesis, including rare and highly 
penetrant mutations in BRCA1, a tumor suppressor gene that plays an essential role in the 
promotion and regulation of DNA repair (348). However, BRCA1 mutations and rare variants of 
other genes appear to only account for 15-20% of suspected genetic predisposition to breast 
cancer, leaving the majority of genetic risk of breast cancer unexplained (349).   
  DNA repair pathways, including base excision repair (BER), nucleotide excision repair 
(NER), mismatch repair (MMR) and double-strand break repair (DSB), homologous 
recombination (HR) and non-homologous end-joining (NHEJ) have been investigated in 
experimental systems and epidemiologic studies. The BER pathway is primarily responsible for 
the repair of DNA damage induced by X-rays, oxygen radicals, and alkylating agents. BER is 
specialized to repair non-bulky DNA base lesions such as base adducts and abasic sites (105). No 
consistent associations between common genetic variation in BER genes and breast cancer risk 
were observed in previous genetic association studies conducted to date including several meta-
analyses (137-139, 141-143, 145, 146, 162, 177-180, 182-184, 186, 187, 189, 190, 194, 206-208, 
212, 350-355). It is possible that conflicting results among study findings may be explained by 
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heterogeneity of association according to tumor subtype and limited coverage of the BER 
pathway. There may also be different associations by race.   
 We conducted a candidate pathway analysis of BER gene variants using data from the 
Carolina Breast Cancer Study (CBCS). CBCS, a large population-based case-control study with 
a racially diverse study population (40% African American and other non-Whites) and data on 
tumor subtype, offered an important resource to evaluate both subtype and race specific effects.  
Previous CBCS reports examined functional SNPs in XRCC1 (rs1799782, rs25487, and 
rs25489) (92, 208); in this report we had substantial coverage of the candidate SNPs in BER, 
including 15 BER genes and 31 associated SNPs. 
3.2 Materials and Methods 
3.2.1 Study population 
 
The Carolina Breast Cancer Study (CBCS) is a population-based case-control study of 
breast cancer conducted in 24 counties of central and eastern North Carolina and has been 
described previously (275, 356). Briefly, rapid case ascertainment was implemented to identify 
cases from the North Carolina Central Cancer Registry (NCCCR) (277). Eligible cases included 
women ages 20-74, living in the study procurement area during the period of study enrollment, 
diagnosed with a primary invasive breast cancer between 1993 and 1996 (Phase 1) and 1996 and 
2001 (Phase 2). In Phase 2 of the study, in situ cases of breast cancer were also eligible. Eligible 
controls were identified using Department of Motor Vehicles (DMV) records for women under 
age 65 and Health Care Financing Administration lists for women ages 65 and older. Controls 
were frequency matched to cases based on race and age using randomized recruitment to 
oversample African American and younger women (278). This study was approved by the 
Institutional Review Board of the University of North Carolina at Chapel Hill.  
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3.2.2 Baseline Study Visit 
 
Study subjects who met eligibility criteria and provided written informed consent were 
scheduled for an in-home visit that included an interview and specimen collection by a trained 
study nurse. In addition, during the in-home visit breast cancer cases were asked to provide 
permission to obtain medical records and tumor tissue. The nurse-administered interview 
collected information about demographics and known and suspected breast cancer risk factors 
such as family history, personal medical history, occupational history, and reproductive factors. 
At the end of the interview, the nurse interviewer collected a 30 mL blood sample. Blood 
samples were collected from 88% of cases and 90% of controls. Whites were more likely to 
provide blood samples than African Americans (88% vs. 83%), but there were no significant 
differences in other risk factors for those who provided a blood sample and those who did not 
(281, 282). A total of 2,311 cases (894 African American and 1,417 Whites) and 2,022 controls 
(788 African Americans and 1,234 Whites) were successfully enrolled in Phase 1 and 2 of the 
study. This included 862 cases and 790 from Phase 1.  The overall response rates for cases and 
controls were 78% and 57% respectively. Other study response rates have been reported 
previously (281).       
3.2.3 SNP selection and genotyping 
         
 We searched SNP500 (http://snp500cancer.nci.nih.gov) and dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP) databases and selected 58 SNPs in 19 BER genes based on  
in vitro or in silico functional effect in BER or previously published studies in the breast cancer 
literature. These SNPs included non-synonymous missense, regulatory (5’UTR and 3’ UTR), and 
intronic variants (including splice SNPs) with a minor allele frequency (MAF) of at least 5% in 
African Americans or Whites (Table 11).   
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DNA was extracted from peripheral blood lymphocytes by standard methods using an 
automated ABI-DNA extractor (Nuclei Acid Purification System, Applied Biosystems, Foster 
City, CA, USA)  (356). High-throughput genotyping of selected SNPs was conducted as part of a 
larger set of 1536 SNPs by the UNC Mammalian Genotyping Core using Illumina GoldenGate 
assay (Illumina, Inc., San Diego, CA) (290).  Assay intensity data and genotype cluster images 
for all SNPs were reviewed individually. Overall, 1,373 of 1536 (89%) SNPs passed quality 
control. Out of the 41 genotyped BER SNPs, we excluded 4 SNPs for which genotyping resulted 
in poor signal intensity or genotyping clustering, as well as, loci that were non-polymorphic 
overall  (rs1805409 and rs34224216) or in either race (11 SNPs in Whites, 3 SNP in African 
Americans). Among the remaining SNPs, 4 SNPs (rs2682558, rs710080, rs4135113, and 
rs323870) failed Hardy Weinberg Equilibrium (HWE) (p<0.05) and were excluded from further 
analysis (Table 12). Our final analysis included genotyped data for 31 SNPs in the base excision 
pathway in 1972 of 2311 (85%) cases and 1776 of 2022 (88%) controls. In addition 144 ancestry 
informative markers (AIMs) were also genotyped to estimate African and European ancestry 
(281). 
3.2.4 IHC analysis and subtype ascertainment 
 
Immunohistochemical (IHC) markers were used as a surrogate for gene expression based 
subtyping (58). IHC staining and scoring procedures have been explained previously in detail 
(22, 53, 58, 59). Briefly, tumor tissue blocks were used to confirm diagnosis by a pathologist and 
to conduct IHC subtyping. Formalin-fixed paraffin-embedded (FFPE) tumor tissue was available 
80% of cases and immunohistochemistry was completed for 62% of cases. ER/PR status was 
abstracted from medical records for 80% of cases while IHC was used for the remaining 20% of 
cases. The concordance between these two methods was 81% (307). A total of 1424 (77% of 
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available tumor blocks) were successfully subtyped and classified into one of five “intrinsic” 
subtype groups:  luminal A (ER+ and/or PR+, HER2-, luminal B (ER+ and/or PR+, HER2+), 
HER2+/ER- (ER-, PR-, HER2+), and basal-like (ER-, PR-, HER2-, HER1+ and/or CK 5/6+), 
with those negative for all 5 markers considered ‘unclassified’ (59). 
For the current study, we classified tumors as either luminal (ER+ and/or PR+; n=788), 
basal-like (ER-, PR-, HER2-, CK 5/6+ and/or EGFR+; n=199) or HER2+/ER- (n=94). We 
excluded ‘unclassified’ tumors from further analysis due to their uncertain status. The major 
distinction between the two luminal subtypes are their proliferation signatures, measured by the 
expression of CCNB1, MKI67, and MYBL2 (49). HER2 expression only identifies about 30% of 
luminal B tumors.  In the current study, we did not have information about these proliferation 
markers and therefore combined Luminal A and B tumors into a single ‘luminal’ category (48, 
49). Additionally, most other studies do not have subtype data available and only have estrogen 
receptor status data. Therefore, we conducted an additional exploratory analysis using estrogen 
receptor (ER) status to evaluate comparability to “intrinsic” subtype results. We found that ER 
positive effects were concordant with luminal subtype results; while ER negative (ER-) effects 
correlated with those of basal-like and HER2+/ER- subtypes (Table 15). There were no 
differences between CBCS cases with and without subtyping data in terms of age, menopausal 
status, or family history. 
3.2.5 Statistical analysis 
 
We calculated allele and genotype frequencies stratified by case status and self-reported 
race (African American or White). We assessed departure from HWE for each locus by 
comparing expected versus observed genotype frequencies among race-specific (White and 
African American) controls using exact χ2 tests (p<0.05). We calculated pairwise linkage 
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disequilibrium (LD) r
2 
using SAS Genetics (version9.1.3) (SAS Institute, Cary, NC) stratified by 
race (Table 17). 
We used unconditional logistic regression models to estimate odds ratios (ORs) and 95% 
confidence intervals (CIs) for race-stratifed effects of base excision repair SNPs on breast cancer, 
based on the additive model. We coded genotype as an ordinal variable (0, 1, or 2 for the number 
of minor alleles carried by the individual). If the minor allele frequency (MAF) differed by race, 
the more common allele in Whites was used as the referent group for both populations. We 
excluded non-polymorphic SNPs or SNPs with a minor allele frequency of less than 0.05 in 
either race. Less than 2% of participants self-identified as another race and were not included in 
the final analysis. We adjusted for proportion of African ancestry, as measured with a set of 144 
ancestry informative markers (AIMs) (297, 306). Final models were adjusted for age at 
diagnosis, proportion of African ancestry and offset term for the sampling design (278). 
3.2.6 Subtype analyses 
 
We coded breast cancer subtype as a categorical variable with four levels (control, 
luminal, HER2+/ER-, and basal-like).  We used unconditional polytomous regression models to 
estimate ORs and 95% CI for each subtype compared to controls. 
3.2.7 Correction for multiple testing 
 
We used FDR correction for multiple testing, following the method of Benjamini and 
Hochberg (313). The false discovery rate is defined as “the expected proportion of errors among 
the rejected hypotheses” (313). Corrections were based on the number of SNPs tested and were 
performed separately for African American and Whites in the race-stratified analysis and 
separately for luminal, HER2+/ER- and basal-like categories in the subtype analysis. Observed 
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p-values from the additive model were used to determine q-values. The q-value is defined as the 
minimum FDR that can be attained when calling a SNP significant (i.e., expected proportion of 
false positives) (314). Q-values were computed using the software package R. Statistical 
significance was set at q<0.10.  
3.2.8 Pathway-based analysis  
We used SKAT (SNP-set Kernel Association Test) to evaluate the combined effects of 
the genotyped SNPs in the BER pathway (333). A SNP-set refers to a set of related SNPs that are 
grouped based on prior biological knowledge. In the case of the current study, SNP groups were 
defined based on the base excision repair pathway (333).  The formation of SNP-sets harnesses 
the potential correlation between SNPs to increase power (328). We chose a linear kernel since 
we assumed a log linear model. Kernel regression methods convert genomic information for a 
pair of individuals to a kernel score representing either similarity or dissimilarity. When applied 
to all pairs of the individuals, this information formed a positive semi-definite matrix (332). We 
tested the global hypothesis for SNPs in the pathway separately for White and African American 
participants (333).  
3.3 Results 
 
Characteristics of the study population with genotyping data are described in Table 10. 
The distributions of age, proportion of African ancestry, and menopausal status were similar 
between cases and controls. African American cases were more likely to be diagnosed at a later 
stage and were more likely to have tumors that were ER negative. African Americans were more 
likely to be classified as having basal-like tumors compared to Whites (22% vs. 11%). 
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3.3.1 Genotype associations by race 
 
The race-stratified odds ratios for BER SNPs are summarized in Table 13. Across both 
race groups, six SNPs from 4 BER genes (OGG1, NEIL2, PCNA, and UNG) were associated 
with an increased or decreased breast cancer risk under the additive model (p<0.05). Among 
Whites, the results revealed that OGG1 rs1052133 and NEIL2 rs1534862 were significantly 
associated with an increased risk in breast cancer (rs1052133 CG/CC vs. GG, OR= 1.17, 95% 
CI: 1.01-1.36, P = 0.036; rs1534862 CT/TT vs. CC, OR=1.24; 95% CI: 1.07-1.44, P=0.004). 
Two SNPs in PCNA were inversely associated with breast cancer (rs17349 CT/TT vs. CC, 
OR=0.79; 95% CI: 0.64- 0.96, P=0.019; rs17352 AC/CC vs. AA, OR=0.76; 95% CI: 0.63-0.93, 
P=0.007), respectively. Among African Americans, we found another NEIL2 SNP to be 
inversely associated with risk of breast cancer (rs8191613 AG/AA vs. GG, OR=0.72; 95% CI: 
0.52-0.98, P=0.038). UNG rs3219275 was also associated with a significant increased risk of 
breast cancer (rs3219275 AT/AA vs. TT, OR=1.44; 95% CI: 1.01-2.06, P=0.044). After 
adjustment for multiple testing, only 2 SNPs (NEIL2 1534862 and PCNA 17352) remained 
significant (q=0.10). 
3.3.2 Genotype associations by subtype 
 
In the tumor subtype analysis, the NEIL2 SNP (rs1534862) was positively associated 
with luminal and HER2+/ER- breast cancer (rs1534862 CT/TT vs. CC; OR=1.27; 95% CI: 1.06-
1.52; P=0.009 and OR=1.68; 95% CI: 1.09-2.57; P=0.018), respectively (Table 14). We also 
found a significant inverse association between FEN1 SNP (rs412334) and basal-like breast 
cancer (rs412334 AG/AA vs. GG; OR=0.56; 95% CI: 0.35-0.88; P=0.011). The ER+ SNPs 
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correlated with luminal SNPs while ER- SNPs correlated with HER2+/ER- and basal-like SNPs 
(Table 15). However, after FDR adjustment for multiple testing, none of these SNPs remained 
significant (q=0.10).  
3.3.3 Pathway-based analysis 
 
We assessed the global p-value for two different SNP-sets (African American and White) 
using the SNP-set Kernel Association Test (SKAT), adjusted for AIMs, and offset term.  We did 
not find any significant associations. A Kernel machine test of no linear effects yielded a global 
p-value of 0.84 and 0.16 for African Americans, and Whites, respectively (Table 16). 
3.4 Discussion  
 
We found evidence for both race- and subtype -specific associations between BER 
variants and breast cancer risk. Some associations represent new findings. In Whites, 2 SNPs 
were associated with an increased risk (OGG1 rs1052133 and NEIL2 rs1534862) and 2 SNPs in 
high LD (r
2
=0.95) in PCNA (rs17349 and rs17352), had an inverse association (Table 13). In 
African Americans, we found a NEIL2 SNP (rs8191613) to be associated with a reduced risk and 
UNG rs3219725 to be associated with an increased risk. Two previous CBCS studies, based on 
the first study phase (1993-1996) had evaluated the association between XRCC1 SNPs 
(rs1799782, rs25487, and rs25489) and breast cancer risk (92, 208).  Duell et al. found XRCC1 
rs1799782 to be significantly associated with risk among African Americans (92); however we 
were unable to replicate this finding in the current analysis, underscoring the contribution of 
small study size to unstable genetic associations. The current study, that includes participants 
recruited from 1993 to 2001, has increased power, essentially doubling the sample size from 
Phase 1 only.   
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Also contributing to previous discordance in BER-pathway genetic associations, distinct 
tumor subtypes show heterogeneity in their associations with BER SNPs. This subtype- specific 
analysis showed NEIL2 rs1534862 to be associated with luminal and HER2+/ER- subtype. FEN1 
rs41334 was associated with basal-like subtype. Previous studies have indicated that other risk 
factor profiles (both genetic and environmental) may differ by tumor subtype and race and our 
suggestive associations require further investigation (22, 357) 
We identified SNPs in several DNA glycosylases (OGG1, UNG, and NEIL2) as being 
associated with breast cancer. To date, there are 12 known DNA human glycosylases that play an 
important role in the initial recognition and repair of a DNA lesion (106). DNA glycosylates 
initiate repair by releasing the modified/damaged base out of the double helix and cleaving the 
N-glycosidic bond of the damaged base (105). The human 8-oxoguanine DNA glycosylase 
(hOGG1) gene located on chromosome 3p26 in exon 7 encodes the bifunctional glycosylase that 
is primarily responsible for the accurate excision of 7,8-dihydro-8-oxoguanine (8-oxoG) (358). 
8-OxoG, a product of oxidative stress, can cause a G-T transversion during DNA replication if it 
not removed.  OGG1 variants have been shown to be highly mutagenic in mice and in vitro 
studies (219, 359). Additionally, OGG1 rs1052133 has been one of the most studied variants in 
breast cancer genetic association studies. Several initial functional studies showed the OGG1 
variant to be associated with reduced DNA repair activity.  In one such study, Vodicka et al. 
found that the capacity to repair oxidative DNA damage was significantly decreased in 
individuals homozygous for the variant (GG) genotype compared to other genotypes (360). 
Subsequently, functional and epidemiological studies that evaluated the role of OGG1 rs1052133 
with breast cancer risk in White and Asian populations showed inconsistent main results (137, 
139, 141, 143, 145, 361). With the exception of a Thai case-control study that reported a 
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subgroup effect with postmenopausal breast cancer (OR=2.05; 95% CI: 1.14-3.67) (138), all 
other studies yielded effect estimates close to or at the null. In the current study, we also found 
CC genotype to be associated with slightly increased breast cancer risk in Whites, however we 
did not have sufficient sample size to evaluate the OGG1 SNP by premenopausal status. 
While various UNG variants have been shown to be associated with colorectal cancer, 
glioblastoma, B cell lymphoma, and esophageal squamous cell carcinoma, (106, 120) previous 
studies have not identified associations between variants in UNG and breast cancer risk. We are 
the first to report a significant increased risk of breast cancer among African Americans.  UNG is 
a monofunctional glycosylase that is involved in removing uracil from DNA as a result of 
spontaneous deamination (362). This spontaneous deamination reaction occurs during hydrolysis 
of cytosine into uracil. If the uracil is not removed before DNA replication, deamination of 
cytosine can result in a GC to AT transition mutation, which may potentially lead to 
carcinogenesis. Our result for rs3219725, which is located in the 3’UTR of the gene, may 
indicate a novel regulatory SNP associated with breast cancer risk in African Americans; 
however this finding requires replication in a larger group of African Americans.  
NEIL2 is a part of a newly discovered family of monofunctional DNA glycosylases 
(106). Laboratory studies have shown that NEIL2 plays an important role in the repair of 
oxidized bases such as pymidines and cytosines (109, 148). Specifically, this NEIL protein 
cleaves the DNA backbone to generate a single-strand break at the site of the removed base with 
both 3'- and 5'-phosphates (114). NEIL2 was shown to interact with POLB and LIG3 in the short-
patch pathway (109, 110, 150). Variants in NEIL2 have been previously associated with 
increased risk in colorectal, head and neck and lung cancers. One report from the Cancer Genetic 
Markers of Susceptibility (CGEMS) Project noted a pair of SNPs in NEIL2 (rs8191649 and 
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rs8191642) to be significantly associated with premenopausal breast cancer (p<0.02) (202). In 
the current study, we found a non-synonymous missense mutation in NEIL2 to be associated 
with a decreased risk of breast cancer (rs8191613 AG/AA vs. GG; OR=0.72, 95% CI: 0.52-0.98) 
in African Americans. Further, we found NEIL2 rs1534862, located in the 3’UTR of the gene, to 
be associated with an increased risk of breast cancer in Whites and two subtypes (Luminal and 
HER2+/ER). Therefore, these NEIL2 SNPs represent a novel finding in association with breast 
cancer risk by race, and subtype.  
FEN1 and PCNA are both genes involved in the ligation step of BER, specifically the 
long-patch repair pathway (112). While most ligation occurs via the short-patch, long-patch 
repair is activated when polymerase beta lyase activity is unavailable. Specifically, PCNA 
elongates the 3’-OH into the repair gap and FENI1 acts as an endonuclease to remove the 5’ flap. 
We found PCNA rs17349 and 17352 to be associated with a significant decreased risk of breast 
cancer in Whites. These SNPs were also in almost complete LD (r
2
=0.95). Several animal 
models have associated PCNA mutations with cancer and genomic instability (203). A 2000 
study that sequenced 9 coding variants in PCNA (all different that the ones selected herein) 
showed no associations with melanoma, breast cancer or lung cancer in a small group of 60 
individuals compared with healthy controls (204). Furthermore, we found FEN1 rs412334 to be 
associated with both basal-like and ER negative- breast cancer.  A recent study showed 
overexpression and hypomethylation of FEN1 in breast cancer cell lines (197). To our 
knowledge, there are no previous epidemiological studies that evaluated FEN1 SNPs and breast 
cancer risk. 
These findings should be considered in light of strengths and limitations of our study. 
Compared to other genetic association studies of breast cancer, CBCS has a sufficient sample of 
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African Americans. In addition, CBCS has detailed subtype data on tumors from a large 
population-based sample of women allowing a unique investigation of the genetics of specific 
breast cancer subtypes. Stratification of the dataset by subtype does reduce power for some race-
specific and subtype comparisons, especially for HER2+/ER- and basal-like tumors. Phase 3 of 
the CBCS which is underway, uses a case-only design to add 3,000 newly diagnosed breast 
cancer cases with equal numbers for the four race/age subgroups (750 each). Future research in 
Phase 3 will have improved power to clarify these subtype associations.  
We had genotype and subtype data for a large proportion of CBCS participants. 
However, 47% were missing IHC-based subtype data due primarily to unavailable tumor blocks. 
A comparison of subtyped and non-subtyped CBCS cases showed that the subtyped cases were 
not different from the CBCS as a whole with respect to age and menopausal status. However, 
cases with subtype data were more likely to be African American and to have a later stage at 
diagnosis, which may bias estimates for SNPs related to race or disease aggressiveness (22). In 
addition, we cannot rule out the role of false positives. With the exception of two SNPs, the other 
associated SNPs did not remain significant after adjustment for multiple comparisons. It is also 
noteworthy that definitions for luminal breast cancer have evolved since original CBCS IHC 
subtyping methods were published (58). As a result, the CBCS -defined Luminal A and Luminal 
B cases do not capitalize on current subtyping differences that suggest use of PR positivity or Ki-
67 to distinguish the two. Therefore, it is likely that there is heterogeneity within the group of 
luminal breast cancers identified herein. Nonetheless, our subtyping methods here have the 
advantage of excluding tumors that were negative for all markers tested. Only triple negatives 
that were also positive for a basal-like marker are included among basal-like cancers, reducing 
outcome misclassification potential in this important subgroup. To our knowledge, this 
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represents one of the largest collections of African American breast cancer cases with tumor 
subtype classification.   
Although we did not find any significant combined effects of SNPs in the BER pathway 
using SKAT, to our knowledge, this is one of the few studies to have used this recent kernel-
based machine learning method to assess pathway effects in cancer (175, 213). We recognize 
that our pathway analysis was limited by the density of SNP coverage across BER pathway 
genes.  Thus SKAT may be better applied to studies that utilize tag-SNP approaches in candidate 
pathways or GWAS.   
In summary, this study adds important new information for the role of BER in breast 
cancer etiology by using tumor tissue to evaluate subtype-specific effects and considers carefully 
selected regulatory and coding SNP-sets in a biologically established DNA repair pathway using 
innovative statistical approaches. After controlling for multiple comparisons, we found two 
SNPs significantly associated with breast cancer in Whites. We identified other suggestive 
associations for breast cancer in SNPs not previously evaluated for their relationship with breast 
cancer incidence.  Larger studies such as the CBCS Phase 3 with improved power for race- and 
subtype-specific analyses and collaborative consortia will help gain further insight into the role 
of genetic variation in the base excision repair pathway and the risk of breast cancer.  
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Table 10. Characteristics of CBCS participants with genotyping data 
 
  
 
Characteristic
N % N % N % N %
Total (N) 742 100.0 1,204 100.0 658 100.0 1,089 100.0
Average age at selection 52 52 52 53
Average proportion of African ancestry 0.78 0.064 0.774 0.066
Menopausal status
   Pre-menopausal 324 41.4 539 30.5 290 59.1 456 62.7
   Post-menopausal 418 58.6 665 69.5 368 40.9 633 37.3
Stage
0
a
88 11.9 349 29.0
1 216 29.1 393 32.6
2 299 40.3 328 27.2
3 76 10.2 68 5.7
4 27 3.6 15 1.3
Missing 36 4.9 51 4.2
Subtype
   Luminal 269 56.3 519 75.6
   HER2+/ER- 38 7.6 56 5.8
   Basal-like 108 22.0 91 10.7
Estrogen Receptor (ER) Status
   Positive 235 49.6 482 68.9
   Negative 251 50.4 242 31.1
a
carcinoma in situ
Cases Controls
African American White African American White
1
0
8
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Table 11. List of successfully genotyped BER SNP in HWE  
 
 
Gene rs# Type of variant
Amino Acid 
Change
Allele 
Change
SIFT 
score
a
XRCC1 rs1799782 missense R194W C/T 0
rs25489 missense R280H A/G 0.05
rs25487 missense Q399R A/G 0.05
rs25496 missense V72A C/T 0.07
APE1 rs1130409 missense D148E G/T 0.09
rs1048945 missense Q51H C/G 0
OGG1 rs1052133 missense S326C C/G 0.05
rs1805373 missense R229Q A/G 0.05
MUTYH rs3219489 missense Q324H C/G 0.4
rs3219497 missense R507Q A/G 0.22
rs3219484 missense V8M A/G 0.02
MBD4 rs140696 splice N/A C/T N/A
rs2307289 missense S342P C/G 0.29
NTHL1 rs3087468 missense D239Y G/T 0
UNG rs3219275 3'UTR N/A A/T N/A
POLB rs3136797 missense P242R C/G 0
LIG3 rs3136025 missense R867H A/G 0.18
rs4796030 3'UTR N/A A/C N/A
NEIL1 rs5745926 missense D252N A/G 0.27
NEIL2 rs8191613 missense R103Q A/G 0.61
rs8191664 missense R257L G/T 0.28
rs1534862 3'UTR N/A C/T N/A
SMUG1 rs3136391 3'UTR N/A C/T N/A
rs3087404 5'UTR N/A A/G N/A
PCNA rs25406 intron N/A C/T N/A
rs17349 splice N/A C/T N/A
RFC1 rs17288820 splice N/A A/G N/A
rs2066791 missense I598V A/G 0.08
rs17287851 5'UTR N/A C/T N/A
FEN1 rs412334 5'UTR N/A A/G N/A
PARP1 rs1136410 missense V762A C/T 0.16
aRanges from 0 to 1. The amino acid substitution is predicted damaging if the score is 
<= 0.05, and tolerated if the score is > 0.05. 
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Table 12. Minor Allele Frequencies (MAFs) of BER variants stratified by race and case status 
 
Gene SNP
a
Minor 
Allele Cases Controls p HWE
b
Minor 
Allele Cases Controls p HWE
b
XRCC1 rs1799782 T 0.063 0.068 0.366 T 0.065 0.067 0.971
XRCC1 rs25489 A 0.049 0.044 0.929 A 0.036 0.027 0.457
XRCC1 rs25487 A 0.365 0.352 0.343 A 0.161 0.146 0.371
XRCC1 rs25496 C 0.000 0.001 N/A C 0.055 0.062 0.300
XRCC1 rs2682558 A 0.210 0.201 0.000 A 0.179 0.181 0.000
APE1 rs3136820 G 0.475 0.481 0.456 G 0.373 0.393 0.708
APE1 rs1048945 C 0.040 0.040 0.810 C 0.010 0.005 N/A
OGG1 rs1052133 C 0.223 0.239 0.629 C 0.167 0.159 0.636
OGG1 rs1805373 A 0.001 0.001 N/A A 0.080 0.084 0.094
MUTYH rs3219489 C 0.244 0.248 0.324 C 0.257 0.262 0.700
MUTYH rs3219497 A 0.000 0.000 N/A A 0.037 0.027 0.421
MUTYH rs3219484 A 0.069 0.069 0.562 A 0.013 0.013 0.737
MBD4 rs140696 T 0.098 0.092 0.645 T 0.201 0.210 0.997
MBD4 rs2307289 C 0.002 0.000 N/A C 0.129 0.110 0.429
MPG rs710080 G 0.014 0.017 0.000 A 0.351 0.354 0.444
TDG rs4135113 A 0.020 0.022 0.457 A 0.158 0.149 0.000
UNG rs3219275 A 0.000 0.001 N/A A 0.055 0.043 0.439
POLB rs3136797 G 0.020 0.020 0.496 G 0.004 0.003 N/A
LIG3 rs3136025 A 0.002 0.001 N/A A 0.090 0.087 0.146
LIG3 rs4796030 A 0.433 0.455 0.498 A 0.133 0.145 0.022
NEIL1 rs5745926 A 0.000 0.001 N/A A 0.018 0.014 0.722
NEIL2 rs8191613 A 0.018 0.017 0.579 A 0.053 0.072 0.336
NEIL2 rs8191664 T 0.018 0.014 0.634 T 0.004 0.003 N/A
NEIL2 rs1534862 T 0.238 0.208 0.020 T 0.327 0.321 0.136
SMUG1 rs3136391 C 0.000 0.000 N/A C 0.049 0.039 0.290
SMUG1 rs3087404 A 0.435 0.436 0.853 G 0.324 0.332 0.532
Whites African Americans
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PCNA rs25406 T 0.408 0.413 0.600 T 0.466 0.452 0.008
PCNA rs17352 C 0.101 0.123 0.505 A 0.435 0.447 0.920
PCNA rs17349 T 0.098 0.116 0.098 T 0.280 0.285 0.101
RFC1 rs17288820 G 0.000 0.000 N/A G 0.019 0.021 0.189
RFC1 rs2066791 G 0.000 0.000 N/A G 0.018 0.017 0.663
RFC1 rs17287851 T 0.000 0.000 N/A T 0.083 0.081 0.481
FEN1 rs412334 A 0.162 0.166 0.808 A 0.032 0.037 0.237
PARP1 rs1136410 C 0.161 0.144 0.688 C 0.047 0.062 0.314
PARP1 rs1805409 A 0.000 0.000 N/A A 0.007 0.011 N/A
PARP3 rs34224216 A 0.000 0.000 N/A A 0.009 0.009 N/A
PARP3 rs323870 G 0.003 0.002 0.000 G 0.168 0.156 0.237
b
P HWE, Hardy-Weinberg equilibrium, p<0.05
N/A indicates non-polymorphic loci or MAF<0.05
a
SNP, single nucleotide polymorphism
  
 
 
Table 13. Association of BER variants with breast cancer stratified by race 
 
 
OR (95% CI)b p  valuec q valued OR (95% CI)b p  valuec q valued
Gene SNP Genotypea N % N % N % N %
XRCC1 rs1799782 CC 1057 0.879 947 0.870 1.00 647 0.872 573 0.871 1.00
CT 140 0.116 135 0.124 0.93 (0.71, 1.21) 0.8691 94 0.127 82 0.125 0.93(0.67, 1.30) 0.4699
TT 6 0.005 7 0.006 0.78 (0.24, 2.48) 0.7165 1 0.001 3 0.005 0.37 (0.04, 3.55) 0.4034
CT +TT 146 0.121 142 0.130 0.92 (0.72, 1.18) 0.5133 0.8723 95 0.128 85 0.129 0.90 (0.66, 1.23) 0.5146 0.8078
rs25489 GG 1082 0.902 991 0.913 1.00 689 0.930 623 0.947 1.00
AG 118 0.098 92 0.085 1.25 (0.93, 1.69) 0.9620 51 0.069 34 0.052 1.37 (0.87, 2.17) 0.2239
AA 0 0.000 2 0.002 NA NA 1 0.001 1 0.002 1.11 (0.07, 18.11) 0.9704
AG + AA 118 0.098 94 0.087 1.19 (0.89, 1.60) 0.2507 0.7123 52 0.070 35 0.053 1.34 (0.87, 2.07) 0.1895 0.7727
rs25487 GG 475 0.403 459 0.427 1.00 519 0.706 473 0.726 1.00
AG 548 0.465 476 0.443 1.06 (0.88, 1.29) 0.7979 195 0.265 168 0.258 1.12 (0.87, 1.44) 0.4914
AA 156 0.132 140 0.130 1.08 (0.82, 1.42) 0.7356 21 0.029 11 0.017 1.71 (0.79. 3.69) 0.2201
AG + AA 704 0.597 616 0.573 1.05 (0.92, 1.19) 0.4940 0.8723 216 0.294 179 0.275 1.17 (0.94, 1.46) 0.1533 0.7727
rs25496 TT 1203 0.999 1087 0.998 1.00 666 0.898 577 0.877 1.00
CT 1 0.001 2 0.0018 NA NA 71 0.096 80 0.122 0.80 (0.56, 1.13) 0.0791
CC 0 0.000 0 0.000 NA NA 5 0.007 1 0.002 4.87 (0.55, 42.89) 0.1270
CT +TT 1 0.0008 2 0 NA NA 76 0.102 81 0.123 0.91 (0.66, 1.26) 0.5571 0.8028
APE1 rs3136820 GG 321 0.268 287 0.264 1.00 297 0.402 244 0.371 1.00
GT 617 0.515 556 0.511 1.09 (0.87, 1.36) 0.6621 332 0.449 309 0.470 1.00 (0.73, 1.38) 0.5316
TT 261 0.218 246 0.226 1.08 (0.84, 1.39) 0.7177 110 0.149 104 0.158 1.17 (0.84, 1.62) 0.2069
GT + TT 878 0.7323 802 0.7365 1.04 (0.92, 1.18) 0.5578 0.8723 442 0.598 413 0.629 1.10 (0.94 1.28) 0.2398 0.7727
rs1048945 GG 1107 0.921 1004 0.923 1.00 726 0.980 651 0.989 1.00
CG 94 0.078 82 0.075 1.06 (0.77, 1.47) 0.6820 15 0.020 7 0.011 NA NA
CC 1 0.001 2 0.002 0.67 (0.06, 7.41) 0.7259 0 0.000 0 0.000 NA NA
CG + CC 95 0.079 84 0.0772 1.04 (0.76, 1.43) 0.7991 0.9316 15 0.02 7 0.011 NA NA
OGG1 rs1052133 GG 721 0.602 628 0.577 1.00 516 0.696 463 0.705 1.00
CG 419 0.350 401 0.369 1.19 (0.79, 1.81) 0.9329 203 0.274 179 0.273 0.72 (0.36, 1.44) 0.5032
CC 57 0.048 59 0.054 1.39 (0.93, 2.08) 0.0464 22 0.030 15 0.023 0.67 (0.34, 1.33) 0.2340
CG + CC 476 0.3976 460 0.4228 1.17 (1.01, 1.36) 0.0359 0.1795 225 0.304 194 0.295 0.90 (0.73, 1.11) 0.3217 0.7774
rs1805373 GG 1202 0.998 1086 0.997 1.00 628 0.846 555 0.844 1.00
AG 2 0.002 3 0.003 NA NA 109 0.147 95 0.144 0.94 (0.69. 1.28) 0.3592
AA 0 0.000 0 0.000 NA NA 5 0.007 8 0.012 0.47 (0.14, 1.55) 0.2395
AG + AA 2 0.0017 3 0.0028 NA NA 114 0.154 103 0.157 0.88 (0.66, 1.16) 0.3561 0.7944
Whites African Americans
Cases Controls Cases Controls
1
1
2
 
  
 
 
 
OR (95% CI)b p  valuec q valued OR (95% CI)b p  valuec q valued
Gene SNP Genotypea N % N % N % N %
MUTYH rs3219489 GG 689 0.577 608 0.559 1.00 417 0.563 355 0.542 1.00
CG 429 0.359 418 0.385 0.89 (0.74, 1.07) 0.1166 267 0.360 257 0.392 0.93 (0.74, 1.17) 0.2291
CC 77 0.064 61 0.056 1.16 (0.80, 1.69) 0.2670 57 0.077 43 0.066 1.22 (0.79. 1.87) 0.2785
CG +CC 506 0.4234 479 0.4406 0.98 (0.85, 1.13) 0.7842 0.9316 324 0.437 300 0.458 1.02 (0.86, 1.21) 0.8199 0.8729
rs3219497 GG 1203 0.999 1088 0.999 1.00 687 0.926 624 0.948 1.00
AG 1 0.001 1 0.001 NA NA 55 0.074 33 0.050 1.58 (1.00, 2.49) 0.9696
AA 0 0.000 0 0.000 NA NA 0 0.000 1 0.002 NA
AG + AA 1 0.0008 1 0.0009 NA NA 55 0.074 34 0.052 1.47 (0.95, 2.30) 0.0866 0.6612
rs3219484 GG 1042 0.865 942 0.865 1.00 723 0.974 641 0.974 1.00
AG 158 0.131 143 0.131 1.05 (0.81, 1.35) 0.6112 18 0.024 17 0.026 1.04 (0.51, 2.11) 0.9764
AA 4 0.003 4 0.004 0.72 (0.15, 3.35) 0.6538 1 0.001 0 0.000 NA
AG + AA 162 0.1345 147 0.135 1.02 (0.80, 1.31) 0.8503 0.9316 19 0.026 17 0.026 1.07 (0.54, 2.14) 0.8428 0.8729
MBD4 rs140696 CC 976 0.811 896 0.823 1.00 475 0.640 410 0.624 1.00
CT 219 0.182 185 0.170 1.15 (0.91, 1.44) 0.1978 235 0.317 218 0.332 0.92 (0.73, 1.17) 0.7963
TT 9 0.008 8 0.007 0.64 (0.24, 1.76) 0.3215 32 0.043 29 0.044 0.78 (0.45, 1.35) 0.4546
CT +TT 228 0.1894 193 0.1772 1.09 (0.88, 1.34) 0.4525 0.8723 267 0.36 247 0.376 0.91 (0.75 1.10) 0.3143 0.7774
rs2307289 TT 1200 0.997 1088 0.999 1.00 564 0.760 519 0.789 1.00
CT 3 0.003 1 0.001 NA NA 165 0.222 133 0.202 1.13 (0.87, 1.48) 0.6462
CC 1 0.001 0 0.000 NA NA 13 0.018 6 0.009 1.67 (0.80, 4.66) 0.3910
CT +TT 4 0.0033 1 0.0009 NA NA 178 0.24 139 0.211 1.16 (0.91, 1.48) 0.2223 0.7727
UNG rs3219275 TT 1204 1.000 1087 0.998 1.00 662 0.892 604 0.918 1.00
AT 0 0.000 2 0.002 NA NA 78 0.105 52 0.079 1.54 (1.06, 2.24) 0.2644
AA 0 0.000 0 0.000 NA NA 2 0.003 2 0.003 0.70 (0.09, 5.28) 0.5807
AT+AA 0 0 2 0.0018 NA NA 80 0.108 54 0.082 1.44 (1.01, 2.06) 0.0446 0.6467
POLB rs3136797 CC 1156 0.960 1045 0.960 1.00 736 0.992 654 0.994 1.00
CG 48 0.040 44 0.040 0.97 (0.62, 1.51) 0.8850 6 0.008 4 0.006 NA NA
GG 0 0.000 0 0.000 0.00 NA 0 0.000 0 0.000 NA NA
CG + GG 48 0.0399 44 0.0404 0.97 (0.62, 1.51) 0.8850 0.9316 6 0.008 4 0.006 NA NA
LIG3 rs3136025 GG 1200 0.997 1087 0.998 1.00 615 0.829 551 0.837 1.00
AG 4 0.003 2 0.002 NA NA 121 0.163 99 0.151 1.09 (0.81, 1.48) 0.0540
AA 0 0.000 0 0.000 NA NA 6 0.008 8 0.012 0.33 (0.10, 1.09) 0.0587
AG + AA 4 0.0033 2 0.0018 NA NA 127 0.171 107 0.163 0.97 (0.74, 1.27) 0.8067 0.8729
Whites African Americans
Cases Controls Cases Controls
1
1
3
 
  
 
 
OR (95% CI)b p  valuec q valued OR (95% CI)b p  valuec q valued
Gene SNP Genotypea N % N % N % N %
rs4796030 CC 379 0.315 329 0.302 1.00 565 0.762 488 0.743 1.00
AC 608 0.505 529 0.486 1.02 (0.83, 1.24) 0.0958 157 0.212 148 0.225 0.90 (0.69, 1.18) 0.7877
AA 217 0.180 231 0.212 0.76 (0.59, 0.98) 0.0142 20 0.027 21 0.032 0.91 (0.48, 1.73) 0.8894
AC + AA 825 0.6852 760 0.6979 0.89 (0.79, 1.01) 0.0645 0.2580 177 0.239 169 0.257 0.92 (0.74, 1.15) 0.4662 0.8078
NEIL1 rs5745926 GG 1203 0.999 1087 0.998 1.00 716 0.965 640 0.973 1.00
AG 1 0.001 2 0.002 NA NA 26 0.035 18 0.027 1.28 (0.68, 2.42) 0.4417
AA 0 0.000 0 0.000 NA NA 0 0.000 0 0.000 NA NA
AG + AA 1 0.0008 2 0.0018 NA NA 26 0.035 18 0.027 1.28 (0.68, 2,42) 0.4417 0.8078
NEIL2 rs8191613 GG 1158 0.963 1053 0.967 1.00 663 0.897 568 0.865 1.00
AG 44 0.037 36 0.033 0.99 (0.62, 1.60) 0.9757 73 0.099 84 0.128 0.72 (0.51, 1.02) 0.9547
AA 0 0.000 0 0.000 NA NA 3 0.004 5 0.008 0.49 (0.11, 2.19) 0.4769
AG + AA 44 0.0366 36 0.0331 0.99 (0.62, 1.60) 0.9757 0.9757 76 0.103 89 0.136 0.72 (0.52, 0.98) 0.0386 0.6467
rs8191664 GG 1160 0.964 1058 0.972 1.00 736 0.992 654 0.994 1.00
GT 44 0.037 31 0.029 1.16 (0.70, 1.91) 0.5670 6 0.008 4 0.006 1.48 (0.41, 5.38) 0.5525
TT 0 0.000 0 0.000 NA NA 0 0.000 0 0.000 NA NA
GT + TT 44 0.0365 31 0.0285 1.16 (0.70, 1.91) 0.5670 0.8723 6 0.008 4 0.006 1.48 (0.41, 5.38) 0.5525 0.8078
rs1534862 CC 691 0.574 695 0.638 1.00 341 0.460 312 0.474 1.00
CT 452 0.376 334 0.307 1.44 (1.20, 1.74) 0.0118 317 0.427 270 0.410 1.07 (0.85, 1.34) 0.5825
TT 60 0.050 60 0.055 1.10 (0.74, 1.63) 0.6581 84 0.113 76 0.116 0.99 (0.69, 1.42) 0.8035
CT +TT 512 0.4256 394 0.3618 1.24 (1.07, 1.44) 0.0038 0.0750 401 0.54 346 0.526 1.02 (0.87, 1.19) 0.8417 0.8729
SMUG1 rs3136391 TT 1204 1.000 1088 1.000 1.00 669 0.904 609 0.926 1.00
CT 0 0.000 0 0.000 NA NA 70 0.095 47 0.071 1.39 (0.94, 2.08) 0.2817
CC 0 0.000 0 0.000 NA NA 1 0.001 2 0.003 0.48 (0.04, 5.47) 0.4689
CT +TT 0 0 0 0 NA NA 71 0.096 49 0.074 1.30 (0.89, 1.90) 0.1727 0.7727
rs3087404 GG 385 0.320 345 0.317 1.00 79 0.107 69 0.105 1.00
AG 590 0.490 538 0.495 0.97 (0.80, 1.19) 0.5883 323 0.435 299 0.454 0.90 (0.72, 1.14) 0.3843
AA 229 0.190 205 0.188 1.05 (0.81, 1.35) 0.6143 340 0.458 290 0.441 1.02 (0.70, 1.48) 0.7083
AG + AA 819 0.6802 743 0.6829 1.02 (0.90, 1.15) 0.8056 0.9316 663 0.894 589 0.895 0.97 (0.82, 1.15) 0.7299 0.8729
PCNA rs25406 CC 419 0.348 368 0.341 1.00 213 0.289 213 0.326 1.00
CT 586 0.487 532 0.493 0.91 (0.75, 1.11) 0.3895 362 0.491 290 0.444 1.27 (0.99, 1.64) 0.0664
TT 198 0.165 180 0.167 0.97 (0.75, 1.26) 0.8812 163 0.221 150 0.230 1.07 (0.79, 1.44) 0.6836
CT +TT 784 0.6517 712 0.6593 0.97 (0.86, 1.10) 0.6515 0.9307 525 0.711 440 0.674 1.05 (0.90, 1.22) 0.5375 0.8078
Whites African Americans
Cases Controls Cases Controls
1
1
4
 
  
 
 
OR (95% CI)b p  valuec q valued OR (95% CI)b p  valuec q valued
Gene SNP Genotypea N % N % N % N %
rs17352 AA 978 0.812 836 0.768 1.00 141 0.190 132 0.201 1.00
AC 209 0.174 239 0.220 0.70 (0.56, 0.87) 0.0655 363 0.489 324 0.492 0.97 (0.76, 1.24) 0.9831
CC 17 0.014 14 0.013 1.11 (0.50, 2.44) 0.4845 238 0.321 202 0.307 0.94 (0.68, 1.29) 0.7201
AC + CC 226 0.1877 253 0.2324 0.76 (0.63, 0.93) 0.0075 0.0750 601 0.81 526 0.799 0.97 (0.83, 1.13) 0.6804 0.8729
rs17349 CC 982 0.816 846 0.777 1.00 382 0.515 345 0.524 1.00
CT 207 0.172 234 0.215 0.71 (0.57, 0.89) 0.0960 304 0.410 251 0.382 1.13 (0.89, 1.42) 0.0706
TT 15 0.013 9 0.008 1.46 (0.61, 3.52) 0.2184 56 0.076 62 0.094 0.77 (0.51, 1.16) 0.1178
CT + TT 222 0.1844 243 0.2232 0.79 (0.64, 0.96) 0.0198 0.1320 360 0.485 313 0.476 0.98 (0.82, 1.16) 0.7707 0.8729
RFC1 rs17288820 AA 1204 1.000 1089 1.000 1.00 715 0.964 631 0.959 1.00
AG 0 0.000 0 0.000 NA NA 26 0.035 26 0.040 1.24 (0.06, 26.51) 0.9910
GG 0 0.000 0 0.000 NA NA 1 0.001 1 0.002 1.58 (0.08, 31.94) 0.6572
AG + GG 0 0 0 0 NA NA 27 0.036 27 0.041 1.27 (0.74, 2.18) 0.3922 0.8078
rs2066791 AA 1203 0.999 1089 1.000 1.00 715 0.964 636 0.967 1.00
AG 1 0.001 0 0.000 NA NA 27 0.036 22 0.033 1.10 (0.61, 1.98) 0.7536
GG 0 0.000 0 0.000 NA NA 0 0.000 0 0.000 NA NA
AG +GG 1 0.0008 0 0 NA NA 27 0.036 22 0.033 1.10 (0.61, 1.98) 0.7536 0.8729
rs17287851 CC 1204 1.000 1089 1.000 1.00 623 0.840 554 0.842 1.00
CT 0 0.000 0 0.000 NA NA 115 0.155 101 0.154 1.00 (0.74, 1.35) 0.8643
TT 0 0.000 0 0.000 NA NA 4 0.005 3 0.005 0.86 (0.18, 4.14) 0.8499
CT + TT 0 0.000 0 0.000 NA NA 119 0.160 104 0.158 0.99 (0.74, 1.31) 0.9297 0.9297
FEN1 rs412334 GG 850 0.706 755 0.694 1.00 695 0.937 611 0.929 1.00
AG 318 0.264 304 0.279 0.86 (0.71, 1.05) 0.2725 47 0.063 45 0.068 0.85 (0.54, 1.33) 0.9777
AA 36 0.030 29 0.027 1.06 (0.62, 1.81) 0.6239 0 0.000 2 0.003 NA NA
AG + AA 354 0.294 333 0.306 0.92 (0.78, 1.08) 0.3076 0.7690 47 0.063 47 0.071 0.79 (0.51, 1.04) 0.2768 0.7774
PARP1 rs1136410 TT 854 0.709 796 0.731 1.00 673 0.907 578 0.878 1.00
CT 313 0.260 272 0.250 1.03 (0.84, 1.26) 0.1252 68 0.092 79 0.120 0.73 (0.51, 1.04) 0.6317
CC 37 0.031 21 0.019 1.78 (1.01, 3.17) 0.0509 1 0.001 1 0.002 1.06 (0.07, 17.33) 0.8764
CT + CC 350 0.291 293 0.269 1.12 (0.95. 1.33) 0.1850 0.6167 69 0.093 80 0.122 0.74 (0.52, 1.05) 0.0912 0.6612
a Minor allele frequency for Whites used as reference for both races
b Odds ratio and 95% confidence interval, adjusted for age, self-identified race, African ancestry, and offset term
c P-value is unadjusted for multiple comparisons
Whites African Americans
Cases Controls Cases Controls
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1
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Table 14. Association of BER variants with breast cancer stratified by subtype
Gene SNP Genotype OR (95% CI)a p valueb q valuec OR (95% CI)a p valueb q valuec OR (95% CI)a p valueb q valuec
XRCC1 rs1799782 CC Referent Referent Referent
CT 0.94 (0.72, 1.23) 0.7634 0.89 (0.46, 1.70) 0.9710 1.12 (0.73, 1.72) 0.9701
TT 1.08 (0.33, 3.58) 0.8566 NA 0.9705 NA 0.9705
CT +TT 0.95 (0.73, 1.23) 0.6865 0.8966 0.86 (0.45, 1.64) 0.6391 0.9054 1.08 (0.70, 1.66) 0.7295 0.9787
rs25489 GG Referent Referent Referent
AG 1.33 (0.97, 1.82) 0.9482 1.39 (0.68, 2.86) 0.9826 1.55 (0.92, 2.61) 0.9672
AA NA 0.9502 NA 0.9834 NA 0.9692
AG + AA 1.30 (0.95, 1.87) 0.1033 0.4474 1.40 (0.68, 2.87) 0.3998 0.8496 1.54 (0.92, 2.59) 0.1206 0.5453
rs25487 GG Referent Referent Referent
AG 1.04 (0.85, 1.26) 0.3977 1.07 (0.68, 1.69) 0.2245 0.99 (0.71, 1.39) 0.8529
AA 1.29 (0.94, 1.77) 0.1289 0.54 (0.19. 1.54) 0.2087 0.91 (0.47, 1.75) 0.7747
AG + AA 1.08 (0.90, 1.30) 0.4252 0.8234 0.98 (0.63, 1.53) 0.9487 0.9717 0.97 (0.70, 1.35) 0.8983 0.9787
APE1 rs3136820 GG Referent Referent Referent
GT 1.08 (0.86, 1.37) 0.7465 1.13 (0.64, 2.01) 0.6510 0.84 (0.56, 1.26) 0.2221
TT 1.11 (0.86, 1.43) 0.5420 1.05 (0.56, 1.97) 0.9535 1.04 (0.68, 1.60) 0.4708
GT + TT 1.09 (0.87, 1.37) 0.4359 0.8234 1.10 (0.64, 1.90) 0.7340 0.9187 0.91 (0.62, 1.34) 0.6413 0.9787
OGG1 rs1052133 GG Referent Referent Referent
CG 1.05 (0.66, 1.68) 0.9129 1.88 (0.44, 8.10) 0.5228 0.96 (0.42, 2.23) 0.7277
CC 1.14 (0.72, 1.80) 0.4228 2.09 (0.50, 8.81) 0.2862 1.10 (0.49, 2.49) 0.6194
CG + CC 1.11 (0.71, 1.74) 0.6554 0.8966 2.01 (0.48, 8.37) 0.3359 0.8362 1.04 (0.47, 2.34) 0.9014 0.9787
MUTYH rs3219489 GG Referent Referent Referent
CG 0.81 (0.67, 0.98) 0.0485 0.98 (0.63, 1.53) 0.8219 0.94 (0.69, 1.30) 0.8433
CC 1.05 (0.73, 1.52) 0.3900 1.11 (0.46, 2.67) 0.8299 0.99 (0.52, 1.87) 0.9918
CG +CC 0.84 (0.70, 1.01) 0.0587 0.4474 0.99 (0.65, 1.52) 0.9717 0.9717 0.95 (0.70, 1.29) 0.7276 0.9787
rs3219484 GG Referent Referent Referent
AG 1.20 (0.89, 1.62) 0.7771 1.68 (0.87, 3.23) 0.9660 1.32 (0.77, 2.28) 0.9700
AA 1.81 (0.39, 8.43) 0.5209 NA 0.9685 NA 0.9711
AG + AA 1.22 (0.90, 1.63) 0.1957 0.5545 1.64 (0.85, 3.16) 0.1446 0.8362 1.31 (0.76, 2.24) 0.3636 0.9287
MBD4 rs140696 CC Referent Referent Referent
CT 0.90 (0.72, 1.12) 0.6702 1.04 (0.63, 1.71) 0.3745 1.23 (0,87, 1.74) 0.9393
TT 0.94 (0.52, 1.73) 0.9878 0.40 (0.05, 3.03) 0.3666 1.46 (0.65, 3.29( 0.5052
CT +TT 0.90 (0.73, 1.12) 0.3497 0.8234 0.97 (0.59, 1.58) 0.9366 0.9717 1.23 (0.88, 1.71) 0.1811 0.6157
Luminal HER2+/ER- Basal-like
1
1
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Gene SNP Genotype OR (95% CI)a p valueb q valuec OR (95% CI)a p valueb q valuec OR (95% CI)a p valueb q valuec
LIG3 rs4796030 CC Referent Referent Referent
AC 1.04 (0.85, 1.28) 0.1820 0.79 (.47, 1.31) 0.2511 0.78(0.54, 1.11) 0.6950
AA 0.67 (0.50, 0.91) 0.0032 1.08 (0.57, 206) 0.5112 0.70 (0.41, 1.20) 0.3737
AC + AA 0.95 (0.78, 1.16) 0.6023 0.8966 0.86 (0.54, 1.38) 0.5287 0.8798 0.77 (0.55, 1.08) 0.1101 0.5453
NEIL2 rs8191613 GG Referent Referent Referent
AG 0.77 (0.53, 1.12) 0.9508 1.29 (0.62, 2.68) 0.9827 0.81 (0.44, 1.46) 0.9669
AA NA 0.9489 NA 0.9833 NA 0.9659
AG + AA 0.74 (0.51, 1.08) 0.1192 0.4474 1.22 (0.59, 2.55) 0.5693 0.8798 0.76 (0.42, 1.37) 0.3824 0.9287
rs1534862 CC Referent Referent Referent
CT 1.28 (1.06, 1.54) 0.2130 1.82 (1.17, 2.82) 0.0327 0.98 (0.70, 1.36) 0.8100
TT 1.23 (0.88, 1.73) 0.6041 1.02 (0.42, 2.49) 0.5352 1.05 (0.61, 1.79) 0.8552
CT +TT 1.27 (1.06, 1.52) 0.0092 0.1564 1.68 (1.09, 2.57) 0.0178 0.3026 0.99 (0.72, 1.34) 0.9278 0.9787
SMUG1 rs3087404 GG Referent Referent Referent
AG 0.99 (0.79, 1.24) 0.5452 0.58 (0.34, 1.01) 0.0040 1.14 (0.75, 1.72) 0.6663
AA 1.09 (0.84, 1.41) 0.3990 1.23 (0.70, 2.16) 0.3084 1.10 (0.70, 1.75) 0.7888
AG + AA 1.02 (0.82, 1.26) 0.8678 0.9220 0.78 (0.48, 1.29) 0.3354 0.8362 1.12 (0.75, 1.68) 0.5657 0.9787
PCNA rs25406 CC Referent Referent Referent
CT 1.05 (0.86, 1.28) 0.5564 1.33 (0.81, 2.17) 0.3441 1.31 (0.92, 1.86) 0.2615
TT 0.99 (0.77, 1.28) 0.7617 1.19 (0.64, 2.23) 0.9297 1.24 (0.80, 1.92) 0.7128
CT +TT 1.03 (0.86, 1.25) 0.7384 0.8966 1.29 (0.81, 2.07) 0.2819 0.8362 130 (0.93, 1.81) 0.1283 0.5453
rs17352 AA Referent Referent Referent
AC 0.91 (0.73, 1.14) 0.2418 0.95 (0.56, 1.61) 0.8211 0.94 (0.63, 1.40) 0.1677
CC 1.07 (0.76, 1.50) 0.4694 0.80 (0.36, 1.80) 0.5928 1.41 (0.85 2.32) 0.8620
AC + CC 0.94 (0.75, 1.17) 0.5497 0.8966 0.91 (0.54, 1.55) 0.7566 0.9187 1.01 (0.69, 1.48) 0.8848 0.9787
rs17349 CC Referent Referent Referent
CT 0.98 (0.80, 1.21 0.9440 0.80 (0.48, 1.31) 0.9546 0.98 (0.69, 1.38) 0.4042
TT 0.95 (.59, 1.53) 0.8499 0.66 (0.20, 2.21) 0.6219 1.35 (0.72, 2.55) 0.3179
CT + TT 0.98 (0.80, 1.20) 0.8416 0.9220 0.77 (0.47, 1.25) 0.3120 0.8362 1.00 (0.72, 1.39) 0.8744 0.9787
FEN1 rs412334 GG Referent Referent Referent
AG 0.86 (0.69, 1.09) 0.6016 0.79 (0.44, 1.41) 0.2689 0.51 (0.31, 0.83) 0.0617
AA 0.59 (0.28, 1.27) 0.2487 1.53 (0.44, 5.39) 0.3948 1.00 (0.33, 3.07) 0.5513
AG + AA 0.84 (0.67, 1.05) 0.1316 0.4474 0.86 (0.50, 1.48) 0.5586 0.8798 0.56 (0.35, 0.88) 0.0111 0.1887
PARP1 rs1136410 TT Referent Referent Referent
CT 0.96 (0.77, 1.20) 0.1182 1.22 (0.73, 2.03) 0.6763 0.93 (0.62, 1.39) 0.1269
CC 1.72 (0.87, 3.42) 0.1079  2.15 (0.48, 9.59) 0.3805 2.41 (0.79, 7. 34) 0.1079
CT + CC 1.00 (0.81, 1.24) 0.9979 0.9979 1.26 (0.77, 2.08) 0.3443 0.8362 0.99 (0.67, 1.46) 0.9787 0.9787
a Odds ratio and 95% confidence interval, adjusted for age, proportion European ancestry, and offset term
b P-value is unadjusted for multiple comparisons
Luminal HER2+/ER- Basal-like
1
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Table 15. Assocation of BER variants with breast cancer stratified by estrogen receptor (ER) 
status.  
 
 
 
 
 
 
 
 
 
 
Gene SNP Genotype ER positive p value q value ER negative p value q value
XRCC1 rs1799782 CC Referent Referent
CT 0.97 (0.73, 1.27) 0.92 (0.67, 1.26)
TT 0.92 (0.25, 3.43) 0.91 (0.19, 4.29)
CT +TT 0.97 (0.74, 1.27) 0.7948 0.9651 0.92 (0.67, 1.25) 0.5805 0.8998
rs25489 GG Referent Referent
AG 1.39 (1.01, 1.92) 1.57 (1.09, 2.27)
AA NA 1.41 (0.14, 14.45)
AG + AA 1.36 (0.99, 1.87) 0.0581 0.2910 1.57 (1.09, 2.25) 0.0144 0.2448
rs25487 GG Referent Referent
AG 1.04 (0.85, 1.28) 1.03 (0.82, 1.30)
AA 1.32 (0.96, 1.83) 0.94 (0.61, 1.44)
AG + AA 1.09 (0.90, 1.32) 0.3639 0.7733 1.02 (0.81, 1.27) 0.8929 0.9670
APE1 rs3136820 GG Referent Referent
GT 1.07 (0.84, 1.36) 1.04 (0.78, 1.38)
TT 1.07  (0.82, 1.39) 1.17 (0.86, 1.59)
GT + TT 1.06 (0.85, 1.34) 0.5804 0.8677 1.09 (0.83, 1.43) 0.5484 0.8998
OGG1 rs1052133 GG Referent Referent
CG 1.08 (0.67, 1.75) 0.87 (0.50, 1.52)
CC 1.15 (0.72, 1.84) 1.06 (0.62, 1.82)
CG + CC 1.13 (0.71, 1.79) 0.6125 0.8677 .99 (0.58, 1.69) 0.9764 0.9764
MUTYH rs3219489 GG Referent Referent
CG 0.81 (0.67, 0.99) 1.00 (0.80, 1.24)
CC 1.11 (0.76, 1.61) 1.10 (0.71, 1.70)
CG +CC 0.85 (0.71, 1.02) 0.0856 0.291 1.01 (0.82, 1.25) 0.9101 0.967
rs3219484 GG Referent Referent
AG 1.29 (0.95, 1.74) 1.10 (0.75, 1.63)
AA 1.95 (0.42, 9.02) NA
AG + AA 1.31 (0.97, 1.76) 0.0783 0.2910 1.07 (0.72, 1.58) 0.7410 0.8998
MBD4 rs140696 CC Referent Referent
CT 0.91 (0.73, 1.14) 1.07 (0.84, 1.37)
TT 0.96 (0.52, 1.77) 0.81 (0.41, 1.59)
CT +TT 0.92 (0.74, 1.14) 0.4234 0.7998 1.04 (0.82, 1.32) 0.7215 0.8998
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Gene SNP Genotype ER positive p value q value ER negative p value q value
LIG3 rs4796030 CC Referent Referent
AC 1.02 (0.83, 1.26) 0.91 (0.71, 1.16)
AA 0.66 (0.48, 0.91) 0.85 (0.60, 1.22)
AC + AA 0.93 (0.76, 1.14) 0.4937 0.8393 0.90 (0.71, 1.13) 0.3540 0.7523
NEIL2 rs8191613 GG Referent Referent
AG 0.73 (0.49, 1.09) 0.82 (0.54, 1.23)
AA NA NA
AG + AA 0.71 (0.47, 1.05) 0.0841 0.2910 0.78 (0.52, 1.18) 0.2342 0.6885
rs1534862 CC Referent Referent
CT 1.25 (1.03, 1.52) 1.24 (0.99, 1.55)
TT 1.23 (0.87, 1.74) 1.00 (0.67, 1.49)
CT +TT 1.25 (1.04, 1.50) 0.0185 0.291 1.19 (0.97, 1.47) 0.1026 0.6885
SMUG1 rs3087404 GG Referent Referent
AG 0.94 (0.77, 1.15) 0.90 (0.71, 1.13)
AA 0.93, (0.70, 1.22) 1.06 (0.78, 1.45)
AG + AA 1.04 (0.84, 1.30) 0.7198 0.9413 0.87 (0.67, 1.13) 0.2994 0.5814
PCNA rs25406 CC Referent Referent
CT 1.01 (0.82, 1.24) 1.24 (0.97, 1.57)
TT 0.94 (0.72, 1.23) 1.23 (0.91, 1.67)
CT +TT 0.99 (0.82, 1.20) 0.9313 0.9871 1.24 (0.98, 1.55) 0.6996 0.7271
rs17352 AA Referent Referent
AC 0.97 (0.77, 1.22) 0.85 (0.65, 1.19)
CC 1.09 (0.76, 1.56) 1.07 (0.74, 1.55)
AC + CC 0.86 (0.70, 1.06) 0.1590 0.3908 0.76 (0.60, 0.97) 0.0243 0.8998
rs17349 CC Referent Referent
CT 1.02 (0.82, 1.26) 0.85 (0.67, 1.09)
TT 1.00 (0.61, 1.63) 0.97 (0.59, 1.58)
CT + TT 1.02 (0.83, 1.25) 0.8763 0.9871 0.87 (0.69, 1.09) 0.2303 0.6885
FEN1 rs412334 GG Referent Referent
AG 0.88 (0.69, 1.11) 0.69 (0.51, 0.93)
AA 0.53 (0.23, 1.20) 1.17 (0.55, 2.51)
AG + AA 0.85 (0.67, 1.07) 0.1609 0.3908 0.73 (0.54, 0.97) 0.0315 0.2678
PARP1 rs1136410 TT Referent Referent
CT 0.96 (0.76, 1.21) 1.00 (0.76, 1.31)
CC 1.74 (0.87, 3.49) 2.29 (1.04, 5.05)
CT + CC 1.00 (0.81, 1.25) 0.9871 0.9871 1.06 (.82, 1.38) 0.6621 0.8998
a Odds ratio and 95% confidence interval, adjusted for age, proportion European ancestry, and offset term
b P-value is unadjusted for multiple comparisons
c FDR adjusted
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Table 16. SKAT analysis for base excision repair SNPs 
 
  
Group Number of SNPs SNP-set Global p-value
African Americans 29 rs1799782 rs25489 rs25487 rs25496 rs3136820 
rs1052133 rs1805373 rs3219489 rs3219497 
rs3219484 rs140696 rs2307289 rs3219275 rs3136025 
rs4796030 rs5745926 rs8191613 rs1534862 
rs3136391 rs3087404 rs25406 rs17352 rs17349 
rs17288820 rs2066791 rs17287851 rs412334 
rs1136410 rs323870
0.8638
Whites 20 rs1799782 rs25489 rs25487 rs3136820 rs1048945 
rs1052133 rs3219489 rs3219484 rs140696 rs4135113 
rs3136797 rs4796030 rs8191613 rs8191664 
rs1534862 rs3087404 rs34857719 rs25406 rs17352 
rs17349 rs412334 rs1136410 rs323870
0.1601
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Table 17. Linkage Disequilibrium by race 
 
XRCC1 rs1799782 rs25489 rs25487 XRCC1 rs1799782 rs25489 rs25487
rs1799782 1.00 rs1799782 1.00
rs25489 0.00 1.00 rs25489 0.00 1.00
rs25487 0.04 0.02 1.00 rs25487 0.01 0.07 1.00
rs25496 0.00 0.01 0.00 rs25496 0.00 0.13 0.01
APE1 rs3136820 rs1048945 APE1 rs3136820 rs1048945
rs3136820 1.00 rs3136820 1.00
rs1048945 0.16 1.00 rs1048945 0.00 1.00
OGG1 rs1052133 rs1805373 OGG1 rs1052133 rs1805373
rs1052133 1.00 rs1052133 1.00
rs1805373 0.04 1.00 rs1805373 0.02 1.00
MUTYH rs3219489 rs3219497 rs3219484 MUTYH rs3219489 rs3219497 rs3219484
rs3219489 1.00 rs3219489 1.00
rs3219497 0.12 1.00 rs3219497 0.11 1.00
rs3219484 0.02 0.01 1.00 rs3219484 0.00 0.00 1.00
MBD4 rs140696 rs2307289 MBD4 rs140696 rs2307289
rs140696 1.00 rs140696 1.00
rs2307289 0.11 1.00 rs2307289 0.53 1.00
LIG3 rs3136025 rs4796030 LIG3 rs3136025 rs4796030
rs3136025 1.00 rs3136025 1.00
rs4796030 0.01 1.00 rs4796030 0.16 1.00
NEIL2 rs8191613 rs8191664 rs1534862 NEIL2 rs8191613 rs8191664 rs1534862
rs8191613 1.00 rs8191613 1.00
rs8191664 0.91 1.00 rs8191664 0.05 1.00
rs1534862 0.06 0.24 1.00 rs1534862 0.03 0.01 1.00
PCNA rs25406 rs17352 rs17349 PCNA rs25406 rs17352 rs17349
rs25406 1.00 rs25406 1.00
rs17352 0.26 1.00 rs17352 0.00 1.00
rs17349 0.29 0.95 1.00 rs17349 0.34 0.31 1.00
ar2= correlation coefficient squared
Whites African Americans
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CHAPTER 4. SINGLE NUCLEOTIDE POLYMORPHISMS IN DNA BYPASS 
POLYMERASE GENES AND ASSOCIATION WITH BREAST CANCER AND BREAST 
CANCER SUBTYPES AMONG AFRICAN AMERICANS AND WHITES 
 
4.1 Introduction 
 
The integrity of DNA is constantly threatened by DNA damage from both endogenous 
and exogenous sources. DNA may be damaged as much as a million times per cell per day (103). 
Unrepaired DNA damage can result in genomic instability, leading to point mutations, deletions 
and insertions, as well as chromosomal alterations.  These defects increase the probability of a 
hit to an oncogene or tumor suppressor and may ultimately lead to carcinogenesis. To maintain 
genomic integrity, there is an intricate system of damage response mechanisms (363). 
Researchers have identified at least 15 different DNA polymerases in humans which are essential 
for DNA replication, DNA repair and the tolerance of DNA damage (222).  
 DNA replicative polymerases which carry out the bulk of DNA synthesis have evolved 
to be very precise and efficient (224). Despite this high fidelity, a replication error may generate 
a one-sided double-strand break (DSB) or degrade to a full DSB if it not repaired prior to 
initiation of DNA replication (225, 226). In order to resume DNA replication at a stalled 
replication fork, two damage tolerance mechanisms have been proposed; template switching in 
homologous recombination (HR) and translesion synthesis (TLS) (227). During template 
switching, synthesis on the undamaged template strands can continue to a limited extent (119, 
222, 227).  In contrast, translesion synthesis is conducted by specialized DNA polymerases that 
do not directly repair the damage, but rather bypass the damage to prevent replication fork 
stalling. Unlike replicative polymerases, bypass polymerases lack 3' to 5' exonuclease 
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(proofreading) activity and are able to resume replication without an undamaged template. 
However, this also contributes to their low fidelity and potential mis-incorporation of nucleotides 
(234).  
Previous research has shown that mutations in bypass polymerases may be associated 
with the risk of cancer. POLH (pol eta) was shown to be highly efficient in the bypass of UV 
lesions, such as cyclobutane pyrimidine dimer (CPD). Germline mutations in POLH were 
identified in patients with xeroderma pigmentosum (XP), an autosomal recessive genetic 
disorder of DNA repair in which individuals are unable to repair damage caused by UV light and 
thus are at high risk of developing skin cancer. Typically mutations in the nucleotide excision 
repair (NER) genes results in XP, however this was the first evidence that bypass polymerases 
may be involved in human cancer (249).  While genetic variation in other DNA repair pathway 
genes have been studied extensively in association with breast cancer, the focus on DNA bypass 
polymerases is relatively recent. Several studies have evaluated bypass polymerases in 
association with breast cancer risk (166, 202, 213, 254, 261, 262). Two reports from a 
comprehensive analysis of DNA repair genes in nested case-control study within the NHS 
(Nurses’ Health Study) II cohort evaluated SNPs from 5 bypass polymerase genes (POLB, 
POLD1, POLE, POLL, POLK) (202, 213). Han et al. reported that 44 SNPs, including 3 SNPs in 
POLK (rs3213801, rs5744533, and rs3756558), were significantly associated with 
premenopausal breast cancer risk (239 cases, 477 controls) (p<0.05) (202). However, in the 
study of postmenopausal women (1,145 cases, 1,142 controls), there were no associations with 
any of the studied bypass polymerase SNPs (213). In an in vivo study of breast cancer cells, 
Yang et al. reported elevated POLI expression when exposed to UV radiation (254).  In a gene 
sequencing study, Wang et al. identified several mutations in POLB, including an 87-bp deletion 
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in the catalytic domain of the gene (166). In two other reports, POLQ overexpression in tumors 
was associated with poor prognosis of breast cancer (261, 273).  
We evaluated the association between DNA bypass polymerases variants and breast 
cancer risk in the Carolina Breast Cancer Study, a large population-based case-control study with 
a racially diverse study population and tumor subtype data. This analysis offered a unique 
opportunity to evaluate both breast cancer subtype and race specific effects of 7 bypass 
polymerase genes. 
4.2 Materials and Methods 
4.2.1 Study population 
 
The Carolina Breast Cancer Study (CBCS) is a population-based case-control study of 
breast cancer conducted in 24 counties of central and eastern North Carolina and has been 
described previously (275, 356). Briefly, rapid case ascertainment was implemented to identify 
eligible cases from the North Carolina Central Cancer Registry (NCCCR) (277). Eligible cases 
included women ages 20-74, living in the selected North Carolina counties during their primary 
breast cancer diagnosis. There were 2 phases of enrollment: Phase 1 (1993-1996) enrolled only 
invasive cancers, while Phase 2 (1996-2001) also included women with in situ cancer. Eligible 
controls were identified using Department of Motor Vehicles (DMV) records for women under 
age 65 and Health Care Financing Administration lists for women ages 65 and older. Controls 
were frequency matched to cases based on race and age using randomized recruitment to 
oversample African American and younger women, a subgroup often underrepresented in 
research studies of breast cancer (278). This study was approved by the Institutional Review 
Board of the University of North Carolina at Chapel Hill.  
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4.2.2 Baseline Study Visit 
 
During an in-home visit, a written signed informed consent was obtained from cases and 
controls Release forms for medical records and tumor tissue were obtained from cases. The in-
home interview consisted of a nurse-administered questionnaire asking about demographic 
factors and known and suspected breast cancer risk factors. A 30mL blood sample was collected 
at the end of the nurse visit.  Blood samples were collected from 88% of cases and 90% of 
controls. Whites were more likely to provide blood samples than African Americans (88% vs. 
83%), but there were no significant differences in other risk factors for those who provided a 
blood sample and those who did not (281, 282). A total of 2,311 cases (894 African American 
and 1,417 Whites) and 2,022 controls (788 African Americans and 1,234 Whites) were 
successfully enrolled in the study. The overall response rates for cases and controls were 78% 
and 57% respectively (281).     
4.2.3 SNP selection  
 
We searched SNP500 (http://snp500cancer.nci.nih.gov) and dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP) databases and selected 30 SNPs in bypass polymerase genes 
to be genotyped based on reported in vitro or in silico functional effect and the DNA repair 
literature (364). These SNPs included non-synonymous missense, regulatory (5’UTR and 3’ 
UTR), and intronic variants (including splice SNPs) with a minor allele frequency (MAF) of at 
least 5% in African Americans or Whites (Table 19).   
4.2.4 Genotyping methods and quality control 
 
DNA was extracted from peripheral blood lymphocytes by standard methods using an 
automated ABI-DNA extractor (Nuclei Acid Purification System, Applied Biosystems, Foster 
City, CA, USA)  (356). High-throughput genotyping of selected SNPs was conducted at the 
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Mammalian Genotyping Core Facility at the University of North Carolina at Chapel Hill. An 
Illumina high-multiplex GoldenGate Genotyping with 1536 SNP Sentrix Array matrix included 
30 SNPs in 7 bypass polymerases genes (POLH, POLI, POLM, POLQ, REV1L, and REV3L) 
(Illumina Inc, San Diego, CA) (290). Assay intensity data and genotype cluster images for all 
SNPs were reviewed individually. Overall, 1,373 of 1536 (89%) SNPs passed quality control.  
Out of the 30 TLS SNPs selected, we excluded 4 SNPs (rs6941583, rs9333500, rs462779 and 
rs3204953) for which genotyping resulted in poor signal intensity or genotyping clustering, 1 
SNP that failed due to poor assay design (rs3218600), and 3 non-polymorphic SNPs (rs3730823, 
rs28382644, and rs28382635). All SNPs were in HWE (P>0.05) (Table 20). Our final analysis 
included genotyped data for 22 SNPs in bypass polymerase genes for 1,972 cases and 1,776 
controls. In addition 144 ancestry informative markers (AIMs) were genotyped to estimate 
African and European ancestry (281). 
4.2.5 IHC analysis and subtype ascertainment 
 
Immunohistochemical (IHC) markers were used as a surrogate for gene expression-based 
subtyping (58). IHC staining and scoring procedures have been explained previously in detail 
(22, 53, 58, 59). Briefly, tumor tissue blocks were used to confirm diagnosis by a pathologist and 
to conduct IHC subtyping. Formalin-fixed paraffin-embedded (FFPE) tumor tissue was available 
80% of cases and immunohistochemistry was completed for 62% of cases. ER/PR status was 
abstracted from medical records for 80% of cases while IHC was used for the remaining 20% of 
cases (for whom clinical status was not available). In cases that had both medical records and 
IHC data available, the concordance of ER/PR status was 81% (307). A total of 1424 (77% of 
available tumor blocks) were successfully subtyped and classified tumors as either luminal (ER+ 
and/or PR+; n=788), basal-like (ER-, PR-, HER2-, CK 5/6+ and/or EGFR+; n=199) or 
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HER2+/ER- (n=94). We excluded ‘unclassified’ tumors from further analysis. The major 
distinction between the two luminal subtypes are their proliferation signatures, measured by the 
expression of CCNB1, MKI67, and MYBL2 (49). HER2 expression only identifies about 30% of 
luminal B tumors.  In the current study, we did not have information about these proliferation 
markers and therefore combined Luminal A and B tumors into a single ‘luminal’ category (48, 
49). Additionally, most other studies do not have subtype data available and only have estrogen 
receptor status data. Therefore, we conducted an additional exploratory analysis using estrogen 
receptor (ER) status to evaluate comparability to “intrinsic” subtype results. We found that ER 
positive effects were concordant with luminal subtype results (Table 23). There were no 
differences between CBCS cases with and without subtyping data in terms of age, menopausal 
status, or family history. 
4.2.6 Statistical analysis 
 
We calculated allele and genotype frequencies stratified by case status and self-reported 
race (African American or White). We assessed departure from HWE for each locus by 
comparing expected versus observed genotype frequencies among race-specific (White and 
African American) controls using exact tests (p<0.05). We calculated pairwise linkage 
disequilibrium (LD) r
2 
stratified by race using SAS Genetics (version9.1.3) (SAS Institute, Cary, 
NC). 
We used unconditional logistic regression models to estimate odds ratios (ORs) and 95% 
confidence intervals (CIs) for race-stratiifed effects of bypass polymerase SNPs on breast cancer 
based on the additive model. Less than 2% of participants self-identified as a race other than 
Caucasian or African American and were not included in the final analysis. We coded each 
genotype as an ordinal variable (0, 1, or 2 for the number of minor alleles carried by the 
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individual). If the minor allele frequency (MAF) differed by race, the more common allele in 
Whites was used as the referent group for both populations. We also adjusted for proportion of 
African ancestry, as measured with a set of 144 ancestry informative markers (AIMs) (297, 306). 
We excluded non-polymorphic SNPs or SNPs with a minor allele frequency of less than 0.05 in 
either race, leaving 20 SNPs in Whites and 29 SNPs in African Americans available for analysis. 
Because of the high number of rare homozygote variants (18 out of 22 SNPs), homozygotes for 
the variant allele were combined with heterozygotes and effect estimates were reported based on 
the dominant model. Final models were adjusted for age at diagnosis, proportion of African 
ancestry and offset term for the sampling design (278). 
4.2.7 Subtype analyses 
 
We coded breast cancer subtype as a categorical variable with four levels (control, 
luminal, HER2+/ER-, and basal-like).  We used unconditional polytomous regression to estimate 
ORs and 95% CI for each subtype compared to controls. 
4.2.8 Correction for multiple testing 
 
We used FDR correction for multiple testing, following the method of Benjamini and 
Hochberg (313). The false discovery rate is defined as “the expected proportion of errors among 
the rejected hypotheses” (313). Corrections were based on the number of SNPs tested and were 
performed separately for African American and Whites in the race-stratified analysis and 
separately for luminal, HER2+/ER- and basal-like categories in the subtype analysis. Observed 
p-values from the additive model were used to determine q-values. The q-value is defined as the 
minimum FDR that can be attained when calling a SNP significant (i.e., expected proportion of 
false positives) (314). Q-values were computed using the software package R. Statistical 
significance was set at q<0.10.  
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4.2.9 Pathway-based analysis 
 
We used SKAT (SNP-set Kernel Association Test) to evaluate the combined effects of 
the genotyped SNPs in bypass polymerases (333). A SNP-set refers to a set of related SNPs that 
are grouped based on prior biological knowledge. Per our study aim, we used a SNP-set that 
contained bypass polymerases. We chose a linear kernel since we assumed a log linear model. 
Kernel regression methods convert genomic information for a pair of individuals to a kernel 
score representing either similarity or dissimilarity. The formation of SNP-sets harnesses the 
potential correlation between SNPs to increase power (328). When applied to all pairs of the 
individuals, this information formed a positive semi-definite matrix (332). We tested the global 
null hypothesis (none are related to breast cancer) for SNPs in the pathway separately for White 
and African American participants (333).  
4.3 Results 
 
Characteristics of the CBCS population with genotyping data are described in Table 18. 
The distributions of age, proportion of African ancestry, and menopausal status were similar 
between cases and controls. African American cases were more likely to be diagnosed at a later 
stage and were more likely to have tumors that were ER negative. African Americans were twice 
as likely to be classified as having basal-like tumors compared to Whites.  
4.3.1.Genotype associations by race 
 
Genotype distributions in race-stratified controls were all in HWE (p <0.05) (Table 20). 
The race-stratified adjusted odds ratios for BER SNPs are summarized in Table 21. Most SNPs 
did not show a meaningfully increased or decreased odds ratio. However, for both race groups, 3 
SNPs in POLQ were associated with an increased odds ratio under the dominant model (p<0.05). 
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POLQ rs487848 (AG+AA vs GG) showed a statistically significant (uncorrected) positive 
association with breast cancer risk in Whites (OR=1.31; 95% CI= 1.08, 1.68) and African 
Americans (OR=1.22; 95% CI=1.00, 1.49).  POLQ SNP rs532411 (CT+TT vs. CC) was also 
significantly associated with increased breast cancer among both races (OR=1.31; 95% CI= 1.02, 
1.66) and (OR=1.22; 95% CI=1.00, 1.48), respectively.  Finally, POLQ SNP rs3218634 
(CG+CC vs. GG) showed an increased risk in breast cancer in Whites (OR=1.29; 95% CI: 1.02, 
1.65) and in African Americans (OR=1.20; 95% CI=0.98, 1.47). After adjustment for multiple 
testing, none of the SNPs remained significant at the 0.10 FDR level. 
4.3.2 Genotype associations by subtype 
 
In subtype-specific analyses, the 3 POLQ SNPs were significantly associated with 
luminal breast cancer (p<0.05 without FDR correction): rs487848 AG+AA vs. GG (OR=1.34, 
95% CI: 1.02-1.67); rs532411 CT+TT vs. CC, (OR=1.33, 95% CI: 1.06-1.65); rs3218634 
CG+CC vs. GG, (OR=1.26, 95% CI: 1.01-1.57). Additionally, another POLQ SNP rs1381057 
(CT+TT vs CC) was significantly associated with HER+/ER- breast cancer (OR=1.44; 95% CI= 
1.06, 1.93) (Table 22).  The same set of POLQ SNPs was significantly associated with ER+ 
breast cancer (Table 23). However, after FDR adjustment for multiple testing, none of these 
SNPs remained significant (q=0.10). 
4.3.3 Pathway-based analysis 
 
We assessed the global p-value for two different SNP-sets (SNPs successfully genotyped 
in African Americans and SNPs successfully genotyped in Whites) using the SNP-set Kernel 
Association Test (SKAT), adjusted for AIMs, and offset term. We did not find any significant 
associations for SNP-sets. A Kernel machine test of no linear effects yielded a global p-value of 
0.40 and 0.54 for African Americans and Whites, respectively (Table 24).  
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 4.4 Discussion 
 
 Given the relatively low fidelity and high mutational potential of bypass polymerases, it 
was initially hypothesized that SNPs in DNA bypass polymerases may be linked to increased 
cancer risk. We did not find a consistent pattern of association with breast cancer risk overall or 
within a given subtype for most SNPs we evaluated.  Subsequently, specialized bypass 
polymerases were shown to bypass lesions in an error-free manner (233, 246, 365). Therefore, 
functional redundancy in this pathway may partially explain the lack of associations between 
bypass polymerases and breast cancer.  Indeed, lesion specificity and functional redundancy are 
both evolutionary tactics which may ensure that genomic integrity is maintained.(366). 
 Despite the weak results for most bypass polymerases, we did observe evidence for both 
race- and subtype -specific associations between three POLQ variants and an increased breast 
cancer risk. To our knowledge, other studies have not investigated these associations. 
Interestingly, all of the SNPs showing an association appeared to predict increased risk of 
luminal breast cancer. Although not statistically significant using the FDR these findings are 
suggestive and warrant replication in other studies. Within each race, these three POLQ SNPs 
were in linkage disequilibrium with each other making it difficult to identify which, if any SNPs 
were most likely to have functional effects.  POLQ rs3218634 had a SIFT score of 0.01 
indicative of being a damaging functional SNP (Table 19), possibly implicating the SNP as the 
most likely causal variant, however functional studies and fine mapping of the region is needed.   
 The POLQ gene, located at chromosome 3q, is a member of the A Family that encodes 
the protein polymerase theta. POLQ has also been implicated as playing a role in other DNA 
repair mechanisms such as base excision repair (BER) and crosslink repair (367, 368). POLQ is 
able to efficiently bypass oxidative DNA lesions such as abasic (AP) sites and thymine glycol in 
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vitro (246, 369-371). Another lab study showed that POLQ successfully extends from 
mismatches and bases opposite (6-4) photoproducts (246). On the other hand, POLQ-deficient 
mutants exhibited hypersensitivity to oxidative base damage induced by H2O2 (263). The results 
of the current study, together with previous experimental evidence, suggest POLQ may play an 
important role in breast cancer risk.  
 Recently, a pair of studies have linked POLQ overexpression in tumors to breast cancer 
progression and poorer prognoses (253, 261, 262). Lemee et al. examined gene expression 
profiles of tumors from two cohorts of European women with untreated primary breast cancer. 
Patients’ tumor cells that overexpressed POLQ had a 4.3-fold increased risk of death compared 
those with normal expression (261). Higgins et al. also found elevated levels of POLQ 
expression in breast cancer cells, which was linked to poor prognosis in early breast cancer 
patients (262). While these findings emphasize the role of POLQ after disease onset, genes that 
influence progression also have been shown to influence early disease/etiology and therefore 
these findings also suggest that POLQ merits further investigation. 
These findings should be considered in light of strengths and limitations of our study. 
Compared to other genetic association studies of breast cancer, CBCS has a larger proportion of 
African Americans (over 40%). In addition, CBCS has detailed subtype data on tumors from a 
large population-based sample of women allowing a unique investigation of the genetics of 
specific breast cancer subtypes as well as the ability to extend study results to the population as a 
whole. Stratification by subtype does reduce power for some race-specific and subtype 
comparisons, especially for HER2+/ER- and basal-like tumors. Future research that includes 
large numbers of breast cancer cases with less common subtypes and focuses on oversampling 
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African American cases should have improved power to more precisely estimate subtype 
associations, especially among African American women. 
We had genotype and subtype data for a large proportion of CBCS participants. Tumor 
tissue was available for 1,845 of 2,311 cases (80%) and subtyping using IHC was completed for 
1,424 of 2,311 cases (62%) (307). A comparison of subtyped and non-subtyped CBCS cases 
showed that the subtyped cases were not significantly different from the CBCS as a whole with 
respect to age and menopausal status. However, cases with subtype data were more likely to be 
African American and to have a later stage at diagnosis, which may bias estimates for SNPs 
related to race or disease aggressiveness (22).  
It is also noteworthy that definitions for luminal breast cancer have evolved since original 
CBCS IHC subtyping methods were published (58). As a result, we were unable to divide 
luminal breast cancers into finer categories (Luminal A vs. Luminal B); current methods require 
use of PR positivity (on a quantitative scale) or Ki-67 to distinguish the two (295, 372). 
Therefore, there is heterogeneity within the group of luminal breast cancers defined here. 
Nonetheless, our subtyping methods here have the advantage of excluding tumors that were 
negative for all markers tested. Only triple negatives that were also positive for a basal-like 
marker are included among basal-like cancers, reducing outcome misclassification potential in 
this important subgroup.  
Although we did not find any significant combined effects of SNPs in the TLS pathway 
using SKAT, use of kernel-based machine learning to assess pathway effects in breast cancer is 
an important advance in studying gene-gene interactions (175, 213). While our pathway analysis 
was limited by the density of SNP coverage across TLS pathway genes, it is important to 
understand gene-gene interactions in breast cancer pathways.  Future application of SKAT to 
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similar data should consider tag-SNP approaches, which may better capture variation in 
candidate pathways.   
4.5 Conclusions 
 
 In summary, this study adds important new information on the role of bypass 
polymerases in breast cancer etiology by using tumor tissue to evaluate subtype-specific effects 
and considers carefully selected regulatory and coding SNP-sets in a biologically established 
DNA repair pathway. We identified three novel SNPs in the POLQ gene, not previously 
evaluated in an epidemiologic study.  With the exception of POLQ, we did not find any other 
bypass polymerase variants to be significantly associated with breast cancer risk. Larger studies 
such as the CBCS Phase 3 with improved power for race- and subtype-specific analyses and 
collaborative consortia will help gain further insight into the role of genetic variation in the DNA 
bypass polymerases and the risk of breast cancer.  
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Table 18. Characteristics of CBCS participants with genotyped data 
 
Characteristic
N % N % N % N %
Total (N) 742 100 1,204 100 658 100 1,089 100
Average age at selection 52 52 52 53
Average proportion of African ancestry 0.78 0.064 0.774 0.066
Menopausal status
   Pre-menopausal 324 41.36 539 30.53 290 59.09 456 62.67
   Post-menopausal 418 58.64 665 69.47 368 40.91 633 37.33
Stage
   CIS* 88 11.90 349 29
1 216 29.10 393 32.6
2 299 40.30 328 27.2
3 76 10.20 68 5.7
4 27 3.60 15 1.3
Missing 36 4.90 51 4.2
Subtype
   Luminal 269 56.31 519 75.63
   HER2+/ER- 38 7.59 56 5.82
   Basal-like 108 21.98 91 10.68
Estrogen Receptor (ER) Status
   Positive 235 49.57 482 68.91
   Negative 251 50.43 242 31.09
*carcinoma in situ
Cases Controls
African American White African American White
1
3
5
 
 
 136 
 
Table 19. List of successfully genotyped TLS variants 
Gene rs# Type of variant
Amino Acid 
Change
Allele 
Change 
SIFT 
score
a
POLH rs35675573 missense T329I C/T 0.01
rs9333555 missense M595V A/G 0.13
rs6899628 3'UTR N/A C/T N/A
POLI rs3730823 missense H449R A/G 0.52
rs3218786 missense F507S C/T 0
rs8305  missense A706T A/G 0.86
POLL rs3730477 missense R438W C/T 0
rs3730475 splice N/A C/T N/A
rs3730463 missense T221P A/C 0
POLM rs28382653 missense V246F G/T 0
POLQ rs487848 missense A581V A/G 0.48
rs3218651 missense H1201R A/G 0.17
rs532411 missense A2304V C/G 0.05
rs1381057 missense Q2513R C/T 0.26
rs3218634 missense L2538V C/G 0.01
rs3218637 missense R1953Q A/G 0.58
rs3218649 missense T982R C/G 0.61
rs702017 missense R66I G/T 0.21
REV1L rs 3087403 missense V138M A/G 0.09
rs 3087386 missense F257S C/T 0.38
rs3087399 missense N373S A/G 0.78
REV3L rs458017 missense Y1078C C/T 0.22
rs17539651 missense P1713S C/T 0.61
aRanges from 0 to 1. The amino acid substitution is predicted damaging if the score is <=0.05, 
and tolerated if the score is > 0.05
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Table 20. Minor Alleles Frequencies of bypass polymerase SNPs stratified by race 
 
Gene SNP
Minor 
Allele Cases Controls p HWE 
Minor 
Allele Cases Controls p HWE
POLH rs35675573 T 0.000 0.000 N/A T 0.012 0.014 0.707
rs9333555 G 0.026 0.026 0.735 G 0.006 0.004 N/A
rs6899628 T 0.039 0.039 0.278 T 0.328 0.342 0.085
POLI rs3730823 G 0.000 0.000 N/A G 0.005 0.007 N/A
rs3218786 C 0.035 0.026 0.375 C 0.007 0.006 N/A
rs8305 G 0.301 0.293 0.914 G 0.060 0.067 0.971
POLL rs3730477 T 0.211 0.224 0.656 T 0.056 0.073 0.773
rs3730475 C 0.284 0.288 0.601 C 0.169 0.186 0.135
rs3730463 A 0.072 0.065 0.199 C 0.103 0.106 0.580
POLM rs28382653 T 0.000 0.001 N/A T 0.051 0.051 0.569
rs28382635 T 0.000 0.000 N/A T 0.000 0.000 N/A
rs28382644 C 0.012 0.008 N/A C 0.000 0.002 N/A
POLQ rs487848 A 0.078 0.062 0.899 A 0.205 0.181 0.354
rs3218651 G 0.167 0.163 0.073 G 0.118 0.109 0.725
rs532411 T 0.078 0.063 0.874 T 0.204 0.181 0.354
rs1381057 T 0.309 0.298 0.696 T 0.367 0.350 0.765
rs3218634 C 0.078 0.063 0.849 C 0.201 0.179 0.103
rs3218637 A 0.001 0.000 N/A A 0.049 0.055 0.446
rs3218649 C 0.361 0.352 0.926 C 0.454 0.441 0.447
rs702017 G 0.000 0.000 N/A G 0.044 0.044 0.504
REV1L rs3087403 A 0.281 0.291 0.464 A 0.291 0.277 0.476
rs3087386 T 0.443 0.451 0.886 T 0.287 0.290 0.550
rs3087399 G 0.127 0.119 0.488 G 0.257 0.257 0.487
REV3L rs458017 C 0.065 0.070 0.208 C 0.040 0.049 0.743
rs17539651 T 0.001 0.002 N/A T 0.113 0.119 0.226
Whites African American
1
3
7
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Table 21. Assocations between bypass polymerase variants with breast cancer stratified by race 
 
 
Gene SNP Genotype Cases (N) Controls (N) OR (95% CI) p q value Cases (N) Controls (N) OR (95% CI) p q value
POLH rs9333555 AA 1142 1034 Referent 733 653 Referent
AG+GG 62 55 0.94 (0.64, 1.38) 0.7398 0.8088 9 5 1.92 (0.62,6.01) 0.2601 0.6134
rs6899628 CC 1117 1007 Referent 336 275 Referent
CT+ TT 87 82 0.92(0.65,1.29) 0.2778 0.716 405 383 0.96 (0.81,1.13) 0.5979 0.7972
POLI rs3218786 TT 1120 1032 Referent 732 650 Referent
CT+CC 84 57 1.41 (0.98, 2.03) 0.065 0.2763 10 8 1.04 (0.39,2.76) 0.9358 0.9943
POLL rs8305 AA 599 543 Referent 657 573 Referent
AG+GG 605 546 1.06 (0.93, 1.21) 0.3791 0.7161 85 85 0.84 (0.61, 1.16) 0.2876 0.6134
rs3730477 CC 739 659 Referent 662 565 Referent
CT+TT 464 430 0.93 (0.80, 1.08) 0.3286 0.7161 80 93 0.79 (0.57,1.08) 0.1438 0.6134
rs3730475 TT 613 548 Referent 511 430 Referent
CT+CC 591 541 0.98 (0.85, 1.12) 0.7612 0.8088 231 228 0.91 (0.74,1.12) 0.3761 0.6134
POLM rs3730463 AA 1041 950 Referent 599 525 Referent
AC+CC 163 139 1.12 (0.88, 1.43) 0.3416 0.7161 143 133 1.00 (0.78, 1.28) 0.9802 0.9943
rs28382653 GG 1204 1086 Referent 670 592 Referent
GT + TT 0 3 N/A N/A 72 66 1.03 (0.73, 1.46) 0.8481 0.9943
POLQ rs487848 GG 1024 957 Referent 469 438 Referent
AG+AA 180 132 1.31 (1.03, 1.68) 0.0279 0.2131 273 220 1.22 (1.00, 1.49) 0.0487 0.482
rs3218651 AA 840 771 Referent 577 521 Referent
AG+GG 364 318 0.96 (0.82, 1.13) 0.6463 0.8088 165 137 1.13 (0.88,1.43) 0.3411 0.6134
rs532411 CC 1024 956 Referent 469 438 Referent
CT+ TT 180 133 1.31 (1.02, 1.66) 0.0318 0.2131 272 220 1.22 (1.00,1.48) 0.0484 0.482
rs1381057 CC 575 534 Referent 298 276 Referent
CT+ TT 629 555 1.02 (0.90, 1.17) 0.7355 0.8088 444 382 1.10 (0.94,1.29) 0.2464 0.6134
rs3218634 GG 1024 955 Referent 30 15 Referent
CG+ CC 180 134 1.29 (1.02, 1.65) 0.0376 0.2131 712 643 1.20 (0.98,1.47) 0.0723 0.482
rs3218637 GG 1202 1089 Referent 672 586 Referent
AG+AA 2 0 N/A N/A 69 72 0.88 (0.62, 1.24) 0.4559 0.6513
rs3218649 GG 497 457 Referent 221 201 Referent
CG+CC 704 632 1.01 (0.89, 1.15) 0.8453 0.8453 521 457 1.08 (0.92,1.26) 0.3358 0.6134
White African Americans
1
3
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REV1L rs3087403 GG 623 543 Referent 377 348 Referent
AG+AA 580 546 0.95 (0.83, 1.09) 0.4451 0.7424 365 310 1.09 (0.92,1.29) 0.3406 0.6134
rs3087386 CC 385 329 Referent 383 329 Referent
CT+TT 819 760 0.96 (0.85, 1.09) 0.5317 0.7532 359 329 0.98 (0.83,1.17) 0.8511 0.9943
rs3087399 AA 915 843 Referent 411 360 Referent
AG+GG 306 259 1.07 (0.89, 1.29) 0.4804 0.7424 331 298 1.00 (0.84, 1.19) 0.9943 0.9943
REV3L rs458017 TT 1054 945 Referent 684 595 Referent
CT+CC 150 144 0.87 (0.68, 1.11) 0.2642 0.7161 58 63 0.83 (0.58, 1.20) 0.3222 0.6134
rs17539651 CC 1201 1085 Referent 582 508 Referent
CT+TT 3 4 N/A N/A 160 150 0.90 (0.70,1.15) 0.3987 0.6134
N/A indicates non-polymorphic
1
3
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Table 22. Association of bypass polymerase variants with breast cancer stratified by subtype 
Gene SNP Genotype OR (95% CI) p q value OR (95% CI) p q value OR (95% CI) p q value
POLH rs6899628 CC Referent Referent Referent
CT+ TT 0.94 (0.74, 1.21) 0.6402 0.873 1.00 (0.57, 1.77) 0.9991 0.9991 0.80 (0.55, 1.17) 0.255 0.425
POLL rs8305 AA Referent Referent Referent
AG+GG 0.99 (0.81, 1.20) 0.8863 0.8863 1.22 (0.76, 1.97) 0.4115 0.8763 0.91 (0.63, 1.30) 0.5897 0.6719
rs3730477 CC Referent Referent Referent
CT+TT 0.98 (0.80, 1.20) 0.8344 0.8863 0.72 (0.43, 1.21) 0.2144 0.6432 0.79 (0.54, 1.15) 0.2168 0.425
rs3730475 TT Referent Referent Referent
CT+CC 0.97 (0.81, 1.17) 0.7731 0.8863 0.68 (0.43, 1.06) 0.867 0.9389 0.93 (0.68, 1.26) 0.6271 0.6719
POLM rs3730463 AA Referent Referent Referent
AC+CC .92 (0.71, 1.18) 0.4994 0.873 0.86 (0.47, 1.58) 0.6358 0.9166 1.34 (0.92, 1.96) 0.1236 0.425
POLQ rs487848 GG Referent Referent Referent
AG+AA 1.34 (1.02, 1.67) 0.0096 0.144 1.21 (0.72, 2.02) 0.4753 0.8763 1.23 (0.86, 1.76) 0.2492 0.425
rs3218651 AA Referent Referent Referent
AG+GG 1.16 (0.65, 2.07) 0.6258 0.873 1.18 (0.28, 5.01) 0.8215 0.9289 1.10 (0.38, 3.15) 0.2492 0.425
rs532411 CC Referent Referent Referent
CT+ TT 1.33 (1.06, 1.65) 0.118 0.3918 1.20 (0.72, 2.02) 0.479 0.8763 1.23 (0.86, 1.76) 0.2487 0.425
rs1381057 CC Referent Referent Referent
CT+ TT 1.11 (0.97, 1.27) 0.1306 0.3918 1.44 (1.06, 1.93) 0.0193 0.2895 1.10 (0.88, 1.38) 0.389 0.5305
rs3218634 GG Referent Referent Referent
CG+ CC 1.26 (1.01, 1.57) 0.0376 0.282 1.18 (0.71, 1.98) 0.5258 0.8763 1.24 (0.87, 1.77) 0.2331 0.425
rs3218649 GG Referent Referent Referent
CG+CC 1.08 (0.95, 1.23) 0.2505 0.6263 1.27 (0.94, 1.71) 0.1235 0.6308 1.04 (0.84, 1.30) 0.7263 0.7263
REV1L rs3087403 GG Referent Referent Referent
AG+AA 1.01 (0.88, 1.16) 0.8611 0.8863 0.78 (0.55, 1.11) 0.1682 0.6308 1.22 (0.97, 1.53) 0.0931 0.425
rs3087386 CC Referent Referent Referent
CT+TT 0.95 (0.83, 1.08) 0.4133 0.873 1.25 (0.93, 1.69) 0.1404 0.6308 0.86 (0.68, 1.07) 0.1771 0.425
rs3087399 AA Referent Referent Referent
AG+GG 1.05 (0.87, 1.28) 0.6069 0.873 0.91 (0.57, 1.46) 0.7042 0.9166 0.84 (0.60, 1.17) 0.3085 0.4626
REV3L rs458017 TT Referent Referent Referent
CT+CC 0.76 (0.57, 1.02) 0.0651 0.3255 1.11 (0.60, 2.05) 0.7333 0.9166 0.84 (0.52, 1.38) 0.4933 0.6166
HER2+/ER- Basal-likeLuminal
1
4
0
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Table 23. Association of bypass polymerase variant with breast cancer stratified by ER status 
 
Gene SNP Genotype OR (95% CI) p q value OR (95% CI) p q value
POLH rs6899628 CC Referent Referent
CT+ TT 0.99 (0.80, 1.21) 0.8827 0.9225 1.03 (0.83, 1.27) 0.7925 0.8491
POLL rs8305 AA Referent Referent
AG+GG 1.08 (0.92, 1.27) 0.3581 0.6714 1.05 (0.86, 1.28) 0.6496 0.847
rs3730477 CC Referent Referent
CT+TT 0.96 (0.80, 1.14) 0.6103 0.8322 0.85 (0.68, 1.06) 0.1413 0.6038
rs3730475 TT Referent Referent
CT+CC 0.98 (0.84, 1.14) 0.7862 0.9225 0.95 (0.79, 1.14) 0.566 0.847
POLM rs3730463 AA Referent Referent
AC+CC 0.99 (0.78, 1.26) 0.9225 0.9225 1.12 (0.87, 1.46) 0.3804 0.8151
POLQ rs487848 GG Referent Referent
AG+AA 1.30 (1.06, 1.60) 0.0113 0.1028 1.18 (0.94, 1.48) 0.1526 0.6038
rs3218651 AA Referent Referent
AG+GG 0.87 (0.73, 1.04) 0.1307 0.2801 1.05 (0.85, 1.31) 0.6393 0.847
rs532411 CC Referent Referent
CT+ TT 1.29 (1.05, 1.59) 0.0137 0.1028 1.18 (0.94, 1.48) 0.1537 0.6038
rs1381057 CC Referent Referent
CT+ TT 1.14 (0.99, 1.31) 0.0638 0.2392 1.04 (0.89, 1.22) 0.5935 0.847
rs3218634 GG Referent Referent
CG+ CC 1.26 (1.02, 1.44) 0.03 0.15 1.18 (0.94, 1.48) 0.161 0.6038
rs3218649 GG Referent Referent
CG+CC 1.11 (0.98, 1.27) 0.1131 0.2801 1.02 (0.88, 1.19) 0.7717 0.8491
REV1L rs3087403 GG Referent Referent
AG+AA 0.99 (0.86, 1.14) 0.8769 0.9225 1.08 (0.92, 1.27) 0.3422 0.8151
rs3087386 CC Referent Referent
CT+TT 0.96 (0.84, 1.10) 0.57 0.8322 0.97 (0.83, 1.13) 0.6776 0.847
rs3087399 AA Referent Referent
AG+GG 1.05 (0.88, 1.25) 0.582 0.8322 0.98 (0.81, 1.19) 0.8539 0.8539
REV3L rs458017 TT Referent Referent
CT+CC 0.80 (0.61, 1.060 0.1184 0.2801 0.86 (0.63, 1.19) 0.3663 0.8151
ER+ ER-
1
4
1
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Table 24. SKAT analysis of bypass polymerase SNP sets 
 
  
Group Number of SNPs SNP-set Global p-value
African American 20 rs35675573 rs6899628 rs8305 rs3730477 rs3730475 
rs3730463 rs2838653 rs487848 rs3218651 rs532411 
rs1381057 rs3218634 rs3218637 rs3218649 rs702017 
rs3087403 rs3087386 rs3087399 rs458017 rs17539651 
0.4027
White 16 rs933555 rs6899628 rs3218786 rs8305 rs3730477 
rs3730475 rs3730463 rs487848 rs3218651 rs532411 
rs1381057 rs3218634 rs3218649 rs3087403 rs3087386 
rs3087399 rs458017  
0.5453
 
1
4
2
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Table 25. Linkage disequilibrium by race  
 
African American White
POLI rs3218786 rs8305 POLI rs3730823 rs3218786 rs8305
rs3218786 1.00 rs3730823 1.00
rs8305 0.00 1.00 rs3218786 0.00 1.00
rs8305 0.00 0.02 1.00
POLL rs3730477 rs3730475 rs3730463 POLL rs3730477 rs3730475 rs3730463
rs3730477 1.00 rs3730477 1.00
rs3730475 0.99 1.00 rs3730475 0.69 1.00
rs3730463 0.00 0.54 1.00 rs3730463 0.02 0.18 1.00
REV1L rs3087403 rs3087386 rs3087399 REV1L rs3087403 rs3087386 rs3087399
rs3087403 1.00 rs3087403 1.00
rs3087386 0.16 1.00 rs3087386 0.32 1.00
rs3087399 0.14 0.14 1.00 rs3087399 0.06 0.11 1.00
REV3L rs458017 rs17539651 REV3L rs458017 rs17539651
rs458017 1.00 rs458017 1.00
rs17539651 0.00 1.00 rs17539651 0.00 1.00
 
1
4
3
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Table 25 continued. 
White
POLQ rs487848 rs3218651 rs532411 rs1381057 rs3218634 rs3218637 rs3218649 rs702017
rs487848 1.00
rs3218651 0.03 1.00
rs532411 1.00 0.03 1.00
rs1381057 0.43 0.07 0.43 1.00
rs3218634 0.94 0.03 0.94 0.42 1.00
rs3218637 0.01 0.00 0.01 0.03 0.01 1.00
rs3218649 0.30 0.10 0.30 0.68 0.28 0.07 1.00
rs702017 0.01 0.01 0.01 0.08 0.11 0.00 0.06 1.00
African American
POLQ rs487848 rs3218651 rs532411 rs1381057 rs3218634 rs3218637 rs3218649 rs702017
rs487848 1.00
rs3218651 0.01 1.00
rs532411 1.00 0.02 1.00
rs1381057 0.17 0.86 0.17 1.00
rs3218634 0.99 0.02 1.00 0.17 1.00
rs3218637 0.00 0.00 0.00 0.00 0.00 1.00
rs3218649 0.14 0.11 0.14 0.79 0.14 0.00 1.00
rs702017 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
1
4
4
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CHAPTER 5. DISCUSSION 
 
Since the discovery of mutations in BRCA1, a prominent DNA repair gene, in the early 
1990’s, researchers have been investigating other DNA repair genes in relation to breast cancer 
risk. Results from many of these DNA repair gene variant studies have been inconclusive; 
however previous CBCS studies have indicated that risk factor profiles may differ by tumor 
subtype and race (22, 59, 373).The purpose of this dissertation was to examine whether there are 
DNA repair gene subgroup SNP effects on breast cancer risk by race or breast cancer subtype. 
We further examined combined SNP effects using a biological pathway-based approach 
separately in each pathway.  
We used genotype data from the Carolina Breast Cancer Study, a population-based study 
of White and African American women in North Carolina the majority of whom had tumor 
samples available for subtyping.  We used unconditional logistic regression to estimate the odds 
ratios (ORs) and 95% confidence intervals (CIs) for the association between 31 SNPs in 15 
genes in the base excision repair pathway and 22 SNPs in DNA bypass polymerase genes. We 
categorized race as White or African-American and classified tumors using immunochemistry as 
luminal (ER+ and/or PR+; n=788), basal-like (ER-, PR-, HER2-, CK 5/6+ and/or EGFR+; 
n=199) or HER2+/ER- (n=94).  
5.1 Summary of Results 
 
 We found evidence for both race- and subtype -specific associations between BER and 
bypass polymerase variants and breast cancer risk. In the BER pathway, two SNPs were 
associated with an increased risk (OGG1 rs1052133 and NEIL2 rs1534862) and two PCNA SNPs 
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(rs17349 and rs17352) in high LD (r
2
=0.95) were associated with an inverse association in 
Whites. Among African Americans, we found a NEIL2 SNP (rs8191613) to be associated with a 
28% decreased risk of breast cancer and UNG rs3219725 with a 44% increased risk. In the tumor 
subtype analysis, the NEIL2 SNP (rs1534862) was positively associated with a moderately 
increased risk of luminal and HER2+/ER- breast cancer. We also found an inverse association 
between FEN1 SNP (rs412334) and basal-like breast cancer. 
The majority of our findings for the BER pathway were in a set of DNA glycosylase 
genes, OGG1, UNG, and NEIL2. These are involved in the initial recognition and response to 
DNA lesions. Therefore, it could be biologically plausible that a mutation in any one of these 
genes may lead to dysfunction in DNA replication or BER repair.  
 OGG1 is a glycosylase that is primarily responsible for the accurate excision of 7,8-
dihydro-8-oxoguanine (8-oxoG), a product of oxidative stress, which can cause a G-T 
transversion during DNA replication if it not removed.  OGG1 variants have been shown to be 
highly mutagenic in mice and in vitro studies and associated with reduced DNA repair activity 
(219, 359). However, the evidence from epidemiologic literature has not been as consistent. The 
majority of studies that evaluated the role of OGG1 rs1052133 with breast cancer risk in White 
and Asian populations showed inconsistent or generally null results (137, 139, 141, 143, 145, 
361). In the current study, the positive association that we observed in Whites did not remain 
statistically significant after adjustment for multiple comparisons.   
We are the first to report a statistically significant increased risk of breast cancer among 
African Americans for UNG SNP rs3219725. Mutational analyses have identified UNG missense 
variants in colorectal cancer, glioblastoma, B cell lymphoma, and esophageal squamous cell 
carcinoma, however there is no evidence for breast cancer. Our result for rs3219725, which is 
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located in the 3’UTR of the gene, represents a regulatory SNP not previously reported for breast 
cancer risk in African Americans. However this finding requires replication in a larger group of 
African Americans since it did not remain significant after adjusting for multiple comparisons. 
 NEIL2 is a part of a newly discovered family of monofunctional DNA glycosylases 
(106). Laboratory studies have shown that NEIL2 plays an important role in the repair of 
oxidized bases such as pyrimidines and cytosines (109, 148). Variants in NEIL2 have been 
previously associated with increased risk in colorectal, head and neck and lung cancers. One 
report from the Cancer Genetic Markers of Susceptibility (CGEMS) Project noted a pair of SNPs 
in NEIL2 (rs8191649 and rs8191642) to be significantly associated with premenopausal breast 
cancer (p<0.02) (202). 
Our analysis showed a different NEIL2 SNP, rs1534862, was associated with increased risk of 
breast cancer in Whites, and also in luminal and HER2+/ER- subtypes. Another NEIL2 SNP 
(rs8191613) was associated with a decreased risk in African Americans.  
 After controlling for multiple comparisons using the FDR, two BER SNPs (PCNA 
rs17352 and NEIL2 rs1534862) remained statistically significantly associated with breast cancer. 
The T allele of NEIL2 rs1534862, located in the 3’UTR of the gene, was associated with an 
increased risk of breast cancer in Whites and two subtypes (Luminal and HER2+/ER-). The C 
allele of PCNA rs17352, located in an intronic region, was associated with a decreased risk of 
breast cancer in Whites. These findings, especially for NEIL2 are new and require further 
replication in larger studies. 
Among bypass polymerase genes, we found evidence for both race- and subtype -specific 
associations between three POLQ variants and an increased breast cancer risk. To our 
knowledge, this is the first study to report these associations. Additionally, all of these SNPs 
 148 
 
were associated with an increased risk of luminal breast cancer. Among each race, all three 
POLQ SNPs were in high LD.  POLQ rs3218634, a missense SNP,  had a SIFT score of 0.01 
indicative of being a damaging functional SNP, implicating that it may be the causal variant. 
Although not statistically significant after adjusting for multiple comparisons, these findings are 
suggestive and warrant investigation in future studies. 
POLQ, located at chromosome 3q, is a member of the A Family of DNA polymerases 
that encodes the protein polymerase theta. Recently, a pair of in vitro studies has linked POLQ 
overexpression in tumors to breast cancer progression and poorer prognoses (253, 261, 262). 
POLQ-deficient mutants exhibited hypersensitivity to oxidative base damage induced by 
hydrogen peroxide (263). The results of the current study corroborate the experimental evidence 
of the potential mutagenicity of POLQ variants.  
With the exception of POLQ, we did not find any other bypass polymerase variants to be 
significantly associated with breast cancer risk. There is also evidence for functional redundancy 
within the oxidative DNA damage repair system. Both BER and bypass polymerases deal with 
DNA damage caused by oxidative stress. Functional redundancy within and between pathway 
genes may in part explain the lack of SNPs associations with breast cancer. Several studies have 
suggested that DNA bypass polymerases are involved in BER and vice versa.  POLQ is one 
example, purportedly implicated in base excision repair and crosslink repair (367, 368). POLQ is 
able to efficiently bypass oxidative DNA lesions such as abasic (AP) sites and thymine glycol in 
vitro (246, 369-371). Another lab study showed that POLQ successfully extends from 
mismatches and bases opposite (6-4) photoproducts (246).  NEIL2 was shown to interact with 
POLB and LIG3 in the short-patch pathway of BER (109, 110, 150). In addition, 
posttranslational modification of PCNA by ubiquitin may play a role in determining which DNA 
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response mechanism to activate. Studies showed that the mono-ubiquitylation of PCNA may 
allow for translesion synthesis by damage-tolerant DNA polymerases, while poly-ubiquitylation 
may initiate error-free pathway involving template switching in homologous recombination (HR) 
(228-231). Therefore, our data may reflect the fact that there is an intricate system of 
functionally redundant DNA damage response mechanisms in place to protect our cells from 
genomic instability and prevent carcinogenesis. 
5.2 Strengths and Limitations  
 
5.2.1 Study design  
 
The Carolina Breast Cancer study is one of the first studies of its kind to integrate 
molecular biology and genetics with population-based epidemiology. One of the main strengths 
of this study was the large proportion of African Americans enrolled in the CBCS. In an 
unpublished review of 10 breast cancer studies, only CBCS and two other studies had an 
adequate proportion of African American cases to evaluate race-specific effects. Randomized 
recruitment, a novel sampling method, was used to oversample younger and African American 
women to improve power to detect associations in these often understudied subgroups of women 
(278). As an alternative to frequency matching, "randomized recruitment" or probability 
matching individually randomizes subjects to be recruited or not based on available screening 
variables and disease status (278). In CBCS, these screening variables, race and age, were 
abstracted from pathology reports for cases and DMV and Medicare records for controls. The 
final dataset included 1,809 White women (55%) and 1,505 African American women (45%).  
In addition to reporting results stratified by self-reported race, we also used AIMs to 
estimate African and European ancestry to control for any residual confounding (i.e. population 
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stratification). Rapid case ascertainment improved access to data from North Carolina’s Cancer 
Registry in a more time-efficient manner that allowed for more complete case ascertainment.  
5.2.2 Genotyping methods 
 
CBCS researchers had several quality controls measures in place to minimize potential 
genotyping errors. Blind duplicates were genotyped to verify the reproducibility of genotype 
calls. Any genotype with a call rate <95% was excluded. In addition, tests of Hardy-Weinberg 
equilibrium were conducted. Four SNPs in the BER pathway failed HWE and were excluded 
from subsequent analyses. Assay intensity data and genotype cluster images were reviewed for 
all SNPs. Across both pathways, a total of 8 SNPs were excluded due to low signal intensity or 
indistinguishable genotype clusters. Overall, there were 3,748 or 97% of enrolled participants 
(1,972 cases and 1,776 controls) with successfully genotyped data.    
5.2.3 Tumor Subtyping  
 
CBCS had detailed subtype data on tumors from a majority of cases (62%) allowing a 
unique investigation of the genetics of specific breast cancer subtypes. However, cases with 
subtype data were more likely to be African American and to have a later stage at diagnosis, 
which may bias estimates for SNPs related to race or disease aggressiveness (22). However, 
there were no significant differences for age, menopausal status, or family history between 
CBCS cases with and without subtyping data.  
Definitions for luminal breast cancer have evolved since original CBCS IHC subtyping 
methods were published (58). As a result, we defined tumor subtypes differently than previous 
studies. The major distinction between the two luminal subtypes are their proliferation 
signatures, measured by the expression of CCNB1, MKI67, and MYBL2 (49). HER2 expression 
only identifies about 30% of luminal B tumors.  In the current study, we did not have 
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information about these proliferation markers and therefore combined Luminal A and B tumors 
into a single ‘luminal’ category (48, 49). We also excluded ‘unclassified’ tumors from further 
analysis due to their heterogeneity. 
Our final subtype analysis was based on three subtypes (luminal, HER2+/ER- and basal-
like). Our subtyping methods have the advantage of excluding tumors that were negative for all 
markers tested. Only triple negatives that were also positive for a basal-like marker are included 
among basal-like cancers, reducing outcome misclassification potential in this important 
subgroup. Since many other studies do not have detailed subtype data but do have ER status, we 
conducted an exploratory analysis using estrogen receptor (ER) status to evaluate comparability 
to “intrinsic” subtype results and found that ER positive effects were for the most part 
concordant with luminal subtype results and ER negative effects with HER2+/ER- or basal-like 
subtype results. 
5.2.4 SKAT analysis 
 
Although we did not find any statistically significant combined effects of SNPs in either 
pathway using SKAT, to our knowledge, this is one of the few studies to have used this recent 
kernel-based machine learning method to assess pathway effects in cancer (175, 213). We chose 
this pathway-based method to harness correlation between biologically related genes. However, 
we recognize that our association analyses including the pathway analysis was limited by the 
density of SNP coverage across our two pathways and perhaps our choice of kernel.  Thus SKAT 
may be better applied to GWAS studies with greater SNP coverage.  
5.2.5 Power issues 
 
While Phase 2 of the CBCS improved power by recruiting more invasive breast cancer 
along with in situ cases, with the exception of two SNPs in the BER pathway, other associated 
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SNPs did not remain significant after adjustment for multiple comparisons using the false 
discovery rate (FDR). Therefore, we cannot rule out the role of chance for our observed 
associations. Traditionally, genetic association studies have been criticized for lack of replicable 
results. In our BER literature review, we noticed that many studies were drastically 
underpowered and as a result had imprecise results (Chapter 1, Table 3). In the current study, 
even with over 1,900 cases and 1,700 controls, we may have been underpowered to detect small 
SNP effects and also had reduced power to detect subtype associations, especially for 
HER2+/ER- and basal-like tumors. Therefore, it is possible that our significant subtype findings 
for NEIL2 rs1534862 with HER2+/ER- subtype and FEN1 rs412334 with basal-like subtype are 
due to chance and need to be replicated in a larger group of women with detailed subtype 
classification. 
5.3 Public health significance 
 
While advances in screening and treatment have improved outcomes in breast cancer, 
breast cancer is still the most common (non-skin cancer) and the second most deadly cancer in 
U.S. women. In particular, premenopausal African American women have a disproportionate 
increased risk of mortality due to breast cancer compared to other subgroups of women. 
Therefore, this subgroup was targeted for enrollment into the study. As a result, CBCS represents 
one of the most comprehensive datasets of African American breast cancer cases with tumor 
subtype information.   
CBCS was one of the first studies to report that breast cancer risk and prognostic factors 
may vary by both race and tumor subtype. Millikan et al. reported that risk factors for basal-like 
subtype included increased parity, younger age at first full term pregnancy, lack of breastfeeding, 
high waist-to-hip ratio, young age at menarche, and higher BMI (22). Of note, many of these risk 
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factors were contrary to risk factors established in luminal tumors. Furthermore, Carey et al. 
reported that premenopausal African Americans had a higher proportion of basal-like breast 
cancer (39%) than luminal cancers (36%). African American women were also two times as 
likely to be diagnosed with basal-like cancer compared to their White counterparts (22% vs. 
11%).  Additionally, Carey et al. showed that compared with luminal A tumors, basal-like 
tumors had poorer prognostic factors such as higher mitotic index, higher grade, and lower 
survival (59). These findings for basal-like breast cancer may partially explain the survival 
disparity in this subgroup of younger, African American women.  
Since younger African-Americans carry a disproportionate burden of basal-like disease, 
this high risk group should also be targeted for early screening mammography and increased 
surveillance by their clinicians and patients themselves. Our knowledge of genetic variation in 
DNA repair or bypass polymerases may also inform research on potential targeted therapies. 
Targeted treatments that exploit DNA repair could greatly benefit women whose tumors are not 
responsive to traditional chemotherapy.  To date, several PARP1 and POLB inhibitors are in 
development and have been investigated as adjuvant therapies for cancer (345, 346).  
5.4 Future research 
 
 We identified several potentially significant SNPs in both our race-stratified and subtype-
specific analyses. Further work is needed to replicate these findings in other study populations 
with an adequate proportion of African Americans and with complete subtype information. The 
AMBER consortium, a large collaborative study of African American women with breast cancer 
subtype information fulfills both of these criteria (374). A similar large collaborative study of 
White women with subtype information is needed to replicate SNP findings specific to Whites.  
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 In the past decade, advances in technology and statistical methods have greatly 
accelerated the field of genetic and molecular epidemiology. Our knowledge of DNA repair 
genes and pathway has also expanded since the early 2000s. Several new DNA repair and bypass 
polymerases genes have been discovered since the initially genotyping of the CBCS which could 
enhance the gene coverage in future studies (119). Our knowledge and technology in defining 
breast cancer heterogeneity of tumors is also evolving rapidly.  Future studies should take 
advantage of more comprehensive marker panels (i.e. PAM 50) used for gene expression 
patterns of tumor subtypes (311, 375, 376).  
   We also suggest a using a more comprehensive set of SNPs for future SKAT analyses. 
In addition we would further explore if other kernels are more appropriate fit for our genetic 
model. We would also expand our pathway-based analysis to explore combined SNP effects 
between DNA pathways (i.e since the literature has suggested interactions between genes in 
multiple DNA repair pathways. We could also use different pathway-based statistical methods 
such as other machine learning methods and hierarchical modeling to evaluate multiple SNP-
SNP interactions.  
 Finally, several environmental factors are known to be associated with DNA damage 
such as X-ray radiation, UV radiation, and folate deficiency, as well as yet to be discovered 
environmental sources of damage.  Further research is needed to investigate the effect on 
environment interaction on the relationship between common variation in DNA damage genes 
and breast cancer susceptibility. 
5.5 Conclusion 
 
 Since its inception two decades ago, the Carolina Breast Cancer Study has been at the 
forefront of many breast cancer research discoveries and innovative methods such as randomized 
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recruitment and rapid case ascertainment. Furthermore, the study has strived to stay relevant and 
has adapted to the ever-evolving changes in technology and methods.  The results from this 
current study have added to the repository of over 100 CBCS publications as well as the breast 
cancer literature. We believe this research has contributed to our understanding of the 
relationship between genetic variation in DNA damage response genes and breast cancer risk. In 
the future, we hope that results from the CBCS will continue to add to our understanding of 
breast cancer as it has in the past.  
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